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INTRODUCTION 
BcfOl-e the discovery of insulin by Bal1ting and Best, inslllin-depcndent (type I 
or juvcnile) diabetes nlcllitus \vas an atrocious discase, characterised by a 
llnquenchable thirst and lcaeling to a11 inevitable death within a short pedod of 
tune_ Mter this pedod, as insulill treatmellt became availablc in 1923, life 
expectancy of patients with insulill-depelldent diabctes mellitus (IDDM) 
illcreased clramatically, but this longcr survival was fOlmd to be accompanied by 
thc clevelopment of microvascular complications_ 
Thesc compJicatiollS, charactcrised by angiopathy of the microvasclllar system, 
c1inieally afièct, primal;})', the eyes, thc kidneys and the pedpheral nelVOUS 
system'. Oiabetic retulOpathy, of whieh the maclllar and proliferative forms eall 
result in blindness, devclops in BlOre than 90% of thc IDDM patients'. Diabetic 
nephropathy, an important eanse of end-stage renal disease in the Netherlands, 
dcvelops in 20-40% '-5. Diabetic neuropathy, which is associated with an 
increascd risk of foot ulccrs and amputation, is found in approximately 60% of 
the paticl1ts6 • 
Microvascular cOluplications occur in patients with IDOM as well as in other 
types of diabetes (e_g secondary diabetes and non-insulin-dcpendent diabetes 
mellîtus), which all share chronic hypcrglycaemia as the primary feature. 
Therefore, it has long becn suspectcd that chTonically clevated glucose levels play 
a causal role in the pathogcllesis of these cOlupJicatiolls. Many studies have been 
published suggestillg that strict metabolic control has a preventive cfièct on the 
devclopmcllt of diabetic ncphropathy',J·7-'J, rctinopathl· ro and neuropathy""'. 
Often, howcver, thcsc studies were regarded as being too short-tenn or too 
s111a11 to provide a definite proof of the 'hyperglycacmia hypothesis' _ 
Furthennorc, in somc studies cven a deterÎoration of diabetic retulOpathy 
during the fiTSt years of stdct mctabolic control was described7•9•rJ . 
However, in 1993 the hypcrglyeaemia hypothesis was confirmed by the results 
of the Diabetes Control anel Complications Trial (DCCT)q-,(" a large 
multicenter trial whieh showcel that strict IllctaboIic control, achicved by an 
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intensive insulîn regime, eflèctively delays the onset and slows the progressioll 
of microvasclllar complications. Given this endorscluent of the 'hyperglycaelllia 
hypothesis' , to achicve (near) normoglycaemia has become the main objective 
of care in IDDM. Ho\vever, it is still qucstionablc whether such strict metabolic 
control can be realized in routine diabetes care[7. 
Despite intensive treatment and strict llletabolic control, a number of patients 
wiII still develop microvascular cOlllplicatiolls,6.[s. Fl1rthermore, overt 
nephropathl' and advanced retinopathy do not seelll to be inflllenced bl' average 
blood glucose concentrations at all[J·'<). These findings suggcst that the 
devel0pluent of diabetic complicatiolls is also dcpendel1t on other [lctors,0-2'. In 
addition, the pathophysiological mechanism bl' which pOOl' metabolic control 
predisposes to the l11icrovascular complicatiollS is not completcll' understood. 
Manl' mechallisms and [lcto1's have been or are still under illvestigation: 
hereditary [lctors'3"(" dietary filCtors 27'30 , blood pressl1rel "H, haemodynamic 
[lctorsH ,)(', endothelial factors l7,J', the polyol patl1\vayw,-V', growth (.lctors[7, and 
Advanced Gll'cosylation End prodllctS 40-P. Still, these studies did not came up 
with a dcfinite ans\Ver up to now. 
OXIDATIVE STRESS 
Allother reccntly proposed lllechanism, which lllight be involved in the 
development and progression of nlicrovascular cOlllplîcations, is based on the 
tissue damage resulting fi'om the forlllation of tree radicals. Free radicals are 
highly reactive particles, since these molecules contain an unpaired electron in 
their outer orbit. The forlllatioll of these radicals is a biological process, which 
takes place, for example, when oxygell is redllced to water in the respiratory 
chain in the mitochondria of living cells or dUl'ing enzymatic synthesis of 
prostaglanclins alld leukotrienes~J..\-t. Under normal phl'siological conditiol1s the 
celi is protected against an overproduction of radicals by several anti-oxidant 
sl'stems. Based on thcir action these anti-oxidant systems could be classified as 
eitller preventive or chain breaking systems. In the latter, the anti-oxidative 
propertl' of the substances involved (e.g. uric acid, tocopherols, beta-carotene) 
is based on their ability to form a morc stabie reaction product af ter the reaction 
with a tree radical, thereby interrupting the oxidative process. Prcventive anti-
oxidallts (e.g. cerllioplasmin, ferritill, transferrin) are preventing the formatÎon 
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of fi-ee radicals by binding substances that act as catalysts in the formation of ft'ee 
radicals. These anti-oxidant systell1s are Iocated intra- as well as extracellllIarly 
and involve enzyll1atic as weIl as non-enzymatic reactions. In case of a distllrbed 
balance between the allti-oxidant defence systems and the formation of fi'ee 
radicals (oxidative stress), free radicals have been suggested to play a role in the 
development ofinsulin-dependent diabetes ll1eIlitus45 as well in other discases t 6 • 
In diabetes, the formation of frec radicals can be induced by increased glucose 
concentration through non-enzynlatic glycation of protein sllbstrates47 , auto-
oxidative glycation4\ activation of protein kinase CW and increased poIyoI 
pathway activity50 , In addition, diabetes is knowll to induce chances in thc 
content and activity of cellular anti-oxidallt enzymes jl-H. 
Free radicaIs, which are not trapped by anti-oxidants during the periods of 
oxidative stress, are suggested to distllrb endothclial dependent vasorelaxation, 
stimulate growth [1ctors, induce the expression of adhesion molecules, promote 
the blood coagulation, alld contribute to the formation of Advanced 
Glycosylation Endproducts s6.57• All these mechanisllls have been implicated in 
the dcvelopment of microvascular complications. Furthenllore, by lllodif:)7ing 
molecules, free radicals may fonn cytotoxic substallces, which may directly 
inducc cndothelial damagejs. In addition, illtcrvention studies lllOStly perfonncd 
in diabetic rats have shown a protective etIect of various anti-oxidants on the 
devel0plllcnt of microvascular cOIllplicatioIls5y-(jl. 
Given these findings, increascd oxidative stress could be a mechanism involved 
in the development of microvascular complications in patients with IDDM. 
Since oxidative stress is not exclusively rclated with hyperglycaemia, but is also 
influenced by other factors like dietary [1ctors (variation of intake of anti-
oxidants) or hercdita1)T factors (regulation of enzymatic anti-oxidants). it might 
also account for the development of microvascular complications under strict 
llietabolic control. 
Because in vivo 111casuremcnt of free radicals is difficult given their reactivity, 
short half-lifc, and very low concentratiol1s6\ various lllcthods have been 
developed to investigate indircctly whether such oxidative processes occur in 
reality. Substances indicating oxidative danlage to DNA (oxidizcd DNA bases), 
proteins (protein carbonyls) and lipids can be tueasured. Another indirect 
indicator of oxidative stress is given hy measurement of anti-oxidant status 6J • To 
study thc relation behvecn oxidative stress and microvasclllar complicatiolls 
lipid peroxidation and its consequences could be useful. Two of these methods 
are the meaSllreluent of malondialdehyde, a degradation product of lipid 
12 
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peroxides and the susceptibility of low-density lipoprotein (LOL) to in vitro 
oxidation. Thc latter has recently been proposed as an appropriate measnre of 
the response to the in vivo oxidative stress, which is thought to occnr within 
the matrix ofthe vessel wall close to the endotheIimn64,6,. 
In the fint part of th is thesis the results of a study will be described focusing on 
the presence of oxidative stress in IDDM patients and its possible role in thc 
devclopment in m.icrovascular complications. Oxidativc stress has been measured 
by allti-oxidallt status, the snsceptibility of LDL to in vitro oxidation and serunl 
malondialdehyde conccntrations. In the second chapter the study population is 
introduced by describillg the rclationship between nIetabolic control, serUlll 
lipids and the presence of l11icrovascular complications. Chapter 3 presents the 
results of a comparison of serunI anti-oxidant status between IDDM patients 
and healthy controls. The presence of oxidative stress assesscd by the 
susceptibility ofLDL to in vitro oxidatioll and malondialdehyde concentrations 
is described in chapter 4, whereas chapter 5 presents the association of these two 
parameters with llletabolic con trol and mÏcrovasclllar cOlllplications. 
HEALTH STATUS 
Since 1948, when the World Health Organizatioll defined health as being not 
only thc absence of diseasc and infinnity, but also the presence of physical, 
mental alld social weIl beingM, quality of life issues have become steadily more 
important in health care practice and research67 • 
Quality of life is notoriously difficuit to captm'e in a comprehensive definition. 
It could best be regarded as an Ulllbrella concept that encompasses health status 
as weil as satisf:1ction in a broader range of dOlllains such as environment, 
economic resources, relationships, work, and leis ure time. The concept health 
status difIers from 'quality of life' in that the latter is broader and also includes 
socio-economie aspects and perceptions of a person's illllllediate envirolllllentM • 
TIecal1se health status represents what a patient perceives as one of the Ol1tcomes 
of medical care, it is regarded as an important adjuvant to traditional biological 
and clinical outcome llleasures. 
lllsulin-dependent diabetes lllellitus is a chronic diseasc which aHects nuny 
aspects of everyday life. To maÏ.ntain satisL.1ctory blood glucose level in order to 
avoid hyperglycaemie complaints and hypoglycaemic events, food intake, 
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excrClse and insulin dose must bc balanced fiom hour to hour. In addition, 
thcre is a grcat risk of dcveloping one or morc microvascular complications. 
This ever-present responsibility for daily balancc and worries abollt future 
health and wcll-being may pose an extra burden to a IDDM patients' daily life. 
As described before, the importance of strict metabolic control for the 
prcvention as weIl as thc progression of long-tcnn diabetic complications has 
been sho\vn for patients with insulin dependent diabetes lllcllitus,6. As reportcd 
by the DCCT, the main side effects of strict llletabolic control are considerablc 
weigilt gain aud a threefold incrcascd risk of serious hypoglycaemia'(" f,.). Ta 
many patients, these side efiècts lllay be an unacceptablc price for strict 
metabolic control, because of both physical alld emotional consequences. 
Furthermore, stricter metabolic control may require more intensive therapy, 
such as multiple daily doses of insulin (by mal1Ual injection or by illsulin pump) 
and frequent measurements of blood glucose vallles. This regime may have its 
own negative efiècts on apatient's health status. 
In the secOlId part of this thesis the results of a study are described, which was 
performed in connection with the ma in investigation. In this stud}' the 
association between lllctabolic control, Însulill rcplacement therapy alld thcir 
COllscquences on health status is investigated. In chapter 6 the eflècts of 
metabolic control and diabetic cOlllplaints on health status arc described. The 
conscquences of insulin thcrapy and sclf-control are assessed in chapter 7. 
Finally, the consequences of the results of this thesis are discussed in cllapter S 
anel cOlllpiled in chapter 9. 
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Metabolic control, lipid profile, and 
microvascular complications in a Dutch 
population of IDDM patients 
Stud)' poptdation 
SUMMARY 
In IDDM, there is a definite relationship bchvcCll thc lcvel of mctabolic control 
(HbA I C levels) and the developmcnt and progression of diabctic microvasclllar 
complications. Still, it is known fiom clinical practicc that HbAIC is not ahvays 
the best predictor for the development of complications. Other variablcs related 
to metabolic con trol may better re.flect thc risk for thc dcvclopmcnt of diabetes 
complications in these patients. We studied the association bctwccn different 
mcasurcs of metabolic control, lipids and diabetes complications in a group of 
281 paticnts with insulin-dependent diabetes mellitns (153 men and 128 
wOlllcn) with a mean age of 38.2 years (SD 12.4) :md diabetes dm'ation of 17.2 
years (IO.7). 
Metabolic control, as asscssed by HbAIc and glycosylated apolipoprotein TI, was 
only weakly corrclatcd with serum lipid concentrations. LDL-phenotype was 
not associated with mctabolic control. Fifty-seven patients (20.2%) werc 
categorÎzed as having ncphropathy, 146 patients (52.0%) as having diabetic 
neuropathy and 93 patients (33.1%) as having diabctic retinopathy. Metabolic 
con trol , most serum lipids and LDL-phcnotypc ,""crc not significantly rclated to 
the presel1Ce of an)' microvascular complicatioll, diabctic llcphropathy, 
rctillopathy or neuropathy. In patients with l11acro-albmllinuria or using ACE-
inhibitors triglycerides were increased compared to l11ÎCro- and norl11o-
albulllinuric patients (1.67 1ll1ll0l/1 (0.]6) vs. 1.14 1ll1ll0l/1 (0.09) and 1.12 
l11111ol/1 (0.05), p $; 0.05 af ter adjustment for age and gender). Lipoprotein [a] 
was significantly lower in paticnts with any m.Îcrovascular complication 
(regression coefticient -51.6 mg/ml (95% confidence interval [-99.8; -].4])). 
These associatiolls were essentially the same aftcr fllrthcr adjustl11ent for 
duration of diabetes, HbAIc and L1sting conditions. In conclusioll, metabolic 
control was not associated with the presence of mÎcro-vasculair complications, 
whereas triglyccridcs werc increased in patients with diabetic nephropathy. 
These results ma)' support to thc hypothesis that serum lipid disturbanccs might 
be an additional risk f,1ctor in microvascular complications in general, and 
diabetic nephropathy in partÎCular. 
Submittcd as:J.H. Assink, R.P. Stolk, D.E. Grobbee, A.F. Casparie, H.G.T. Nijs, E.Y.l1l U:tlIegooie, 
HJ.G. Rilo. iVlet.lbolie control, lipid profile, and micro\'ascular complicatiom in:1 Dutch poptdation 
of lOOM p.<tients. 
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INTRODUCTION 
Insulin-depcndcnt diabetes mellitus (IDDM) affliets an incrcasing nUlllbcr of 
subjects worldwide. In The Netherlands, it is estünatcd that approxilllatcly 
45.000 subjccts suffer fi'om th is disease, aften acqllired at an carll' agc' and 
associated with an increased morbiditl' and I1lortality, lllainll' dllC to thc 
presence of diabctic cOll1plications~. Although non-insulin-depcndcnt diabctcs 
is filf more conllnon, the risk of especially microvasclllar cOlllplications 
(retinopathl', ncphropathy, neuropathy) in IDDM is such that its trcatment 
lllel;ts I1luch attention. 
In IDDM, there is a dcfinitc rclationship between the level of metabolic control 
(HbA I C levels) and thc dcvcl0pl11cnt and progression of diabetic microvascular 
cOlllplicationsJ • The mechanisllls by which thc diabetic state per se or lack of 
gll'cclllic control predispose to thc dcvcl0plllcnt of diabetic complications is 
incolllplctcly understood. From clinical practicc it is known that even a normal 
(or a Hear to nonnal) HbA1C does not totally prccludc thc dcvcloplllent of 
diabetic cOlllplications. This apparent discrepancy lllight bc cXplaincd bl' 
HbA1C being not the best indicator of glycemic control for all paticnts. Othcr 
glycos)'lated protcins like apolipoprotein B or advanced gl)'cosl'lation cnd 
produets (AGE)) l11a)' bc more appropriate measures. AIso, other variables 
rclated to metabolic control, notabil' lipids llla)' bettel' reflect the risk for the 
dcvclopment of diabetes cOlllplicatiollS in these patients. We studied the 
association between different meaSllrcs of lllctabolic control, lipids and diabetic 
complications in a large popuIation of IDDM paticnts. 
PATIENTS AND METHODS 
Patients 
Thc prcscnt study was conducted at thc outpaticnt clinic of the 'Dc 
Weezelllalldcn' hospita I in Zwolle, a middle-sized town in thc castcrll part of 
the Netherlallds. From January 1995 to Januarl' 1996, 293 consccutivc IDDM 
patients wcrc invitcd to participate in the stud)'. IDD.i\ll was defincd as starting 
insulin l'eplacclllcnt tllerapy within six months aftel' the fil'st sign of diabetes 
mellitus and bcforc thc agc of 30 )'ears, or the absence of C-peptide secretion. 
Twelve patients rcfllscd to participate in the study, so the presented resnlts are 
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based on the renuining 28 I patients. Thc study protocol was approved by the 
hospital scientific and ethical conuuittees and all patients gave their informed 
consent. 
Study protocol 
Patients were examined according to a standardized protocol by one trained 
physician. Smoking habits, alcohol use, as weil as used medication, including 
and frequency of iqjections were recorded. Body mass index was calculated as 
wcight (kg) divided by the square of height (m'). Body fat distribution was 
asscssed by the ratio of waist and hip circumferences. Blood prcssurc 
mcasurements were perf0l111ed after five and seven mÎnutes of rest in thc supinc 
position using a precalibrated standard mercury sphygmomanometer. Diastolic 
blood prcssure was recorded at the disappearance of the KorotkofI sounds 
(phase V). Thc n1can of thc two measurements was uscd in the analysis. 
Hypertension was dcfincd as systolic blood prcssurc of 140 mml-Ig or over 
and/ or diastolic blood prcssllrc of 90 nlllilig or ovcr4 • Patients who were 
treated with antihypertensive tuedication ,vere also considered hypertensive. 
Blood sampling was performed aftel' 30 minutes rest in sllpine position. In 122 
sllbjccts (79 males, 43 females) blood sampling was perfonned undcr fasting 
conditions, bcforc thc nlOnlÏng dose of insulin was adm.ÎllÏstcrcd. As most 
participating paticnts livcd at son1C distancc fron1 thc hospital, thc blood samples 
of the other 159 patients were collected af ter thcir llsual 1ll0nlÏug insulin close 
and nOl'l11al breakfast. 
The clinical chenlÏstry assays for total serum cholesterol, HDL-cholcstcrol and 
triglyceridcs wcrc pcrfonllcd on a Hitachi 7 I 7 chelllistry analyzcr based on 
commercially availablc tcchlliqucs (Bochringcr ManuhcÎln, Mallnheim, 
Germany). Total serum cholesterol was dctennillcd by llleallS of the CHOD-
PAP method. HDL-cholesterol was measured after precipitation with sodium 
phosphotungstate-MgH • Triglycerides were deternlÏned by means of the GPO-
PAP method. LDL-cholesterol was calculated according the formula of 
Fricdcwald'. Apolipoprotein A-I, and apolipoprotein Band Jipoprotein [a] wcrc 
determillcd by conlll1ercially available immunochemistry techniques on thc 
BeckInan AlTay Analyzer (Beckman, Fullerton, California). 
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Metabolic control was assessed by l11easuring glycos.ylated haemoglobin AI c 
(HbAIC) and gll'cosl'lated apolipoprotein B. HbAIC was llleasured bl' affiuit)' 
chrOlllatography (picrce columns, Glyco tes.t II) (llpper limit of normal 6.0%Y'-
Glycosylated apolipoprotein 13, as percentage of total apolipoprotcin B was 
dctenllined, accordillg to PanteghinF. 
The procedure for assessing LDL-phenotype was bascd on the 111ethod 
dcscribed by Mc Nal1lara et a1.$, with the follo,ving modifications. Plasma fron1 
cach subject was rapidly thawcd, diluted tcn times with a physiological salt 
soilltion and nli-xed with a solution containing 40% sucrosc and 0.1% 
bromophenol bille. Onc microliter of this sample was loadcd onto the 
applicator of the Phanllacia Phastsystcm containing 4-15% nondenaturing 
polyacrylalllide gradient gels aud the appropriate buffer strips (Pharmacia) aud 
subjectcd to electrophoresis for 18 hom"s at 225 V alld 15°C. Af ter 
clectrophoresis the gels were silver stained using the Biorad Silvcr Stain kit, The 
electrophoretic patterns were examincd independently by two examincrs to 
assign LDL-subclass phenotypes, There was never a disagrcement between the 
two examiners assigning LDL-Sllbclasses. LDL-Sllbclass patterns wcre defined as 
phcnotype A (lll'\ior subelass >25.5 nm), phcnotype B (m'\ior subdass <25.5 
lllIl) or phenotype AID (intermcdiate phenotype) according to Austin et al.""I(>. 
In twenty-follr hour urine samples, collected by the patients the day before their 
outpatient visit, albl1l1lin was measured, lISing all inllllunonephclOllletric 
techniquc on the Array immune analyzer (Beckman, Fl1llerton, California). 
Urinary albumin excretion rate (UAER) was calculated and divided inta du'ce 
categories: nonllo-albuminuria: UAER <30 mg/24h; micro-albuminuria: 
30 mg< UAER <300 lllglz4h; macro-albuminuria: UAER >300 mglz4h. 
Sevcn paticnts with nonllo-albumÎnuria and fourteen paticnts wÎth micro-
albuminuria used ACE-inhibitors. Thc hospital filcs showed that in all these 21 
patients the illdication for this treatlllent was albulllillluia repeatedly over 100 
mg/24h. Thereforc, these paticnts were catcgorised as macro-albuminuric. 
Serun1 as weIl as urine creatininc cOllcentrations were measurcd kinctically on 
the Hitachi 717, as described hy Jaftè", Creatinine clearance rate was calculatcd 
according to the Cockroft fonllula 12 • 
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In order to assess thc degree of diabetic retinopathy the examination included 
direct and indirect ophthalmoscopy throllgh dilated pupils by an experienced 
ophthalnlOlogist. Rctinopathy was graded according to llatiollal standards in 
three categories: no retinopathy, background rctinopathy and pre-proliferative 
or proliferative retinopathy'J. 
Neuropathy was assessed by vibration threshold Ineasurement using a Somedic 
vibrametcr type IV and by sensibility-testing using monofilamcnts according to 
Semmes-Weinstein (monofilaments by Gillis W Long Hansons disease centre 
Carreville USA). The vibration threshold was. determined aceording to a 
standardizcd procedurc at six test sites: the dorsomedial aspect of the first 
metatarsal bone, the flat surt:1ee just above the medialmalleolus and the dorsum 
of the metacarpal bOlle of the index finger for both left and right site of the 
body. Vibration meaSllrement was dcfined as abllormal when onc of the 
measurements was two stalldard deviations above the referenee value for age 
and localizatioll. 
Sensibility-testillg was perfonncd at five rcgions on both legs and classificd as 
ahnonllal when in one of the rcgions preSSllre of monofilament 5.07 was not 
feltl4. Peripheral neuropathy was defined as at least one abnormal vibration 
measurement or sensibility test-result. Severity of peripheral neuropathy was 
graded as thc llumber of abnormal tests. 
Data analysis 
The ebi-square test was used to eompare frequencies. Aualysis of variance was 
perfonlled to test for diflèrences between groups. Partial correlation coefficients 
were calculated to describe the relations between scrum lipids and age, BMI, 
WHR and parameters of metabalic control. Multiple linear regression analyses 
were used ta analyse the other associatiolls between contilluouS measures. Two-
sided P-values ::; 0.0 5 were considered to be statistically significant. All analyses 
were perfonned ming SPSS 6.1.3 for Windows. 
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RESULTS 
Clinical characteristics 
Thc clinical characterÎstics of the studl' population are sUllllnarised in Table I. 
Systolic blood pressure increased sigllificantly with age and duration of diabetcs 
(regression coefficients 0.64 nllul-:Ig pcr year (SEM 0.08) and 0.3 I mmHg pcr 
year (0.10), respectively aftel' adjustlllcllt for geneIer, anel age and gender). Both 
systolic and diastolic blood pressure were associated with body mass index 
(regression coefficient 1.30 nunHg per kg/m' (0.3 I) and 0.5' IlllllHg per kg/m' 
(0.15)) as weIl as with waist hip ratio (regression coefficient 29.4 mmHg per 
cm/cm (14.4) and 17.6 IIIlIIHg per cm/cm (7.1), rcspcctivell' all four pOS: 0.05 
af ter acljustment for age and gellder). 
Current smokers had signillcalltll' higher WHR (0.96 (0.01) vs 0.94 (0.01)), but 
lowel' BMI (24.1 kg/m' (0.31) vs. 25.0 kg/m' (0.24)). Systolic and diastolic 
blood prcssure were lawel' in smokers (135.0 nllnHg (1.60) vs. 141.0 nllnHg 
(1.42) and 8LO IlllIlHg (0.76) vs. 83.8 nmiHg (0.63)). These diffcrences were 
csselltially the same aftel' further adjustlllcnt far BMI or WHR. Thc number of 
cigarettes smaked daily was inversely assaciated with BMI (regression 
coefficient -0.64 kg/m' per eigarette (0.3 I) pOS: 0.05 after adjustment for age and 
gellder). Smokers had a shorter duration of diabetes (14.9 l'ears (0.9) vs. 18.3 
years (0.8)). Alcoholuse was not related with BMI, WHR or blood pressure. 
RCllal functian, as assessed bl' creatinine clcarance was better in men compared 
to wamen (Tabie I) and significantll' invcrsely associated with agc and duration 
af diabetes (regression coefficicllts -1.30 mI/min per year (0.10); anel -0.24 
m1lmin per year (0.14)). Albumill/ creatinine ratio was significantly associatcd 
with age, systolic blood prcssure as weH as creatininc clcarance (regression 
coefficients 0.36 per year (0.12); 0.50 per mmHg (0.08) and -0.16 per 11111111111 
(0.07) l'espectivcly. Itcllal function was not rclated to diastolic blood prcssure, 
waist/ hip ratio, thc consumption of alcohol, or smoking. 
Metabolic control and lipids 
Metabolic control, as assessed bl' HbAlc alld glycosl'latcd apolipoproteill B did 
not significantly differ between men and \Vomen, although tllere appearcd to 
be a tendency in females for worse metabolic control. No difference could be 
fOlU1d regarding thc various schenlcs of insulin adlllinistration (2-3 or 4 tÎ1nes 
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Table I. Clinical characterÏstics of the study population 
Men \Vomen Total 
Number of patients 153 128 281 
Age (years) 39.5 (12.5) 36.6 (12.1) 38.2 (12.4) 
Duradon of diabetes (years) 17.0 (11.5) 17.4 (9.7) 17.2 (10.7) 
Body mass index (kg/m2) 24.5 (3.1) 25.0 (3.3) 24.7 (3.2) 
Waist hip ratio 0.98 (0.06) 0.90 (0.08)'" 0.94 (0.08) 
Systolic blood pressure (mmHg) 139.1 (18.4) 139.0(18.6) 139.1 (18.4) 
Diastolic blood pressure (nnllHg) 83.2 (8.2) 82.6 (8.5) 82.9 (8.3) 
Hypertension 64 (41.8%) 46 (35.9%) 110 (39.1%) 
CUITent smokers 54 (35.3%) 37 (28.9%) 91 (32.4%) 
Number of cigarettes/ day 11.4 (8.1) 15.2 (9.9)* 12.9 (9.0) 
Alcohol uscrs lil (72.5%) 61 (47.7%)*** 172 (61.2%) 
Nllmbcr of units/ \veek 10.0 (7.8) 6.8 (6.6)" 8.9 (7.5) 
Frequency of insulin injcction5 
- 2 or 3 tunes a day 25 (16.3%) 9 (7.0%)*** 34 (12.1%) 
- 4 tunes a day 102 (66.7%) 73 (57.0%) 175 (62.3%) 
- CSII/ CIPII 26 (17.0%) 46 (36.0%)*** 72 (25.6%) 
Creatinine dear,mee (mllmin) 115.1 (25.8) 97.8 (25.6)A** 107.0 (27.1) 
Albumin /ereatinil1e ratio 6.08 (21.88) 5.92 (27.75) 6.01 (24.68) 
HbAlc(%) 8.07 (1.99) 8.49 (1.76) 8.27 (1.90) 
Glycated apolipoprotein B (%) 3.12 (0.91) 3.00 (0.92) 3.07 (0.91) 
Total cholesterol (lIllIlOlIl) 4.92 (1.07) 5.05 (0.93) 4.98 (1.01) 
HDL-cholesterol (llunolll) 1.26 (0.30) 1.53 (0.39}A** 1.39 (0.37) 
LDL-cholesterol (nul10lIl) 3.10 (0.89) 3.02 (0.83) 3.06 (0.86) 
Triglycerides (mmolIl) 1.28 (1.19) 1.07 (0.66) 1.18 (0.99) 
Apolipoprotein A (mg/l) 1.30 (0.21) 1.48 (0.25)*** 1.38 (0.25) 
Apolipoprotein B (mg/l) 0.90 (0.25) 0.88 (0.23) 0.89 (0.24) 
Lipoprotcin [a] (mg/l) 139.7(197.9) 108.9(153.9) 125.6 (179.4) 
LDL-phellotype 
- type A 121 (79.1%) 93 (72.7%) 214 (76.2%) 
- type AlE (intermedia te) 25 (16.3%) 31 (24.2%) 56 (19.9%) 
- type B 7 (4.6%) 4 (3.1%) 11 (3.9%) 
CS IJ:::: eOlltumous subclltaneous ill'iulill illfusion. 
CIPII:::: eOlltinuous intra-peritoneal insulin infusion. 
Values are numbcr of patients or means with percentage or standard deviatioll'i betweetl paren-
theses. Difference betweelllllen Jnd women : A:::: p5 0.05, **:::: p5 0.001, HA:::: p5 0,001 
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daily, and CSII). Blood prcssurc, BMI, WHR, duration of diabetes and reuaI 
function were also not rclated with of ll1etabolic control. In contrast to HbAIC, 
glycosylated apolipoprotein B was significantly associated with age (regression 
coefficient 0.009 % per year (0.004». Current smokers had significantly lo"\ver 
levels of glycosylated apolipoproteiu B (2.88 % (0.08) vs. 3.16% (0.07)). 
Glycosylated apolipoprotein B was associated with HbAIC (regression 
coefficient 0.15 % per percent (0.03), p ::; 0.05 aftel' adjustment for age and 
gender) 
Fasting did not influence most lipid levels, except for HDL-cholcsterol and 
apolipoprotein A, which were significantly lower under fasting conditions (I.30 
mmol/l (0.03) vs. 1.45 mmol/l (0.03) and 1.33 ll11110lil (0.02) vs. 1.43 mmol/l 
(0.02), respectively). Patients using alcohol had higher levels of HDL-
cholesterol and lower levels of triglyccrides (1.42 ll1mol/1 (0.03) vs. 1.33 (0.03) 
and 1.09 ll11110l/1 (0.05) vs. 1.33 ll11110l/1 (0.13) both p$ 0.05 af ter adjustment for 
age, gender and L1Stillg conditioll). Total Sen1l11 cholesterol and apolipoproteill 
B were sigllificantly associated with the number of alcohol consull1ptions 
(rcgression coefficient 0.03 mm01l1 per consumption per week (0.01) and 0.005 
1l11110l/1 per consumption per week (0.002). Sel'l1m lipid concentrations did not 
differ between ClllTent smokers and non smoking patients. Urillary albumin 
excretion, as assessed by albumin/ creatinine ratio, "ras associated with total 
serum cholesterol, apolipoprotein Band triglyceridc concelltrations (regression 
coefficients 0.005 mmol/l (0.002); 0.001 mg/mI (0) and 0.007 mmol/l (0.002), 
respectivcly p ::; 0.05 af ter adjustment for age, gender and fasting conditions). 
Most lipid parameters were associated with age, BMI, WHR and the paranlcters 
of luetabolic control (Tabie 2). No significant association was found between 
Iipid concentratÎons and creatinine clearance or duration of diabetes. These 
results were essentially the same when the analyses werc rcstricted to patients of 
Wh0111 fasting blood was obtained. 
Sixty-sevcll paticnts (23.8%) werc classificd as having an abnormal LDL-
phcuotype (type B or iutermediate type (A/B)). LDL-phenotype was not 
associated with age, gender, fasting condition, BMI, WHR, duration of 
diabetes, smoking, alcohol consumption, renal functÎon, metabolic control, or 
the use of Iipid lowering drugs. Total serum cholesterol and apolipoprotcill B 
concentrations were higher in patients with an abnormal LDL-phcnotype 
(5.1 Il1mol/1 (0.1) vs. 4.6 Il1mol/1 (0.1) and 0.93 mg/mI (0.02) vs. 0.77 mg/.1l11 
(0.03))· 
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" Tablc 2. Relationship between lipid concentrations, clinical characteristics and metabolic control 
CL 
" 
'C 
,g 
S 
Age BMI WHR HbAlc GapoB Cholt HDL LDL Tg ApoA ApoB " g' 
Total cholesterol (Cholt) 0.32* 0.21* 0.19* 0.17* 0.28* 
HDL-cholesterol (HDL) 0.21* -0.18* -0.12* -0.05 0.07 0.13* 
LDL-cholesterol (LDL) 0.27* 0.17* 0.18* 0.16* 0.33* 0.91* -0.11 
Triglycerides (Tg) 0.04 0.31* 0.20* 0.15* -0.10 0.37* -0.31* 0.25* 
<..> Apolipoprotein A (ApoA) 0.15* -0.04 -0.08 0.06 0.07 0.33* 0.75* 0.09 -0.02 0 
Apolipoprotein B (ApoB) 0.18* 0.19* 0.23* 0.19* 0.24* 0.82* -0.21* 0.87* 0.28* 0.03 
Lipoprotein [a] -0.03 -0.06 -0.07 0.03 0.04 0.09 0.01 0.14* -0.08 -0.04 0.12* 
BMI= body mass index,; WHR = waist hip ratio; GapoB= glycosylated apolipoprotein B. 
Values are partial correlation coefficients adjusted for age, gender and fasting condition. * = p :5: 0.05 
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Diabetic complications 
Thc prevalenee of the diabetic complications is shown in Table 3. Table 4 
summa ri zes the assocÎatioll betwccn thc prescnce of an)' microvascular 
complication, the parameters of mctabolic control and lipid concentrations. 
Mean level of HbA I C or glycated apolipopratein B did not differ between 
patients with or without any microvascular c01nplication, nephropath)', 
rctinopathy, neuropathy onl)'. In paticnts with abllormal vibration thrcshold 
HbArc was significantly incrcascd compared to those with no abnorInal test 
(8.64% (0.18) vs. 8.00% (0.14)). Metabolic contral did not diftèr between 
paticnts with or without abnol'llul sensibility testing. 
Most scrum lipid conccntrations \vcre not related with the prcscncc of all)' 
microvascular complication, retinopathy, nephropathy or ncuropathy onl)'. In 
paticnts with lnacro-albulllinuria or using ACE-inhibitors triglycerides werc 
increased cOlllparcd to micro- and normo-albuminuric paticnts (1.67 11111101/1 
(0.36) vs. 1.14 llllllolll (0.09) and I. 12 mmolll (0.05), p'; 0.05 af ter adjustmcnt 
Table 3. Prevalence of diabetic complications 
Men \Vomen Total 
any microvascular complications 
- na cOlllplications 46 (30.1%) 47 (36.7%) 93 (33.1%) 
- 1 complication 55 (35.9%) 52 (40.6%) 107 (38.1%) 
- 2 complications 33 (21.6%) 22 (17.2%) 55 (19.6%) 
- 3 complicatiolls 19 (12.4%) 7 (5.5%) 26 (9.2%) 
retinopathy 
- na retinopathy 103 (67.3%) 85 (66.4%) 188 (66.9%) 
- back ground 32 (20.9%) 34 (26.6%) 66 (23.5%) 
- pre-/ proliferative 18 (11.8%) 9 (7.0%) 27 (9.6%) 
ncphropathy 
- normo-albuminuria 116 (75.8%) 108 (84.4%) 224 (79.7%) 
- micro-albuminmia 16 (10.5%) 9 (7.0%) 25 (8.9%) 
- macro-albuminuria 21 (13.7%) 11 (8.6%) 32 (11.4%) 
+ACE- inhibitor 
periphcral ncuropathy 
- 0 abnormal test 62 (40.5%) 73 (57.0%) 135 (48.1%) 
- 1 abnormal test 48 (31.4%) 35 (27.4%) 83 (29.5%) 
- 2 abnonnal tests 43 (28.1%) 20 (15.6%) 63 (22.4%) 
Values arc number of paticllts with percentage between parentheses. 
Study population 
for agc, gender and f:lsting conditions). Lp[a] was significantly luwer in patients 
with any microvascular complication (Tabie 4). These associations were 
csscntially the same af ter further adjustment for duration of diabetes, HbAIC, 
LDL-phenotype and fasting conditions. LDL-phenotype was not associated 
with the presel1Ce of retinopathy, neuropathy, nephropathy or any 
microvascular complication. 
Tablc 4. Association between degree of metabolÎc control, lipid concentrations 
alld absence or presel1Ce of compIications 
Ally microvascular complicatiom 
- HbAlc 0.33 
- Glycosylated apolipoprotein B -0.03 
- Total senun cholesterol -0.11 
- HDL-cholesterol -0.03 
- LOL-cholesterol -0.12 
- Triglycerides 0.08 
- Apolipoprotein A -0.02 
- Apolipoprotein B -0.02 
- Lipoprotein [aJ -51.6 
Model 1 
[-0.14; 0.79J 
[-0.28; 0.21 J 
[-0.36; 0.13J 
[-0.12; 0.06J 
[-0.34; 0.10] 
[-0.09; 0.26] 
[-0.08: 0.041 
[-0.09; 0.04J 
[-99.8; -3.4J 
Model 2 
-0.05 [-0.31; 0.21] 
-0.02 [-O.l!; 0.08J 
-0.10 [-0.33; O.13J 
0.14 [-0.04: 0.32J 
0.01 [-0.06; 0.07J 
-0.02 [-0.08; 0.05J 
-61.5 [-111.7;-1I.2[ 
VaJucs arc regression coefficients with 95% cOllfidence intervals between parentheses. 
Model t parameters of metabolic control and lipid concentrations adjusted for age alld gender . 
Model 2 parameters of metabolic control and lipid cOl1centrations adjusted for age gender, 
duratioll of diseJ.se and metaholic coutrol. 
DISCUSSION 
The results of th is study in 28r lOOM patiellts show that the presel1Ce o(any 
microvascular complication was not associated to metabolic control, LDL-
phellotype 1101' to most of the serum lîpids. Triglyceride concentrations were 
illcreased in paticnts with nephropathy. 
The laboratory assays used in our study are according to international standards 
and applied to an unselected group of diabetic patients and control subjects. 
Although most blood samples ,,"cre obtaincd in thc llOll-fàsting state, adjusting 
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for the f:1stillg conditioll or limitillg the allalysis to sllbjects with a f:1sting blood 
sample revcalcd the salue associations. 
The prevalcnce of nucrovascular complications in dlis Dutch IDDM population 
is in general comparabie to other population studies'j"Ó, as are most of the risk 
L1ctOrs for these complications. Our paticllts werc on average oldcr and had a 
langer duratioll of diabetes compared to the paticnts, that participated in the 
studies previously mentioncd. Therefore differences in methodological 
procedures are the luost obvious explanation for the slightly lowcr prevalances 
of nepllIopathy alld retinopathy in these studie compared to our rcsults, 
Most of our re:mlts regarding serum lipid conccntrations are in agreement with 
results of other studies as summariscd by Drullzell and Lopes 17,,8. Although the 
lipid profile of thc patients participating in our study was measured on a yeady 
basis, sixteen (5.6%) patients had increased scrum lipids concentratiollS (no lipid 
lowering medication alld total cholesterol concentration above 6.5 nllllo1!l, or 
triglycerides above 2.2 lluuol/l) under fasting conditions, In twenty three (7%) 
patients thc scrum lipids were increased llllder nonfàsting conditiolls and had to 
be measurcd again. In addition, ten patients (3.5%) werc classified as having 
LDL-phcnotype B, although their lipid concentrations \vere with the normal 
ranges. Given its [ale in the development of macravascular complicatiolls 
regt.ilar assessment oflipid profile is important in the care ofIDDM patients, 
The absence of an assocÎation betwecn metabolic control and diabctes 
complications in our trallsversal stud)', is in agreemcnt with baselinc data of the 
DCCT', which reported glycosylated haemoglobin levels of 8.8% for the 
primairy intervention group (no complications) alld 9.0% for the secondairy 
interventioll group. A possible expl1nation for the abscnce of this association 
could be tbat a single mcasnremcllt of HbArc is an imprecisc estimate of an 
individual usual glycaemic control, given the reported variability of glycated 
haemagiobin concentrations 19 • All other explanation could be the smaJl range 
of HbAIc in this stud)'. Strict luetabolic control (HbAIC within 11or111al range) 
was achicvcd in 33 patients (12%). Gaod metabolic control, defilled as all 
HbArc lown than 7.2% (20% abovc the upper limit of11ormal) was reached in 
84 (29%) of the patients, Thcse results are cOlllparable with a reccntly described 
group of IDDM patients in The Nctherlands!O, 
A third reason, alld in Dur opinion the most obvious explanatioll for thc absence 
of this associatioll, cDuld be that patients who arc aware of thcir diabetic 
cOluplications arc morc lik:ely to improve their control as a consequence of th is 
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knowIedge. The finding that in patients \vith all abnonllal vibration threshold 
HbA I C levels \Vere increased support of this theory. 
The main interest for lipid profile disturballces in patients with IDDM is based 
on the associated risk of atherosclerosis. As shown by the results fiom our study 
SOllle serum lipids arc associated, independcntly fi-onl metabolic control, with 
microvascular complications. These results are in agreement with the findings 
reported by previous studies I6.21,n. It ShOldd be emphasized however, that the 
prcscnted data Call11ot pro vide evidence regarding a causal relatiollship between 
the scrum lipids and diabetic cOlllplications since it was a cross-sectional study. 
Therefore, prospective studies, investigating the role of Iipids and Iipids 
lowering in thc development of microvascular complications wonld be of value. 
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Serum anti-oxidants in insulin-dependent 
diabetes mellitus and diabetic 
complications 
Anti-oxidant status 
SUMMARY 
Oxidative stress is postulated to be increased in patients with diabetes melIitus. 
Scrum anti-oxidants play a role in protccting vascular endotheliulll against 
oxidative injUl)', and provide a possible defence against diabetic angiopathy. We 
studied serum anti-oxidant concentrations in 281 patients with insulin-
dependent diabetes mellitus and 98 control subjects, as weIl as the association 
between anti-oxidants and microvascular complications. ltetinol, transferrin 
and uric acid concentrations were significantly decreased in diabetes paticnts 
compared to contrals (1.83 ~ltl1olll (0.04) vs 2.3 I ~.molll (0.06); 2.24 gil (0.02) 
vs. 2.50 gil (0.04); 0.25 1ll1llOlli (0) VS. 0.31 mlllolli (0.01), p~ 0.05 respectivcl)'). 
No differences were fOllnd for alpha- and gaulllla-tocopherol, beta-carotelle, 
ferritill and ceruloplasmin. In diabetes patients uric acid, ganulla-tocopherol and 
transferr:in were significantly associated with glycosylated apolipoprotein B, a 
parameter of short term llletabolic control (regression coeffic:ients -0.01 
llllllolli per percent (0.00+), 0.25 mmolil per percent (0.12) and -0.06 gil per 
percent (0.02». HbAlc was onl)' significantI)' rebted with alpha-tocophcrol and 
galllllla-tocopherol (regression coefficients 0.85 ~llnolll per percent (0.29) and 
0.15 ~ul1ol!l per percent (0.04), respectivcly). Most anti-oxidants were 
significantly associated with lipid coucentrations. Patients with nephropathy had 
increascd levels of retinol, ferritin and uric acid compared to other diabetic 
patie."s (1.75 jlmolll (0.04) vs 2.16 ~.mol/l (0.14); 83.4 ~.g/l (4·4) vs. 128.0 jlg/l 
(19.'); 0.2+ mmolll (0.04) vs. 0.28 mmolIl (0.01». No significant associations 
were fOlllld for the other ·,ll1ti-oxidants. Retinopathy and neuropathy \Vere not 
assoc:iated with any of the anti-oxidants llleasured. In conclllsion, some 
relationships between serum anti-oxidants, nletabolic control and serum lipids 
were found. However, the contrastillg findings of decreased anti-oxidants levels 
in diabetes patients compared to control subjects and increased levels in diabetes 
patients with microvascular complications, suggest that the investigated anti-
oxidants arc not involved in the etiology of microvascular complicatiolls. 
Submitted as:J.H. Assink, R.P. Stolk, D.E. Grobbee, A.F. Casp,lrie, H.G.T. Nijs, HJ.G. Dilo. 
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INTRODUCTION 
It has been postlliated that diabetes mellitus is characterised by increased 
oxidative stress"'. Itesults fIom studies in animals alld hUlllans have suggested 
that oxidative ceil injur)' caused b)' [ree radicals contributes to the development 
ofboth macroangiopath)"·M and microangiopathy"s-s. Changes in the intraceilular 
level and aetivity of anti-oxidant enzymes, like superoxide dismutase or 
glutathione peroxidase, arc known to oceur in diabetes nlellitus,')-Jl. Extraceilular 
fluids contain several anti-oxidants that dela)' or inhibit the oxidative process b)' 
their presencc at a lower concentration than the oxidizable substrate'J, For this 
reason senUll anti-oxidants can play a roie in protecting vascular endotheliUlll 
against oxidative injury, and provide a possible defellee against diabetic 
allgiopathy. 
Previous studies q -" on serum anti-oxidants in diabetic paticnts were limited to 
a single category of individual anti-oxidants. Other researchers reported ani)' 
on subgroups of diabetes patients, such as ehildren~J. or made na distinction 
behveen IDDM and NIDDM patiellts. We conducted a stud)' to eompare 
serum eoncentrations of various allti-oxidants betwecll patients with insulin-
dependent diabetes mellitus and subjects without diabetes mellitus. In addition, 
the relationship between these serum anti-oxidants and the presence of 
microvascular complicatiolls was assessed, \vithin thc group of diabetic patients. 
PATIENTS AND METHODS 
Study poptliation 
The present study was conducted at the outpatient clinic of the 'De 
Weczelllanden' hospital in Zwolle, a middle-sized town in the eastern part of 
the Netherlands. From ]anuary 1995 to ]anuary 1996, 293 consecl1tive IDDM 
patients were invited to participate in the stud)'. IDOM was deflned as the start 
of insulin therapy within six 1110nths af ter the first sign of diabetes mellitus and 
before the age of 30 years, or the absence of C-peptide secretioll. In the same 
period I06 consecutive health)' l11el1 and wamen (control group), who were 
admitted for minor surgery (e,g. cosmetic sm"gery. sterilisatioll or arthroscopy), 
were invitcd to participate in the study. Health in the Jatter group was dcfllled 
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as no cUlTent diseases except the indication for sllrgery (ASA classification 
category I) and not using ruedication, except oral contraceptives. Twelve 
diabetes patients and 8 control subjects rcfused to participate in the study, so the 
presented results are based on thc remaining 281 diabetic patients and 98 control 
subjects. The study protocol was approved by the hospital nledical ethical 
cOI1uuittee and all patients gave their informed consent. 
Measurements 
Patients were examined according to a standardised protocol by one trained 
physician. Smoking habits, alcohol use, as well as used mcdication, including 
illsulin dose and fi'equency of injcctions, were recorded. Body mass indcx was 
calculated as weight (kg) divided by square ofheight (111'). Body fat distributiol1 
was assesscd by the ratio of waist and hip circumferenccs. Blood prcssm'e 
meaSllremcnts werc perfonlled af ter five alld seven minutes of rest in the supine 
position using a prccalibrated standard mercury sphygmomanometer. Diastolic 
blood pressure was recorded at thc disappearance of the Korotkoff sounds 
(phase V). The mean of thc two measurements \vaS used in the analysis. 
Hypcrtension was defined as systolic blood pressm'e of 140 mmHg or over 
and/ or diastolic blood presslIre of 90 mmHg or over'~. Patients who were 
tteated with antihypertensive medication were also cOllsidered hypcrtensive. 
Blood sampling \vas perfonned af ter 30 lllinutes rest in supinc position. In 122 
diabetes patients (79 males, 43 feruales) blood sampling was pcrformed lIndcr 
L1Stillg conditions, bcfore thc morning dose of insulin was administered. As 
most participating paticnts livcd at same distance frolll the hospital, the blood 
samples of thc other 159 diabetes patients were collccted after their usual 
morlling insulin dose and norlllal breakfàst. Blood sampling in the control 
subjects was never under Clsting conditions. 
Glycosylated haeUloglobin AIC (HbAIC) was measured by affinity 
chromatography (Pierce columns, Glyco test II) (upper limit ofnorma16.o%)l5. 
The routine clinical chemistry assays for total serum cholesterol, HDL-
cholesterol and triglycerides were performed on a Hitachi 717 chemistry 
analyzer based on commercially available techniques (Boehringer Mannheim, 
Manllhcim, Germany). Total serum cholesterol was detennined by means ofthe 
CHOD-PAP lllcthod. HDL-cholesterol was nleasured af ter precipitation with 
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sodium phosphotungstate-MgH • Triglycerides were determined using thc 
GPO-PAP method. LDL-cholesterol was calclllated according the formula of 
Friedewald'6 • Glycosylated apolipoprotein B, as percentagc of total 
apolipoprotein B was dctermined according to Pantcghini'7. 
Plasma vitamin A (rctinol). beta-carotcne :md vitamin E (alpha-tocopherol alld 
gamma-tocopherol) were determilled sillmltaneously by means ofHPLC in anc 
analytical run, essentially according to Zaman et a1. 2 \ with the following 
modifications: instead of a progranllllabie UV-VIS detector, a 996 Photo Diode 
Array Detector (Waters Associates, Milford, USA) ·was used, and in the 
extraction procedure methanol and hexane instead of ethanol and hexane. To 
prevent oxidation of the tocopherols during the extraction procedure, butylated 
hydroxytolucnc (BHT), pyrogallol, vita min C and EDTA were added. 
Transferrin, cendoplasmin and uric acid werc determined according to routine 
procedurc imnmnonephelomctrically on an Array immune analyzer (l3eckman, 
Fullcrton, California). Ferritin was routincly analysed with thc ferrÎtill Enzymun 
tcst on the ES 607 analyzcr (Boehringer Mannheim, Malll1heim, Genllany) 
In twenty-four hour urine samples, collected by the diabetes paticnts the day 
befot'e their outpatient visit, albumin was measured, ming all 
immunonephelOlllctric techniquc on the Array inullune allalyzer (BeckIllan, 
Fullerton, Califorllia). Urinary albumin excretion rate (UAER.) \vas calculated 
and dividcd iuto three catcgories: normo-albuminuria: UAER <30 Illg/24h; 
micro-albllIninuria: 30 mg/24h < UAER <300 mg/24h and n1acro-
albuminuria: UAER >300 mg/24h. Scven patients with normo-albuminuria 
and fourteen paticllts with micro-albulllimll;a llscd ACE-inhibitors. The 
hospital files showcd that in all thesc 21 patients thc illdication for this treatmcllt 
was albuminuria repeatedly over IOO mg/24h. Therefore, these patients were 
categoriscd as macro-albmuinurÎC. Serun1 as weil as urine creatinine 
concclltrations were Illeasurcd kinetically on the Hitachi 717, as described by 
jaffey • Creatinine clearance rate was calculated according to the Cockroft 
fonllula Jo. 
In order to assess thc degree of diabetic retinopathy the exalllination included 
direct and indirect ophthalllloscopy through dilatcd pupils by an cxperienced 
ophthalmologist. Retinopathy was graded accordillg to national standards in 
three categories: no retinopathy, background rctillopathy and pre-prolifcrative 
or proliferativc retinopathyJT. 
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Nel1ropathy was asscssed by vibration thrcshold meaSl1rement using a Somedic 
vibrameter type IV and by sensibîlity-testillg using Illonofilaments according to 
Selllmes-Weillstcill (lllonofilaments by Gillis W Long, Hansons Disease Centre, 
Carreville, USA). The vibration threshold was deterlllined according to a 
standardised procedure at six test sites: thc dOISomedial aspect of the first 
nletatarsal bone, the flat surfàce just above thc lllediallllaHeolus and the dorsulll 
of the metacarpal bone of the index finger for both the left and right side of thc 
body. Vibration lllcasurClllent was defined as abnormal when one of the 
l11easurements was two standard deviations above the refercncc value for age 
and localization. Sensibility-testing was performed at five regions on both legs 
and classified as abnormal when in one of the regions prcssure of monofilament 
5.07 was not fele~. Peripheral neuropathy was defined as at least one abnormal 
vibration measurement or scnsibility test resllit. Severity of peripheral 
neuropathy was graded as the number of abnoflllal tests. 
Data analysis 
Thc chi-square test was tlsed to comparc frequcncies. Analysis of variancc 
(ANOVA) was pcrforlllcd to test for differenccs betwecn groups. In additioll, 
multiple regressioll analyses \Vere peJ'forrned to adj lIst for possible confounders. 
Partial correlation coefficients were calculated to describe the rclations behveen 
anti-oxidants and age, body lllass and serum lipids adjusted for potential 
confounding [.lctors, notably age and gender. For serum triglyceride alld LDL-
cholesterol conccntrations additional calculations were performed limiting the 
analyses to subjects of whom fasting blood was obtained. Af ter adjustlllent for 
age and gender two-sided P-values ::; 0.05 were cOllsidercd to be statistically 
significant. All analysis were pcrformed using SPSS 6.1.3 for Windows. 
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RESULTS 
IDDM patients versus control subjects 
The clinical characteristics of diabetes patients and controls are sUlllluarised in 
Table I. Both systolic and diastolic blood pressure werc higher in diabetic 
patients. Althol1gh there was a tendenc)' in the control suojccts for a worse Iipid 
spectrum compared to diabetes subjects, on 1)' tbc difièrellcc for serum I-IDL-
Table I. Clinical characteristics of tbe stud)' populatioll 
IDDM patients Contra} group 
Numoer of patients 281 98 
Gender (Men) 153 (54.4%) 49 (50.0%) 
Age (yem) 38.2 (0.7) 38.2 (1.0) 
Body mass index (kg! m') 24.7 (0.2) 25.5 (0.4) 
Duratioll of diabetes (years) 17.2 (0.6) n.a. 
Systolic blood pressure (nllllHg) 139.1 ( 1.1) 125.6 (1.0)*** 
Diastolic blood pressure (nllllHg) 82.9 (0.5) 78.1 (0.7)*** 
Currcnt smokers 91 (32.4%) 40 (40.8%) 
Number of cigarettes/ da)' 12.9 (1.0) 13.7 (1.5) 
Never alcohol users 109 (38.8%) 33 (33.7%) 
HbAlc (%) 8.27 (0.11) 4.62 (0.06)*** 
Total cholesterol (nllllolll) 4.98 (0.06) 5.18 (0.10) 
HDL-cholesterol (nllllolll) 1.39 (0.02) 1.29 (0.03)* 
LDL-cholesterol (nllllolll) 3.06 (0.05) 3.22 (0.09) 
Triglycerides (nllllolll) 1.18 (0.06) 1.37 (0.07) 
Values are number of paticnts or lllcallS 'i.vith standard errors between 
parentheses. N.a.= not applicablc. Difièrence between diabetes patients and 
control subjects adjusted for age and gender: *= p=> 0.05, ***= p=> 0.001 
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cholesterol was fonnd to be statistically significant. This difference could not be 
attributed to the fact, that thc blood sampling of control patients was not 
performed tlllder fàsting conditions or to a dift:èrence for one of the other 
clinical characteristics. The anti-oxidant concentrations in the diabetic patients 
and the control sllbjects arc shown in Table 2. Uric acid, retinol and transferrill 
were significantly lower in diabetes paticnts. Af ter further adjustment for L1stillg 
condition, and creatinine clearance, body mass index, waist hip ratio and serum 
lipids or restricting the analyses to patients without hypcrtensioll, these 
differences remained essentially the salUC. 
Table 2. Alltioxidant-concentrations in rDDM patients and healthy controls 
IDDM patients Control gronp 
Urie Acid (1ll1l101l1) 0.25 (0) 0.31 (0.01)*** 
Alpha-tocopherol (~n101I1) 31.34 (0.56) 32.22 (0.87) 
Gamma-toeopherol (flm01l1) 2.99 (0.11) 2.85 (0.14) 
Beta-carotene (muol/l) 324.8 (16.0) 271.6 (18.1) 
Retinol (funol/I) 1.83 (0.04) 2.31 (0.06)*** 
Ceruloplasmin (g/l) 0.38 (0.01) 0.37 (0.01) 
Ferritin (flg/l) 92.7 (45.3) 106.9 (11.0) 
Transferrin (g/l) 2.24 (0.02) 2.50 (0.04)*** 
Values are l1leans with standard errors between parentheses. 
Difference between IDDM paticnts and control group adjusted for age and 
gender: ***= p:O: 0.001 
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Anti-oxidants in IDDM patients. 
Bcta-carotene, ceruloplasmin and transfeIT:in concentrations wcre significantly 
higher in \VOIUen than in nIcn \vith diabetes (379.4 nmol/l (SE 30.1) vs. 278.8 
nmol/l (14.0); 0.46 1111110111 (0.01) vs. 0.3 I mlllol/l (0.01); and 2.40 gil ( 0.46) 
vs. 2.II gil (0.02), respectivcly). Urie acid (0.22 mm01l1 (0.01) vs. 0.27 I11mol/l 
(0.01» and ferritin levels (52.4 ~g/l (4.4) vs. 126.5 ~g/l (8.2» were lower. Most 
anti-oxidants were strongly associated with age and body lllass index (Tabic 3). 
No relatiollship was prescnt between any of the anti-oxidant levels and blood 
pressllre, daily insulin doses and thc nllmber of cigarettes smoked. 
Hypertension, smoking and fasting condition were not associated with anti-
oxidant levels. Diabetcs patiellts drillking alcohol, had increased levels of udc 
acid and ceruloplasmin (0.26 1111110111 (0.05) vs. 0.23 mlll01l1 (0.06); 0.36 gil 
(0.01) vs. 0.42 gil (0.02), respectivcly p~ 0.05 adjusted for age and gender). 
Only retinol was associated with the number of alcohol consmnptions 
(regression cocfficient 0.01 ~Ullo1i1 per alcohol consumption per wcck (o.OS); 
p~ 0.05 aftcr adjustment for agc and gender). Duratioll of diabetes showed a 
significant inverse relatÎon with transferrin (regression coefficient) -0.006 gil per 
year (0.002». 
Mctabolic control, as estimated bl' HbAIe, was not related to the levels of most 
anti-oxidants. Howcver, alpha-tocopherol and ganlllla-tocopherol showed a 
positive association: coefficients of linear regression 0.85 ~lInoIlI per percent 
(0.29) and 0.15 fun01l1 per percent (0.04), respectivcly p~ 0.05 af ter adjllstment 
for age alld gcnder). Glycosylated apolipoprotein B was sÎgnificantly associated 
with ganlllla-tocopherol, uric acid and transfcrrin (regression coefficients 0.25 
funol/l per percent (0.12); -0.01 1111110111 per percent (0.004)alld -0.06 gil per 
percent (0.02). respectivcly. Most anti-oxidants werc significantly associated 
with Iipid concentrations (Tabie 3). These relations remailled essentially the 
same af ter fi.trthcr adjustment for body lllass index, waist hip ratio or fasting 
condition or limitillg the analyses to subjects of whom f:1sting blood was 
obstained. None of the allti-oxidants was related to lipoprotein [a] 
conccntrations. 
Diabetic complications. 
Ninety-three patients (33.1%) had diabctie retinopathy (27 (29.3%) with pre-
proliferative or prolifcrative retinopathy). 57 patients were categorised as having 
nephropathy (32 (56.1%) using an ACE-inhibitor or having macro-albmninuria) 
and 146 paticnts as having diabetic neuropathy (63 (43.2%) of these patients had 
45 
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Table 3. Relationship between age, body mass index, lipid and antioxidant-concentrations in patients with insulin-dependent 7' 0 
x 
diabetes mellitus ~ g 
Age Body- Cholesterol HDL- LDL- Triglycerides iJ 
mass index cholesterol cholesterol 
g 
Uric Acid 0.08 0.23* 0.15* -0.23* 0.15* 0.31* 
Alpha-tocopherol 0.28* 0.14* 0.48* 0.002* 0.43* 0.55* 
Gamma-tocopherol -0.06 0.27* 0.23* -0.12* 0.23* 0.31* 
+-0, 
Beta-carotene 0.23* -0.10 0.11 0.19* 0.06 -0.04 
Retinol 0.06 0.10 0.32* -0.05 0.22* 0.31* 
Ceruloplasmin -0.16* 0.18* 0.17* 0.07 0.05 0.24* 
Ferritin 0.19* 0.23* 0.09 -0.11* 0.08 0.42* 
Transferrin -0.28* 0.09 0.18* O.OS 0.11 0.05 
Values are partial correlation coefficients after adjustment for age, gender and fasting condition (age only for gender): *= p:f 0.05 
.... 
'" 
Table 4. Antioxidant concentrations in IDDM patients by the number of microvascular complications 
Diabetic complications 
No complications 1 complication 2 complications 3 complications Any complications 
Utic Acid (mmolil) 0.25 (0.01)# 0.23 (0.01)* 0.26 (O.Ol)t 0.30 (O.Ol)#*t 0.25 (0.01) 
Alpha-tocopherol (J.lmolll) 31.06 (0.81) 31.19 (0.81) 32.33 (1.74) 31. 92 (1.83) 31.63 (0.73) 
Gamma-tocopherol (J.lmolll) 2.86 (0.18) 3.09 (0.17) 3.23 (0.29) 2.52 (0.27) 3.06 (0.14) 
Beta-carotene (nmol/l) 306.8 (19.4) 306.8 (40.8) 332.3 (45.8) 371.3 (62.5) 354.0 (28.0) 
Retinol (J.lmol/l) 1.78 (0.05)# 1.77 (0.05)* 1.75 (0.09)t 2.45 (0.27)#*t 1.86 (0.06) 
Ceruloplasmin (gil) 0.38 (0.02) 0.39 (0.01) 0.38 (0.02) 0.37 (0.02) 0.38 (0.01) 
Ferritin (J.lg/l) 81.9 (7.7)# 88.9 (6.23)* 110.8 (17.7) 134.1 (22.4)#* 98.6 (7.0) 
Transferrin (gil) 2.31 (0.04) 2.22 (0.04) 2.21 (0.06) 2.11 (0.06) 2.20 (0.03) 
Valucs arc mcans vvith stanmrd crrors of thc mean bctwccn parentheses. 
[#) diffcn:ncc bctwccn paticnts vvithout diabcuc complications and paticnts with thrcc complications adjustcd for agc and gender: p:f 0.05 
[*] diffcrcncc bctwccn paticnts widl anc and threc diabetic complication adjustcd for agc and gender: p::; 0.05 
[tl diffcrcncc bctwccn paticnts with two and three di:1bctic complication adjustcd for agc and gender: p::; 0.05 
n g-
'" 1;: 
w 
Anti-oxidant status 
two abnOrIllal tests). More than twenty-five percent of the patients had two or 
nlOre microvasclllar complications. Patients with all duee microvasclllar 
complications had significant higher concentration of ferritin, retinol anc! uric 
acid compared to those with two or less cOlllplications (Tabie 4). R .. etinopathy 
and neuropathy were not associated with any differences in anti-oxidant 
concentrations. Patients with onIy diabetic nephropathy had increased 
concentrations of retinol, ferritin and udc acid (I. 75 ~lmolll (0.04) vs 2. I 6 
funo1l1 (0.14); 83.4 Mg/l (4.4) vs. r28.0 f!g/1 (r9.r); 0.24 1111110111 (0.04) vs., 0.28 
mmolIl (o.or), pS; 0.05 adjusted for age and gender ). For these threc allti-
oxidants a trend was found: showing higher concentratÎons with increasing 
UAER. These difièrences did not change markedly aftel' ftll'ther adjustillent for 
metabolic control and dm'ation of disease. The results were the same \vhen 
instead of a classification corrected far ACE-inhibition, patients were classified 
only by UAER. Retinol was aho associated with creatinine clearance 
(regression coefficient -0.02 /.ulloll1 per mi/min (0.002) p':::; 0.05 aftel' adjustment 
for age and gender). The albumin/ creatinine ratio was sigllificantly related with 
retinol, ferritin and udc acid (regression coefficients 0.01 ~ullolll (0.002); 0.69 
f!g/l (0. I9) o.oor ml1101l1 (o.oor), respeetively. Af ter further adjustmellt for body 
mass index, waist hip ratio or creatinine clearance these relations were 
essentially thc same. 
DISCUSSION 
The reslllts of this study show that udc acid, retinol and transferrin 
concentrations are decreased in patients with insulin-dependent diabetes 
mellitus. Short ternl metabolic control, as lueasured by g;lycosylated 
apolipoprotein 13;;, was associated with llric acid, ganlllla-tocopherol and 
transferrin levels. HbAIC was onl)' significantl)' related with alpha-tocopherol 
and gamma-tocopherol. l'vlicrovascular cOlllplications, notably nephropath)', 
were associated \vith an increase in uric acid, retinol and ferritill levels. Most 
anti-oxidants were associated \vith lipid concentrations. 
13lood samples were onl)' obtaîned lllldcr C1sting conditions in a subgrollP of the 
diabetes poptilatioIl and in none of the control subjects. However, adjustnlent 
for C1sting coudition, or limiting the analyses to subjects with a fastillg blood 
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sample revealed the same associations. In the present study laboratolY assays 
used were according to inten1ational standards and pcrformed on blood samples 
of an unselccted group of diabetes patients and healthy subjects, without 
knowledge of thcir clinical characteristics. Thereforc, in our opinion selection 
bias has not influenced the results of this stud)'. 
The Iower uric acid levels found in diabetes patients compared to controls, as 
its relation with gender, age, metabolic control and lipids are in agreement with 
other stl1diesH -n. Serum mic acid levels have been shown to be largely 
determil1ed by genetic factors, purine production and renal fimction'5. Resl1lts of, 
prcviol1s studies on metalion chelating and oxidizillg anti-oxidallts (ceruloplasmin 
ferritin and transferrin) have shown increased'7. 2), l1nchangcd)~--!-O and decrcased4 ' 
levels in IDDM paticnts. The conflicting results of these studies lllight be 
explained hl' the small sample sizes (n<30), and the difIerences in analytical 
procedures. The rchltionships found for alpha- and ganuna-tocopherol, retinol 
and beta-carotelle are in agreement with other studiesll,..p-#. Results that contrast 
with those foulld in our study, arc 1l10Stly from studies, ming older analytical 
procedures (e.g. measuring only total tocopherollevcls}H--I7_ 
With respect to microvascular complications aud the serum anti-oxidants 
cxamined in Dur study, wc only found two reports of similar work. ane study 
reported udc acid as a risk factor for proliferative retinopathy~S, in the other 
study increased alpha-tocopherol levels were associated with increased llrinary 
albumÎn excrctioll rate but not with diabetic retinopathy'-1- In the latter study 
retinol levels ,vere also found to be increased in patients with macro-
albumilluria, as in our study. 
In illslllin-dependent diabetes meHitus thcrc is a deal' rclationship between 
llletabolic control alld the developmcnt alld progression of microvascular 
complications49 • Although the pathophysiology of these complications is 
probably multif.1ctorial, results ofin vitroso, anima}5', and human studies S suggcst 
th at oxidative stress through an Îllcreased formation of fi'ee radicals might be 
involvcd in the development of complications. Increased gencratioll of reactive 
o.:\'ygen nletabolites such as superoxide anion and hydrogen peroxide has been 
shown to occur in diabetes mellitus in association with hyperglycaemia'. 
Increased glucose concelltration can inducc formation of free radicals through 
non-enzymatic glycation of protein substratesP , auto-oxidative glycation'iJ, 
activation of protcin kinase eH and illcrcased polyol pathwayH. These reactivc 
49 
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oxygen SpeCIeS, if not trapped by anti-oxidants, are snggested to disturb 
enelothelial dependent vasorclaxation, stimulate growth L.lctors, induce the 
expression of adhesion molecules, activate the blood coagulation, and 
contribute to the formatioll of advanced glycosylated end-products. All these 
mechanisms have been implicated in the dcvelopment of microvascular 
cOl11plicatiolls j ". Furthenllore by 1110difYing lllOlccules, free radicals may form 
cytotoxic substances, which can directly induce cndothelial damagc. In addition 
diabetes is known to induce chances in the content anel activit)T of ccllubr anti-
oxidant enzl'mes 9-1>. 
As they are active at diftèrent places, depellding on the chemical properties of 
the anti-oxidants, changes in concentratiol1s of anti-oxidants should be seen as 
Ioca! alterations of anti-oxidant dcfences. Absolute levels of individual anti-
oxidants 1l1ight not be the onll' L.lctor that detenlline anti-oxidant defences. 
Activit)7 of these allti-oxidants could be enhanced or depressed. Furthermore, 
most antl-oxidants are regulated bl' more control l11echanisms, in which the 
formation of radical active species is in general not the most important. For 
example, as stated earlier uric acid levels are mainly detennincd by purine 
production, genetic and renal L.lctors 'j • In studies by Tsai '6 and Asayama T5 chaill 
breaking as ,veil as preventivc Jllti-oxidant fUllCtiollS in general were shown to 
be decreased in subjects with poody controHed IDDM, despite normal or even 
increascd levels of individual anti-oxidants. This supports the view of Jones2l 
that no conclusions can be drawn frOln levels of individual serum anti-oxidants 
as indicator of oxidative stress. 
Our study shows a decrease of some anti-oxiclative substallccs in IDDM 
patients. Despite this, the data lend no support to the view, that low levels of 
alltl-oxidative slIbstances are associated with thc presellCe of diabetic 
microvascular complications. In diabctic ncphrapathy, levels werc even 
increased and similar to those in non-diabetic sllbjects. If the anti-oxidants 
measured in our studl' would play an Ïlnportant pathogelletic ralc, one woulcl 
cxpcct the opposite. It is difficult to accept, that low levels of anti-oxidants 
initially lead to microvascular damage, and sllbscqucntly hl' same unknown 
mechanisl11, anti-oxidants would rise to COllnteract further damage. In spite of 
the limÎtations inherent to a cross-sectiollal study our results suggest that thc 
anti-oxidants investigated are not relevant in the occurence of microvascular 
complicatiol1s. 
Chaptcr 3 
The hypo thesis that oxidativc stress, induced by hypcrglycaem.ia, causes 
endothclial damage and is the final conllllon pathway in thc development of 
both macroangiopathy and microangiopathy, is not supported by our cross-
sectional study. Prospective studies, to the role of bath anti-oxidants and pro-
oxidants (notably ft·ce radicals) in endothelial damage, may cOllfirm these 
findings. 
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Lipid peroxidation in insulin-
dependent diabetes mellitus: 
comparison with healthy controls 
Lipid peroxidation: comparison with controls 
SUMMARY 
Oxidative stress is postulated to be increased in patients \vith diabetes mellitus. 
Becallse in vivo measurement of free radicals is difficult to cstablish, variaus 
methads have been developed to investigate indirectly whcthcr such oxidative 
processcs occur in vivo. Two of these methads are the l1lCaSllrClllcnt of plasma 
malOlIdialdehyde concentration, as a reflection of lipid peroxidation and the 
susccptibility of LOL to in vitro oxidation. 
We studied these two parameters in 281 patients with insulin-dependent 
diabetes l11cllitus and 98 subjccts without diabetes mellitus. 
Age, gender, plasl11a levels of total serum cholesterol, LDL-cholesterol, 
ttiglyccride and LDL-phenotype did not significantly diflèr between the two 
groups. HDL-cholesterol conccntrations wcre significantly higher in diabetic 
paticnts compared to contrals (1.39 11111101/1 (0.02) vs. 1.29 l1l111olil (0.03) mca11 
(SEM). With regard ta compasitian of LDL-chalcstcrol, the amaunt of LDL 
triglycerides was significantly increased in diabetic paticnts, whilc the :lmount 
of cholesterol esters was decreased (7.8 % (0.1) vs. 6.9 % (0.2) and 28.5 % (0.2) 
vs. 29.5 (0.4) both p~ 0.05). In line with this, the size of LDL-subclass I 
particles was found to be significantly incre.sed in IDDM p.tients comp.red to 
the control subjects (26.59 mll (0.03) vs. 26.42 n111 (0.05)). There was no 
diftèrence in thc in vitro susccptibility of LOL ta oxidation, maximum ratc of 
oxidation and MDA concentrations bCtWCCll lOOM patients alld control 
subjccts. 
Our results do not support the presence of increased oxidativc stress in patients 
with insulin-dependent diabetes mellitus, as assesscd by thc susccptibility of 
LDL to in vitro oxidation or plasma malondialdehyde concentratiol1s. 
Submitted as:J.H. Assink, R.P. StaIk, D.E. Grobbee, A.F. Casparie, H.G.T. Nijs, H. M.G. Princen, 
L.D Dikkeschei, H.J.G. 13ilo. Lipid peroxidatioll in insulill-dcpcndcnt diabctcs Illcllitus: comparuon 
with healthy controls. 
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INTRODUCTION 
Oxidative stress is pastulated to be illcreascd in paticllts with diabctcs lllcllitus ',.1. 
H .. esults fron1 several studies, bath in anllllals alld in humalls, havc sllggested that 
oxidative ceil ü~ury (in particular to cndothclial cclls) by ficc radicals 
contributes to the development of bath lllacroangiopathi·J.-l- and 
llucroangiopathy"s-s. Because in vivo 11leaSUrClllcnt of .trec radicals is difficllit 
givcn their reactivity, short half-life, and very lo\v concentrations", various 
11lcthocls have been developed to investigate indirectly whether such oxidative 
proccsscs occur in vivo. 
The susccptibility of LOL to in vitre oxidation has recently been proposed as a 
measurc of thc response of LOL to the in vivo oxidative stress, which is thought 
to occur WitlUll thc matrix ofthe vessel wan closc to the endothelilUl1 lO • Whcreas 
the remlts of thc susccptibility of LDL to oxidation are inconclusivc,o-r\ 
concentrations of lllaiondialdchydc, a markcr of gcneraIIipid pcroxidation and 
oxidative stress, have becn found to bc increased principally in paticnts with 
non-insulin-dependent diabetes lnellitus("rS-l". 
Wc compared the susceptibility of LOL for oxidation and malondialdehyde 
cOllccntrations betwcen patients with insnlin-depenclent diabetes meJlitus 
(IDDM) and subjects without diabetes mellitus. 
PATIENTS AND METHODS 
Study population 
The present study was conducted at the outpatient clinÎc of the 'De 
Weezellianclcll' hospital in Zwolle, a middle-sizcd town in the castern part of 
The Nethcrlallds. From January 1995 to January 1996, 293 consecutive IDDM 
patients were invitcd to participatc in thc study. IDDM was dcfillcd as thc start 
of insuIin therapy within 6 lllonth aftcr thc fiTSt sign of diabctcs lllCllitus and 
bcforc the age of 30 years, or the abscncc of C-pcptidc sccrction. In thc same 
pcriod 106 consecutive healthy men and women (colltrols), who were admitted 
for llullor surgery (e.g. cosmetic surgery, sterilization or artheroscopy), were 
illvited to participate in the study. Health in the latter group was defined as no 
currcllt diseascs, except the indicatioll for sUl'gel)' (ASA c1assificatÎon catcgory I), 
and not using medication, except oral contraceptives. Twelve diabetic patients 
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and 8 controls sllbjects refused to participate lt1 the study, sa the presented 
results are based on thc rcmaining 281 diabetic patients and 98 controls subjects. 
The study protocol ,vas approved by the hospital medical ethical cOlllmittee and 
all patients gave infonllcd consent. 
Measurements 
Patients were examined according to a standardized protocol. Smoking habits, 
alcohol use, as weIl as uscd llledication, were recorded. Body mass index was 
calculated as weight (kg) dividcd by square of heiglll (111'). Blood pressure 
llicasurements were perfOrIlled aftel' fivc and seven ll1inutes of rest in the supine 
position using a precalibrated standard mcrcury sphygll1oll1anometer. The ll1ean 
of thc two measurements was used in thc analysis. Hypertension was defined as 
systolic blood pressm'e of 140 nUllHg or ovcr and/or diastolic blood pressm'c of 
90 mml-Ig or over'''. Patients using antihypertcnsivc l11cdication wcrc also 
considered to bc hypertensive. 
Blood sampling was pcrforll1ed af ter 30 minutes rest in the supinc position. In 
122 diabetes patients (79 males, 43 females) blood sampling ,vas perfol1ned 
under t:'lsting conditiollS, befm'e the lllorning dose of insulin was administered. 
As most participating patients livcd at some distance from the hospital, the 
blood samples ofthe other 159 diabctcs paticnts were collected af ter their usual 
lllorning insulin dose and normal breakf.1st. Blood sampling in con trol subjects 
was never Ullder fàsting conditions. The blood samples to be used for LDL-
oxidation and detcnllination of malondialdehyde, were collcctcd in EDTA 
Vacutainer tubes, placed on ice immediately and cooled to 4 °C. Plasma, 
prepared for the determination of ll1alondialdehyde, was protected agaillst 
oxidation by addition of 2 mg/ml rcduced glutathione and 1.2 mghnl butylated 
hydro:x'ytoluene (final concentrations) as well as by flushing the empty space of 
the tubes with nitrogen. Except for the routine clinical chemistry, all blood 
samples stored at -80°C. The entire blood processing procedure was completed 
within one hour. 
Thc procedure for preparation and oxidation of LDL was adapted fronl the 
method as described by Esterbauer et al. H wÎth IllOdificatiolls as described 
previously1>,.lJ. Briefly, fr0111 each subject 2 mi of fiozen plasma was rapidly 
tllawed and used for isolation of LDL by ultracentrifugation at 4 °C in the 
prcscnce of IQ ~{M EDTA. To minimize the time between isolation and 
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oxidation and to prevcnt the loss of Iipophilic anti-oxidants4 , LDL was not 
dialysedn ,.-'J,2 j • By omitting dialysis a more stabie LDL preparation is obtained, 
which can be stored in thc dark at 4 oe under nitrogen for several days without 
afIccting resistance thne (lagtime) and maximum rate of oxidation (propagation 
rateY-;. This improves thc prccision of the method, since each LDL preparation 
could be oxidized consecutively in triplicate. 
Thc kinetics ofLDL-oxidation wcre followed by continuously 1l1OnitoIÎng the 
change of absOl'bance at 234 lllll. AbsOl'bance curves of LDL-preparations 
obtahlcd fÏ"om six diabetes patients alld two control subjects were detennined 
in parallel. Each LDL-preparation ,vas oxidizcd in three conseclltive oxidation 
runs on the same day; the values shown for rcsistallce time, maximum rate of 
oxidation and maximal diene production arc lllcans of these three values. 
The illtra-assay coefficients of variatioll for resistallcc time and maximum rate 
of oxidation were 2.6% and 3.1%, respectively, upon oxidation of the same 
LDL- samples in duee conseclltive runs on olle day. The inter-assay coefficients 
were 4.9% and 7.4% respectively, and were obtained by dctcnllining the 
oxidation ofLDL-samplcs .&0111 the same sllbjects prepared on different days. In 
every oxidation run anc refcrcnce LDL-sample, prepared fi'Olll a reference 
plasma stored at -80 oe, was used as a control. Oxidation runs with a deviation 
higher than 10% from the valucs of fonner reference measurements were 
omitted. 
By using this stalldardized methad, resistance thne alld maXlll1Um rate of 
oxidation do not differ between LDL prepared fiOIll plasma fi'ozen in liql1id 
nitrogen and that fÏ"OIll freshly collected plasma from the sallle subjcct. In 
addition, no differences in these parallletcrs were found upon storage of plasma 
at -80 oe up to 18 monthU ,.-'J.16. 
The procedure for measuring LDL-particle size was adapted from the method 
described by Mc Namara et al.'7, with the following modifications. Plasma fi'OIll 
cach subject was rapidly thawed, diluted ten times with a physiological salt 
solution and mixed ,vith a solution containing 40% sucrose and 0.1% 
broIllophenol blue. One mjcroliter of this sample was laaded anto the 
applicator of the Pharmacia Phastsystelll containing 4-15% non-denatllring 
pol)'acr)'larniclc graclient gels ancl the appropriatc buffer sttips (pharmacia) ancl 
was sllbjectcd to electrophoresis for 18 hours at 225 V and 15°C. Af ter 
electrophoresis thc gels were silver stained UShlg thc Biorad Silver Stain kit. 
High moleclliar wcight standards (thyroglobnlin (size 17.0 nm) and ferritin (size 
12.2 nm) (Phanllacia)) were used together with a refcrcncc serum containing 
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alpha 2- lnacroglobulin (20.0 lllll) and LDL-particles with a size of 26.0 11111. 
Mter staÏ..lling, the gels \Verc scanned with au LKB Ultrascan 2202 laser 
densitomctcr (Pharmacia). In gcncral, two major LDL-subclasses were observed 
and in SOlllC cases a third subclass could be identified. Thc 1111gration dista11ces 
of thc two lllajor LDL-subclasses were compared \Vith those of the standards 
(ferritin, thl'roglobulin, alpha 2- lllacroglobuIin) anel \Vith thc upper band of the 
reference LDL. The migration distances ofthe two major LDL-bands \Verc useel 
to calculate the LDL-particle sizes. The inter-assay variation for the upper and 
Iower bands of the reference LDL was o. I nl11 and 0.2 n111, respectivcll" The 
electrophoretic patterns were examined independeutll' bl' two examiners to 
assign LDL-subclass phellotypes. LDL-subclass patterns were dcfined as 
phenotype A (major subelass >25.5 nm). phenotypc B (m;tior subcbss <25.5 
n111) or phenotype A/B (intcrmediate phenotype) according to Austin et al.'~·'~. 
Plasma malondialelehl'de concentratiol1s \Verc determined in plasma lipid 
extracts, using I,3-diethyl-2-thiobarbituric acid, cxactly as described by Hoving 
ct a1. 30• 
Routine clinical cllemistry 
The clinical chemistry assays for total serum cholesterol, HDL-cholestcrol and 
triglyceddcs '\vere perfOl'llled on a Hitachi 717 chemistry analyzer bascd on 
commercially available tcchniqlles (Boehringer Malluheim, Maunheim, 
Germany). Tota! serum cholesterol was determil1cd bl' lneans of thc CHOD-
PAP method. HDL-cholcsterol was measurcd aftcr precipitation with sodiUlll 
phosphotungstatc-Mg'+. Triglycerides wcre dctcnnined using thc GPO-PAP 
mcthod. LDL-cholesterol concentrations wcre calculated according the formula 
of Fricdewald1' . Phospholipid conccntrations in LDL were determined using a 
conullcrcially available colour reagcnt (Wako Chemicals, Neuss, Gennanl')' 
One hundred l11icroliter ofLDL-sal11ple (0.25 mg protcin/l111) and 750 ft! colour 
reagent were mixed for 10 minutes at 37°C aud the concentration was 
measured at a wavelength of 500 l1m. The protcill content ofLDL-preparations 
was measured according to Lowry et. aP'. 
HbArc was mcasured by aflinity chromatography (pierce columns, Glyco tcst 
Il) (uppcr limit of norl11al 6.0%)33. Scrum creatinine conccntratÎon were 
measllrcd killctically on the Hitachi 717, as described by JaflèH • Creatinine 
clearance was calculated according to the Cockcroft formulalS . 
Data analysis 
The chi-square test was used to compare frequcncies. Analysis of variancc 
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(ANOVA) was pcrfonncd to test for differences bctwcen groups. In addition 
multiple linear regression analyses were performed to adjust for possible 
conrounders. T\vo-sided P-values S; 0.05 were considered to be statistically 
significant. All analyses were performed using SPSS 6.I.3 for Windows. 
RESULTS 
The clinical characteristics of diabetic patients and control subjects are 
summarized in Table 1. Although there was a tendency in control subjccts for 
a less beneficial lipid profile compared to diabetic subjects, only the difIcrence 
of serum HOL-cholesterol was found to be statistically significant. This 
difièrence could not be attributed to the (;lct, th at the blood sampling of control 
patients was not performed undcr Elsting conditions or to a difference for one 
of the other clinical characteristics. LDL-phenotype did not diftèr between 
diabctic patients and con trol subjects. 
With regard to composition of LOL-cholesterol, thc triglyceride fi'action of 
LOL was significantly increased in diabetic patients comparcd to control 
patients, whilc thc cholesterol ester fraction was fOlllld to bc dccreased. 
Malondialdehyde concentrations alld the snsceptibility of LDL for oxidatioll, 
did not difièr significalltly bctween diabetic patients and control subjccts. These 
resuits were essentially the sallle when diabetic patients, of whom f.lsting blood 
was obtained, were compared with con trol subjects or when patients with 
hypertension were removed fiom thc allalysis. In addition, blood sampling 
cOllditions (f.lsting versus non-f.lsting), the usc oflipid lowering drugs alld anti-
oxidant suppletion or the presence of hypertcnsioll in lOOM patient were not 
associated with any difrèrence in malOlldialdchyde conccntrations or thc 
susceptibility of LDL to oxidation. 
DISCUSSION 
The resuits of this study showed no diffcrcllcc in the vitro susceptibility ofLDL 
betwccn lODM patients alld control sllbjccts. Thcrc was also na diftèrence in 
maxinullll ratc of oxidation, oxidation maxÎmulll alld tv1DA concentrations. 
Although all blood samples of the control sllbjccts werc obtaincd in thc llon-
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Tablc 1. Clinical characteristics of the study poplilation 
lDDM patients Contral group 
Number of patients 281 98 
Age (years) 38.2 (0.7) 38.2 (1.0) 
Men (%) 153 (5404%) 49 (50.0%) 
Body mass illdex(kg/m2) 24.7 (0.2) 25.5 (004) 
Duration of diabetes (years) 17.2 (0.6) n.a. 
Systolic blood pressure (mmHg) 139.1 (1.1) 125.6 (1.0)'" 
Diastolic blood prcssure (mmHg) 82.9 (0.5) 78.1 (0.7)*" 
Currcnt smokers 91 (3204%) 40 (40.8%) 
Number of cigarettesl day 12.9 (1.0) 13.7 (1.5) 
Never alcohol uscrs 109 (38.8%) 33 (33.7%) 
Creatinine clearance (mI/min) 107.0 (1.6) 111.3 (2.6) 
HbA1c (%) 8.27 (0.11) 4.62 (0.06)'" 
Total cholesterol (nllllol/l) 4.98 (0.06) 5.18 (0.10) 
HI)L-cholesterol (nullo1/l) 1.39 (0.02) 1.29 (0.03)' 
LDL-cholesterol (mmolIl) 3.06 (0.05) 3.22 (0.09) 
Triglycerides (11ll1101/1) 1.18 (0.06) 1.37 (0.07) 
LDL-phenotype 
- type A 214 (76.2%) 81 (82.7%) 
- type 13 56 (19.9%) 15 (15.3%) 
- type A/B 11 (3.9%) 2 (2.0%) 
LDL-particlc sizc 
- LDL subclass I (nm) 26.59 (0.03) 26042 (0.05)" 
- LDL subclass 2 (nm) 24.35 0.03) 24.33 (0.02) 
Values are mllllber of patients or means with percentage or standard errors between 
parentheses. n.a.:::: not applicable. 
DitTcrcllce between IDDM patients and control subjccts. af ter adjustment for age and 
gender: * :::: p:O:; 0.05. **:::: p~ 0.01, ***:::: p~ 0.001 
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fasting state and in diabetic patients LUlder f..1sting conditions as well as in the 
non-fasting state, limiting the analysis to subjects with a non-fasting blood 
sample revealed the same associations. In addition, blood sampling cOlldition in 
IDDM patients was not associated with any difference in malolldialdehyde 
concentrations or sllsceptibility ofLDL to oxidation. 
In our study the assays used, are according to international standards and applied 
to an unselected group of diahetic patîents and control subjccts. Although all 
control patients, were c1assified as ASA c1assification category I, indicating no 
ClUTent diseases except the indication for minor surgcly and not using any 
medication, we were surpriscd to find a lcss f.1vourable lipid profile in control 
patients. This difièrence was not assocÎatcd with L1sting conditions or the use of 
lipid lowering medication in fivc of thc IDDM patients. A possible explication 
for this rcsult might be thc diffcrence in diet between IDDM patients and the 
non11al population. 
Table 2. Parameters of lipid peroxidation and LDL composition 
IDDM paticllts Contral group 
MalOlldialdehyde (~llllol/l) 1.52 (0.02) 1.52 (0.02) 
LDL oxidation resistance 
- resistancc time (min) 97.8 (0.6) 96.1 (0.8) 
- maximum rate of oxidation (lllllollmg/ min) 10.6 (0.1) 10.5 (0.1) 
- t11ax die ne production (nmol/mg) 451.1 (2.3) 446.5 (3.9) 
U)L composition (percentage) 
- cholesterol ester 28.5 (0.2) 29.5 (004)* 
- free cholesterol 9.7 (0.1) 9.7 (0.2) 
- phospholipid 25.0 (0.2) 25.0 (0.3) 
- protein 29.1 (0.2) 29.0 (0.3) 
- triglyceride 7.8 (0.1) 6.9 (0.2)*** 
Values are nUlllber of patients or means with percentage or standard errors between 
parentheses. 
Difièrence between IDDM patients and control subjects, af ter adjustment for age and 
gender: *::=: p:5: 0.05, ***::=: p:::::; 0.001 
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Thc results of our study are in contrast with previously rcported results 
regarding the susccptibilit)' of LOL to oxidation"-Q·)f,.-4'\ as weil as for 
nlalondialdehyde concentrations 1,"""', but in agreement with thc results of the 
marc recent studies for botb parameterslO.1,.tl. The differences between these 
studies might result u'om the small sample size of most of these studies (11< 60), 
or from the [lct that in most studies cxamining LDL-oxidation, NIDDM 
patients or a mixture of IDDM and NIDDrvl patients ,vere compared with 
healthy controls'2-Q .J7-J'. The elecrease in oxidatiol1 resistance in these studies ma)' 
thercforc be based on the well-known dimillished resistance to oxidation of 
small LDL-particles, which are common1y fotmd in NIDDM paticntsH • In our 
study no difièrence in LDL-phenot)'pe was f0l1lld between IDDM patients and 
control subjects, while the size ofLDL-subclass I was smaller in controls. 
An other cxplanation might be methodological diflèrences of the oxidation 
procedureI2-Il.J9. Babi)"3 aud his coworkers used ganlllla ray radiation in stead of 
copper to oxidize LDL, while in a stud)' perfonned bl' Gugliucci'~ bath LOL 
anel VLDL wcre oxielized in vitra. Given the absence of a correlation between 
the susceptibility ofLDL and HbAIC leveIlO.", a diflèrencc inmetaboJic control 
seems to be of minor importance. 
Thc stlsceptibility ofLDL to in vitro oxidation is influenced by its anti-oxidant 
cOlltcntll.lJ.H,..Is, and its lipid and f.ltty acid composition2SrI-\,..j.r,,..I7. Although we did 
not nlcasure anti-oxidant concentrations in LOL, we fotllld a small but 
significant difference in LDL-lipidcomposition, between the control sllbjects 
and IDDM patients, which was also reflected in LDL-size. These difièrences, 
however, did not result in a significant difièrencc in resistance time or 
lllaximum rate of oxidation. 
Givcn our findings, one could reject thc hypothesis that oxidative stress is 
illcrcased in patients with insulin-dependcnt diabetes mellitus, but as rcvicwed 
by Giugliano' , there arc man)' other filldings strongly supporting this 
hypo thesis. In diabetes, thc formation of free radicals ma)' be ellhanced by 
increased glucose concentratioll through non-enZ)'luatic glycation of protein 
substrates~~, auto-oxidation of glucose\ activation of protein kinase CS"' and 
illcreased activity of the polyol pathwaySI. In addition, diabetes is known to 
induce changes in the content and activity of cellular allti-oxidant enzymes P ' S6• 
Therefore it is more likely that thc assa)'s used in tlus studie do not reflect 
oxidative stress in IDDM patiellts, properly. In intervention studies with high 
doses of vitamine E (25 mg/da)') or with fish oil (5 g/da)' ) in non-diabetic 
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subjects the susceptibility ofLDL to oxidation, assesed bl' the same methads as 
in Dur studl' was significantly decreased22,..>s. Howevel", for observational studies 
like ours, th is l11ethod nul' not be sensitive enough. 
In concll1sion, the hypothesis that oxidative stress is increased in patients with 
IDDM and Illight be the con1111on patlnvay in the development of 
microvascl1lar complications, is not supported bl' the resnlts of our cross-
sectÎOllal studl', using lllaiondialdehyde and the susceptibilitl' ofLDL to in vitro 
oxidation as parameters of oxidative stress. 
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SUMMARY 
In insulin-dependcnt diabetes lliellitus there is a dear relationship between 
11letabolic control (HbAI c levels) and the development and progression of 
microvascular cOlnplications. Although the pathophysiology of these 
complications is probably multif..1ctorial, oxidative stress through incrcased tissue 
damagc by formatioll of ft'ee radicals, lllight be illvolved in the devclopillellt of 
diabetes complications. We studicd the rele of oxidative stress in thc 
development of these cOlllplications by assessing the susceptibility of LDL for 
oxidation and serum lualondialdehyde concentrations, in a group of 28 r 
patients with insulin-depcndent diabetes nlellitus. 
Fifty-seven patients (20.2%) weIe categorized as havillg nephropathy, 146 
patients (52.0%) as having diabetic neuropathl' and 93 paticnts (33.1%) as having 
diabetic retinopathy. More than twenty-five percent of thc diabetes patients had 
hvo or morc nllcrovascular complications. No significant difference in 
malondialdehyde or oxidatioll resistance was found betwecll patients with or 
without microvascular complications, nor by thc number of nlÎcrovascular 
complications. In addition, nephropathy, retinopathy and neuropathy wcre not 
associatcd with anl' difference in malondialdehl'de level or the snsccptibilitl' of 
LDL oxidation. 
Metabolic control, as asscssed by HbArc was not relatcd to malondialdehyde 
concentrations or to the oxidation rcsistancc of LDL. In contrast glycosylated 
apolipoprotcin B was significantly associated with lagtime (rcgrcssion coefficient 
I.85 min per percent (0.59», but not with malondialdehyde cOllcentrations. 
The rcsults of this cross-sectiollal study do not support a role of oxidative stress 
in the presence of microvascular complicatiolls in patients with insulin-
dependent diabetes mellitus, at least not when assessed by the susceptibility of 
LOL to in vitre oxidation or malondialdehyde cOllcentratÎon. In addition, \ve 
could not confirm a direct association between these parameters of lipid 
pcroxidation and HbArc. 
Submitted as: J.H. Assink, R.P. Stolk, D.E. Grobbee, A.F. Casparie, H.G.T. Nijs, H.M.G Princen, 
C].A. Doelm:m, H.].G. Bilo. Lipid pcroxidation :md microvascubr complicatiollS in insulin-
dependent diabetes mellihls . 
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INTRODUCTION 
In insulin-dependent diabetes mellitus (IDDM), there is a dcfinite relatiollship 
between the level of mctabolic control (HbArc levels) and the development 
and progression of diahctic microvascular complications'. Thc mechanisllls hy 
which this lack of glycacmic control predisposes to the developlnent of diabctic 
complications are incompletely understood. Despite intensive treatment alld 
strict metabolic control, a number of patients still devclops microvascular 
complicatiol1s"'. 
A recently proposed lllechanism, which might be responsible for microvascnlar 
complications, is bascd on tissue damage induced by frec radicals. This damage 
could occur in case of a dis tm-bed balance between thc fonnation of frcc radicals 
and the anti-oxidants defence systcms acting against it (oxidative stress). Since 
oxidative strcss is not exclusively related with hyperglycaemia\ but is also 
influcnced by other factors like dietary factors (the intake of anti-oxidants) or 
hcrcditary L1ctors (regulation of enzymatic anti-oxidants) it may account for the 
developmcnt of microvasc111ar complications l1llder strict metabolic control. 
The susceptibiIity ofLDL to in vitro oxidation has recently bcen proposed as a 
parameter of the response of LDL to in vivo oxidative stress, which is thought 
to occur within thc matrix of the vcssel wall, close to thc endothclil1m~. 
Whereas tbc resl1lts of the association between diabetes lllellitus and in vitro 
susceptibility of LOL to oxidation are inconclusive4~s, concentrations of 
malolldialdchydc, a marker of generallipid peroxidation, have been found to be 
increased in diabetic paticnts1• We studicd the relationships bchveen the 
susccptibility of LDL for oxidatÎon, malolldialdehyde concentrations, alld 
metabolic control as weil as the prevalcllcc of microvascular complications in 
IDDM patients. 
PATIENTS AND METHODS 
Study popttlatioll 
The present stud)' was conducted at the outpatient clinic of thc 'De 
Weezenlanden' hospital in Zwolle, a middlc-sizcd town in thc eastern part of 
The Netherlallds. FrOluJanuary 1995 to January 1996,293 consecutivc IDDM 
patients were invitcd to partîcipatc in thc study. TI)DM ,vas dcfined as the start 
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of insulill tllerapy beforc the age of 30 years within 6 nlOnths af ter diagllosing 
diabetes lliellitus, or thc absence of C-pcptide secretion. Twelve patients rcfused 
to participate in the study, sa the prcscnted results arc based on thc rctuaining 
28 I patients. The study protocol was approved by the hospital medica! ethica! 
conllllittce and all paticnts gave thcir informed conscnt. 
Measurenlcnts 
Patients were examincd according to a standardizcd protocol by onc traincd 
physician. Smoking habits, and used medication, including fi-equcncy of 
Îl~ections were recorded. Blood pressurc measuremcnts were performcd aftel' 
five and seven minutes of rest in the supine position using a precalibrated 
standard lllcrcury sphl'gmomanometcr. The mean of the two measuremcnts 
was used in the analysis. Hypertension \vas defined as sl'stolic blood pressure of 
140 mmHg or over and/or diastolic blood presslue of 90 mll1Hg or ovcr'). 
Patients who were treated with antihypcl'tensive mcdication were also 
considered hl'pcrtensive. 
Blood sampling was perfonued af ter 30 minutes rest in the supine position. In 
122 diabetes patients (79 malcs, 43 females) blood sampling was perfonlled 
undcr Llsting conditions, bef are thc morning dose of insulin was administCl'ed. 
As tllost participatÎllg patients livcd at some distance fi'om the hospital, thc 
blood samples of the other 159 diabetcs patients werc collected af ter their usual 
nlOrning insulin dose and llormal breakf.lst. The blood samples to be used for 
LDL-oxidation and detenllination of malondialdehl'de, werc collected in 
EDTA Vacutaincr tubes, placed on ice inlll1cdiatcly and cooled to 4°C. Plasma, 
preparcd for the dctermination of malondialdehyde, was protected against 
oxidatioll by additioll of 2 mg/ml reduced glutathionc and 1.2 mg/ml butylated 
hl'droÀ'ytoluene (final concentrations) as weil as bl' flushing the empty space of 
the tubes with nitrogcn. Except for the routine clinical chemistry, all blood 
samples wcre stored at -80°C. The entire blood processing procedure was 
completed within one hour. 
The procedure for preparation and lipid peroxidation ofLDL was adapted fi'om 
the lncthod as dcscribed by Esterbauer et aL'O with modifications as described 
previollsll'",'2. Bricfly, fi'om each subject 2 mI of frozen plasma was rapidly 
thawed and used for isolation of LDL bl' ultraccntrifugation at 4 oe in thc 
presencc of 10 ~LM EDTA. Ta m.Î.llimize the tune bctween isolation alld 
axidation and ta prevcnt the 10ss of lipophilic allti-oxidants'J, LDL was not 
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dialysedTl •'2"-l-. By omitting dialysis a more stabJe LDL-preparation is obtaincd, 
which call be stored in the dark at 4 oe under nitrogen for several days without 
affecting resistance tÎllle (lagtÎIlle) and nlaximum rate of oxidation (propagation 
rate)''i. This improves the precision ofthe method, since each LDL-preparatioll 
could be oxidized consecutivell' in triplicate. 
The killCtiCS of LDL-oxidation was followed by cOlltinuousIl' monitoring the 
change of absOl'bance at 234 llln'Q.'2. Absorbance curves of LDL-preparations 
obtained fiom six diabetes patients were detennilled in parallel. Each LDL-
preparatioll was oxidized in tluee consccutÎve oxidation runs on the same dal'; 
the values shown for resistance time, maxÎmum rate of oxidation and maxima} 
diene production are means of these tluee values, 
Thc intra-assay coefficients of vatiation for l'csistance time and nl.'LxÎmulll rate 
of oxidation wcre 2.6% and 3.1%, respectivcll', upon oxidation of thc same 
LOL-samples in duee consecutive runs on one day. The inter-assal' coefficients 
were 4,9% alld 7.4% respectivcll', and were obtained by determinillg the 
oxidation of LOL-samples fiom the same subjects prcpared on different days. In 
every oxidation run one reference LDL-sample, prepared &om a reference 
plasma stored at -80 oe, was uscd as a coutrol. Oxidation runs with a deviation 
higher thall 10% &Oln the values of former rcference measuremcllts wcre 
omittcd. 
Dy USÎllg this highly standardized method, resistance time and maximum rate of 
oxidation do not differ between LDL preparcd from plasma ti'ozen in liquid 
nitrogen and that from fieshly collected plasma trom the sanle subject. In 
addition, no differenccs Îll these parameters \vere fot11ld upon storage of plasma 
at -80 oe up to IS month"· I2 •I 'i. 
The procedure for lneasurillg LDL-particle size was adapted from the mcthod 
described by Mc Namara et aLIG, with the following lllOdifications. Plasma &om 
each subject was rapidly thawed, diluted tcn times with a phl'siological salt 
solntion and mixed with a solution containing 40% sucrose and o. r% 
bromophcnol blue. One microliter of this sample was loaded onto thc 
applicator of the Pharmacia Phastsystcul containing 4-15% nondenaturing 
polyacrylamide gradient gels and the appropriatc buffer strips (phannacia) alld 
was subjected to clectrophoresis for 18 hours at 225 V and IS oe. Aftel' 
electrophoresis thc gels werc silver stained USÎllg the Biorad Silver Staill kit. 
High molecular \veight standards (thl'roglobulill (size 17.0 11m) and ferritin (size 
12.2 nm) (phannacia)) were used together with a rcfcrence scrum containing 
aipha 2- macroglobulin (20.0 nm) alld LDL-particlcs with a size of 26.0 nm. 
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Aftel' staining, the gels were scanned with an LKB Ultrascan 2202 laser 
densitometer (Pharmacia). In general two lll~or LDL-subclasses were observed 
and in SOllle cases a third subclass could be identified. The migration distances 
of the two m~or LDL-subclasses were compared with those of the standarcls 
(ferritin, thyroglobulin, alpha 2- macroglobulin) and with the upper band ofthe 
reference LDL. The migration distances ofthe two lnajor LDL-bands were l1sed 
to calculate the LDL-particle sizes. The inter-assay valiation for the upper and 
lowcr bands of the reference LDL was 0.1 nm alld 0.2 I1m, respectiveIy. The 
e1ectrophoretic patterns were examined illdependently by two examiners to 
assign LDL-slloc1ass phenotypes. There was never a disagreeluent between the 
two examiners assigning LDL-subclasses. LDL-subclass patterns were defined as 
phenotype A (major subelass >25.5 nm), phenotype B (major subelass <25.5 
mn) or phenotype AIB (intennediate phenotype) according to Austin et al. '7,ls, 
Plasma malondialdehyde concentrations were detennined in plasma lipid 
extracts, using I,3-diethyl-2-thiobarbitwic acid, exactly as described by Hoving 
et al,'9. 
Routine clhlÎcal chemistry 
The clinical chemistry assays for total serum cholesterol, HDL-cholesterol and 
triglycerides were performed on a Hitachi 7 I 7 chemistry analyzer based on 
conllllercially availablc techniques (Boehringer MannheÎ1n, Mannheün, 
Germany). Tota! serum cholesterol W.1S cletermined by means of the CHOD-
PAP method. HDL-cholesterol was llleasured aftel' precipitation \vith sodium 
phosphotungstate-MgH • Triglycerides were dctermined using the GPO-PAP 
method. All obtained from lloehringer Mannheim. LDL-cholesterol 
concentrations were calculated according the formula of FriedewaldB • 
Phospholipid concentrations in LOL were detennined using a commercially 
available colour reagent (Wako Chemicals, Neuss, Germany). One hundred 
microliter ofLDL-sample (0.25 mg protein/ml) and 750 fil colour reagent were 
nll.'Xed for 10 minutes at 37°C and the concentration was ll1easured at 500 11111 
wavclength. The protein content ofLDL-preparations was llleasured according 
to Lowry2l. Apolipoprotein A-I, apolipoprotein TI and lipoproteill[a] \Vere 
detennined by conullercially available illlll1unochell1istry techlliques on the 
Beekman Array Analyzer (I3eckman, Fullerton, California). 
Metabolic control was assessed by measuring glycosyIated haemoglobin AIC 
(HbAIC) and glycosylated apolipoprotein B. HbAIC was measured by affinity 
chromatography (Pierce columns, Glyco test II) (upper limit of llormal 6.0%) 22. 
Glycosylated apolipoprotcin 13 (as percentage of total apolipoprotein 13) was 
Chaptcr 5 
deterlllined, according to PantheghÎni~J. 
Plasma vitamin A (retinol), beta-carotenc and vitalllin E (alpha-tocopherol and 
ganuna-tocopherol) were detcnnined according ta Za man et al. -4, with the 
following modifications: instcad of a programmabic UV-VIS detector, a 996 
Photo Diode Array Detector (Waters Associates, Milford, USA) was used, and 
in thc extraction procedure mcthanol and hexane wcrc nsed instead of ethanol 
and hcxane. To prevent oxidation of thc tocophcrols during the extraction 
procedure, butylated hydroxytolueue (BHT), pyrogallol, vitamin C oud EDTA 
were added. Trallsferrin, uric acid and ceruloplasmin wcre determined 
according to routine procedure inllllunonephclometrically on an Array 
inunune analyzcr (Beckman, Fullerton, California). FerritÎn was routinely 
analysed with the ferritin Enzymun test on thc ES 607 analyzer (Boehtingcr 
Mannheim, Ivlannheim, Germany). 
In twenty-four hour urine samples, collected by the patients the day before their 
outpatient visit, albumin was llleasured, using an Înullunoncphelometric 
techniquc on the Array immune analyzer (Becktnan, Fullerton, California). 
Urinary albumin excretion ratc (UAEH .. ) was calculatcd and divided into three 
catcgories: norlllo-albuminuria: UAEll <30 mg/24h; micro-albuminuria: 30 
mg< UAER <}oo mg124h; macro-albuminuria: UAER >300 mg124h. Seven 
paticnts with nonllo-albuminnria and fourteen patients with micro-alblllninuria 
used ACE-inhibitors. Thc hospital files showed that in all patients thc indicatioll 
for this trcatment was repeatedly proven albuminuria of over 100 lllg/24h. 
Thereforc, these patients were categorized as macro-albuminuric. Serum as weIl 
as urinc creatinine conccntri1tions were ll1easured kineticallyon thc Hitachi 
717, as described by Jaffé ~5. Creatinine clearance rate ,vas calculated according 
to the Cockroft for111ula16• 
In order to asscss the degree of diabetic retinopathy the cxal11ination included 
direct alld indirect ophthall11oscopy through dilated pupils by an expericnced 
ophthalnlOlogist. Retinopathy was graded according to national standards in 
three categories: na retinopathy, background retinopathy and pre-/ proliferative 
retinopathy'7. 
Neuropathy was assessed by vibration threshold measurelllcllt using a SOl11edic 
vibrameter type IV and by sensibility-tcsting using lllOnofilanlellts accol'ding to 
Selllllles-Weinstein (l11onofilamcnts hy Gillis W Long, Hansons Discase Centre, 
Carreville, USA). The vibration threshold was detennined according to a 
stalld1rdized procedure at six test sites: thc dorsomedial aspect of thc first 
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Table I. Clinical characteristics of the stud)' population 
Number of patients 
Agc (years) 
Duration of diabetes (years) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mm1--:lg) 
Hypertension 
Current smokers 
NUlllber of cigarettesl day 
Frequency of insulill iqjections 
- 2 or 3 times a day 
- 4 times a day 
- CSll/ CIPll 
Creatinine clearance (mI/min) 
HbAlc(%) 
Glycosylated apolipoprotein B (%) 
Total cholesterol (nllnolJl) 
HDL-cholesterol (m01oI/l) 
LDL-cholesterol (mmo1/l) 
Triglycerides (mmoI/l) 
Apolipoprotcin A (lllg/l) 
Apolipoprotcin B (lllg/l) 
Lipoprotein [a] (lllg/l) 
Udc Acid (mmo lil) 
Alpha-tocophcrol Ünllol/I) 
Ganuna-tocopherol (Junol/l) 
Beta- carotene (mno1l1) 
Retinol (JunolJl) 
Ceruloplasmin (gil) 
Ferritin (lIg/I) 
Transferrill (gil) 
Total group 
281 
38.2 (12.4) 
17.2 (10.7) 
139.1 (18.4) 
82.9 (8.3) 
110 (39.1%) 
91 (32.4%) 
12.9 (9.0) 
34 (12.1%) 
175 (62.3%) 
72 (25.6%) 
107.0 (27.1) 
8.27 (1.90) 
3.07 (0.91) 
4.98 (1.01) 
1.39 (0.37) 
3.06 (0.86) 
1.18 (0.99) 
1.38 (0.25) 
0.89 (0.24) 
125.6 (179.4) 
0.25 (0.06) 
31.34 (9.37) 
2.99 (1.80) 
324.8 266.9) 
1.83 (0.69) 
0.38 (0.14) 
92.7 (89.5) 
2.24 (0.40) 
CSII= continuous subclItancous insulin iufusion. CIPII::::: contilluous intra-peritoneal 
illSulin infilsion. Values are number of patients or meallS with percentage or standard 
deviations bet'.yeen parentheses. 
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metatarsal bone, the flat surL1cc just above the media} mallcolus and the dorsunI 
ofthe metacarpal bone ofthe index finger for bath the left and right side ofthe 
body. Vibration measuremcnt was defined as abnonnal whcn one of thc 
measurel11ents was two standard deviations above the refcrcncc ;valne for agc 
and localization. Sensibility-tcsting ,vas perfOrtlled at five rcgions on both legs 
and c1assified as abnormal whcn in one of the region pressUl'c of lllOnofilament 
5.07 was not feles, Peripheralncuropathy was defined as at least one abnormal 
vibration measurement or sensibility test-result. Scverity of periphcral 
neuropathy was gradcd as thc nmllber of abnonnal tests. 
Data analysis 
Table 2. Parameters oflipid peroxidation, LDL-phenatypes and LDL-particle 
sizc, specified by gen der 
Men Women Total group 
MalOlIdialdehyde unnol/1) 1.54 (0.32) 1.50 (0.27) 1.52 (0.30) 
LDL particle size 
- LDL 1 (nm) 26.6 (0.5) 26.6 (0.5) 26.6 (0.5) 
- LDL 2 (nm) 24.4 (0.5) 24.3 (0.4) 24.4 (0.5) 
LDL-phcnotypc 
- type A 121 (79.1%) 93 (72.7%) 214 (76.2%) 
- type A/B (intermediate) 25 (16.3%) 31 (24.2%) 56 (19.9%) 
- type B 7 (4.6%) 4 (3.1%) 11 (3.9%) 
LDL-composition (percentage) 
- cholesterol ester 29.2 (3.6) 27.7 (3.4)'" 28.5 (3.6) 
- free cholesterol 9.6 (2.1) 9.8 (2.3) 9.7 (2.2) 
- phospholipids 24.6 (3.0) 25.4 (2.3)' 25.0 (2.8) 
- protein 29.3 (2.5) 28.9 (2.7) 29.1 (2.6) 
- triglycerides 7.4 (1.9) 8.2 (2.1)'*' 7.8 (2.0) 
Ll)L-oxidation rcsistancc 
- lag time (min) 97.1 (8.6) 98.7 (9.3) 97.8 (9.0) 
- propagation rate (lllllol/mg/mill) 10.6 (1.3) 10.5 (1.3) 10.6 (1.3) 
- lllax diene production (nlllol/mg) 449.9 (38.0) 452.4 (39.0) 451.1 (38.4) 
Valucs are number of patients or llleans with percentage or standard deviations 
between parentheses. Dillèrence between men and women; 
* = p::::; 0.05, ***= p:::'; O.OOI 
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Table 3. Parameters of lipid peroxidation: thc association with serum lipids 
alld LDL-composition. 
LDL-oxidatioll 
MDA Lag timc Propagation rate Maxima! diene 
Senllll lipids 
- Tota! cholesterol 0.31* -0.10 0.04 0.02 
- HDL-cholesterol 0.16* 0.07 0.11 0.21* 
- LDL-cholesteroI 0.14* -0.06 0.05 0.05 
- Triglycerides 0.40* -0.16* -0.12* -0.25* 
- Apolipoprotein A 0.28* 0.01 0.01 0.06 
- Apolipoprotein 13 0.15* -0.09 0 -0.07 
- Lipoprotein [aJ 0.02 -0.08 -0.03 -0.02 
LDL-composition 
- cholesterol -0.01 0.02 0.15* 0.21* 
- frcc cholesterol -0.05 0.11 0.05 0.06 
- phospholipids -0.01 -0.06 0.08 0.15* 
- protcin -0.02 -0.18* -0.17* -0.37* 
- triglycerides 0.12 0.16* -0.20* -0.16* 
MDA= MalOlIdialdehyde concentr;ltion. Values are partial corrclation coefficictlts after 
adjustmcnt for age, L1Stillg conditions and gender. *= p:S; 0.05 
Table 4. Parameters of lipid peroxidation: the association with Jllti-oxidallts 
LDL-oxidatioll 
MDA Lag time Propagation rate Maxima! dienc 
Allti-oxidallts 
Vric Acid 0 -0.13* -0.18* -0.22* 
Alpha-tocopherol 0.13* 0.11* 0.21* 0.32* 
Gamma-tocopherol -0.01 0.06 0 0.08 
Beta-carotene 0.16* -0.02 0.05 0.10 
Retinol 0.12* -0.11* -0.14* -0.16* 
Ceruloplasmin -0.004 -0.05 -0.08 -0.23* 
Ferritill 0.04 -0.15* -0.02 -0.03 
Transferrin 0.11 -0.07 -0.01 -0.11 
.MDA= Ma!ondialdehydc concentration. Values are partial corrclatioll cocfficicnts after 
adjustmcl1t for age, gender alld triglycctide concentrations. *= p:S; 0.05 
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Table ). Association between parameters oflipid peroxîdation and diabetes complications 
Neuropathy Ncphropathy Rctinopathy Any microvl$cubr complication 
absent present absent present absent prc'Sent absent present 
Malondialdehyde (mmoI/I) 1.51 (0.03) 1.54 (0.03) 152 (0.02) 1.54 (0.05) 1.53 (0.02) 1.51 (0.03) 1.51 (0.03) 153 (0.02) 
LDL-oxidatian 
lag time (min) 97.8 (0.7) 975 (0.8) 98.0 (0.6) 97.1 (1.3) 98.6 (0.6) 96.3 (1.0) 97.7 (0.9) 97.7 (0.7) 
propagation rate (nmo1!mgJmin) 10.8 (0.1) 10.4 (0.1) 10.6 (0.1) 10.4 (0.2) 10.6 (0.1) 10.5 (0.1) 10.8 (0.1) 105 (0.1) 
ma..ximal diene (nmo1!ml/mg) 454.5 (3.6) 448.7 (3.0) 453.6 (2.5)' 441.6 (5.7)' 451.8 (2.9) 449.6 (4.1) 454.4 (4.3) 450.1 (2.8) 
LDL-composition (percent.tge) 
- cholesterol 28.3 (0.3) 28.7 (0.3) 28.4 (0.2) 28.9 (05) 28.4 (0.3) 28.6 (0.3) 28.2 (0.3) 28.7 (0.3) 
- free cholesterol 9.8 (0.2) 95 (0.2) 9.7 (0.1) 9.6 (0.3) 9.8 (0.2) 9.6 (0.2) 10.0 (0.2) 9.5 (0.2) 
- phospholipid'\ 25.3 (0.2) 24.6 (0.2) 25.1 (0.2) 24.4 (0.5) 25.0 (0.2) 24.9 (0.3) 25.4 (0.2) 24.7 (0.2)' 
- protein 28.9 (0.2) 29.3 (0.2) 29.0 (0.2) 29.3 (0.4) 29.1 (0.2) 29.1 (0.3) 28.9 (0.2) 29.2 (0.2) 
- trigIyceridc'S 7.7 (0.2) 7.8 (0.2) 7.8 (0.1) 7.8 (0.3) 7.7 (0.2) 7.8 (0.2) 7.5 (0.2) 7.9 (0.2) 
Values arc means with stand:lrd errors benveen parenth(.'Ses. Difference betwcen patients with :md without diabetic camplication. af ter adjustment far age and 
gender: *= p <0.05 
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The chi-square test was used to compare fi-equcncies. Analysis of variance 
(ANOVA) was perfonned to test for differences between groups. In addition 
multiple regressioll analyses were perf01111ed to adjust for confounders. Partial 
corrclation coefficicnts were calculated to describe the rclations between 
paralIleters of lipid per oxidation and serum lipids or anti-oxidallts. For serum 
triglyceride and LDL-cholesterol concentratiolls additional calculatious were 
perfonned limitillg the analyses to subjects of wh01n f."lsting blood samples were 
obtailled. Two-sidcd P-values S; 0.05 were cOllsidered to be statistically 
significant. All analysis were perfonlled using SPSS 6.I.3 for Windows. 
RESULTS 
The clinîcal characterîstics of the study popldation are shown in Table I. Table 
2 summarizes thc parameters of lipid peroxidation, serum lipid concentrations, 
LDL-phenotypcs and LDL-COluposition. Malolldialdehyde concelltratiolls were 
sigllificantly associated with the susceptibility of LOL for oxidatioll (regression 
coefficients for lag tune -0.004 ~tmol/l per min (SEM 0.002) and for propagatioll 
rate -0.02 flJ11oll! pcr nmollmg/mlll (0.01)). Lag tllnc was associated with 
propagation rate (regression coefHcient -I.59 min per llmol/mg/min (0.42», as 
was propagation rate with tbe maximal dielle production (regression coefficient 
0.03 nmolhng/min per lllnolJmg (0); pS; 0.05, both after adjllstment for age, 
and gender). 
No relationship was found between .MDA levels or the susceptibility of LDL 
for oxidation and gender, f<lsting cOllditions, blood pressllrc or hypertension. 
Malondialdehyde concelltrations ,vere significantly associated with age 
(regression coemcient 0.003 ~llnol/l per year (0.001». Smoking, duration of 
diabetes or frequellcy of insulin administration werc al50 not associatcd with the 
parameters of lipid peroxidatioll. 
Metabolic control, as assessed by HbAI c was not related to malondialdehyde 
con centra ti ons nor to the oxidation resistance of LDL. Glycosylated 
apolipoprotein TI was significantly associated with both lag time (regression 
coefficient 1.85 min per percent (0.59)) and maximal diene production (5.46 
1l1ll0lJmg per percent (2.58), but not with lnalondialdehyde concentrations. 
Malondialdehydc concentrations were significantly associated with ll105t senlm 
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lipids, but not with LDL-COlllposition (TabIe 3). Oxidation resistance was 
associated ,vith sermll triglyceride levels, the triglyceride fraction of the LDL-
cholesterol as ,vell as the protein fi-action of the LDL-composition. Both 
malondialdehyde concentrations and oxidation resistance were not associated 
with particle size nor with LDL-phenotype. Table 4 summarizes the associations 
betwecn scnUIl anti-oxidants and the parameters of lipid peroxidation. 
Malondialdehydc was significantly correlated with alpha-tocopherol, beta-
carotenc as ,vell as with retinol. Oxidation resistance \vas significantly correlated 
with alpha-tocopherol, retinol, ferritin and uric acid concentrations. These 
results were essentially the same af ter adjustment for body mass index, total 
cholesterol, HDL- or LDL- cholesterol or metabolic control. 
Ninety-three patients were categorized as having diabetic retillopathy (of them 
27 (29.3%) with pre- or proliferative retillopathy), 57 patients as having 
nephropathy (32 (56.1%) patients using an ACE inhibitor or having l11acro-
albuminuria), and 146 patients as havillg diabetic neuropathy. Sixty three 
(43.2%) of these patients had 2 abnonnal tests. No significant difièrencc in 
lnalondialdchyde or oxidation resistancc was found between patients with or 
without lllicrovasclllar cOlllplications nor with the number of microvascular 
complicatiol1S (Table s). In addition, nephropathy, retinopathy and ncuropathy 
were not associated with malondialdehyde level or the susceptibility ofLDL for 
oxidation. No trend was found showing shorter lag tinle with illcreasing 
severity of nephropathy and neuropathy. These results were cssentially the same 
after adjustment for serum anti-oxidants. Rcnal function as assessed by 
crcatinine clearance was also not associated with any of the parameters of lipid 
peroxidation. 
DISCUSSION 
The rcsults of this study show that nephropathy, neuropathy, retinopathy, as well 
as lllicrovascular cOlnplicatiollS in general, were not associated with the 
susccptibility of LDL for oxidation or malondialdehyde concentrations. There 
was also no association with duration of diabetes or HbAIC. In contrast, 
glycosylated apolipoprotein D, was related to oxidation resistance. Most serum 
lipids were weakly correlated with malondialehyde concentrations. LDL-
oxidation resistance was weakly correlated with senUll triglyccride concentrations 
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as weIl as with the triglyceride and protein fraetion of LDL-cholestcrol. 
The laboratory assays used in our study are aceording to international standards 
and applied to an unsdected group of diabetie patients and control subjeets. 
Although most blood samples were obtained in thc non-L1sting state, adjusting 
for the L1sting eondition or limiting the analysis ta subjcets with a fasting blood 
sample rcvealcd the same associations. 
Most of thc results dcseribed in th is article arc in agreemcnt with thc results of 
other studies performcd in diabetie paticnts, both for malondialdchydc'')-JI as 
weIl as for susecptibility ofLDL oxidationP •P -H , also not showing an assoeiation 
between lipid peroxidation parameters and diabctie complieations. Thc 
diftèrent results as rcportcd for malondialdehyde by other studicSlH7 rcgarding 
its re1ationship with HbAle or the presenee of albuminuria may bc rclatcd to 
thc slllal! sample si ze in most of thcse studies (n<70), together with thc L1ct that 
in same studies a eombination of IDDM anel NfDDM were comparcd with 
healthy controls. Also methodologieal diffèrences of the oxidation procedure 
might play a role. 
As revie\ved by GuillanoJ there are many pathways by which hyperglycaemia 
cDuld lead to an increased formation of fi-cc radicals. Proposed mcchanisllls 
indude all inereased influx of substrates through the polyol pathway, protcin 
glycation produetsl~ alld glucose itselfby auto-oxidationJ<J,+o. The absence of an 
association in oul' study betwecll the used parameters oflipid pel'oxidatioll alld 
HbArc, is in accordance with thc findings of smaller studies+·',15, In contrast, 
glyeosylated apolipoprotein B, was fOllnd to be positively related with oxidation 
resistanec, rathcr indicating that glyeosylation protccts LDL fi'om in vitro 
oxidation. This finding was al50 reportcd in NIDDM paticnts7 and might bc 
explained hy thc L1Ct that, fi'ee glucose molecules havc bcsidcs thc prcviously 
stated pro-oxidant propcrties, anti-oxidant propertics by aeting as a fi-cc radical 
scavengertl , It thcreforc likcly that glucose or furthel' glueose-ulctabolites 
covalcntly bOlll1d to thc lipoprotcin particles might also act as a frce radical 
scavcnger. 
Although thc pathophysiology of mierovascular complications is probably 
multiE1ctorial; rcsults of in vitro-P, an.imalH , -H, and hu man studiesU suggest that 
oxidative stress lnay be involved in their ctiology. Howcvcr, LDL-oxidation 
and malondialdchydc concentrations were not associatcd with thc prescllcc of 
microvascular eomplieations. 
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Considering the limitations of a cross-sectional study, therapy directed against 
thc progression of these microvascular camplicatians may be an explanatian far 
the absence of these relations. Far example certain ACE-inhibitors have been 
shown to exhibit anti-oxidant properties. In addition paticnts with 
microvascular complications may be more Iikely to change their life style to a 
more 'healthier' wal' of living, e.g. using vitamin supplements. Although \ve 
can not exclude this effects, we found no difference in lipid peroxidatian 
parameters comparing the patients with micra- or macra-albulllinuria, ming 
ACE-inhibitors and those without medication. The reported usc of anti-
oxidants supplements was fotmd to be equally distributed across the different 
subgroups (data not shown). In addition, no difièrence was found for 
neuropathy, a complication most patients arc unawarc of its prcsence. 
Given our results one could rejcct thc hypothcsis, that oxidative stress, induced 
by hyperglycaclllia, couJd be thc final can11110n patll\vay in the development of 
lllicroangiopathy. Howcvcr, as rcviewcd by Guilland, other findings strongly 
support the role of dus lllcchanism in the development of microvascular as well 
as macravasclliar cOlllplications. Therefare it is more Iikely that the assays med 
in dus study are not reliable estimates of oxidative stress in IDDM paticnts. This 
view is supported by the ['let that în smokers oxidative stress was also not fannd 
ta be increased, while there is strong evidence that slllOking is associated with 
an increased axidative 11l0dification ofbiological nlOlcclllcs in vivo-j.('. 
In conclusion, thc hypothcsis that oxidative stress is the common pathway hl' 
wluch hyperglycacnua causes microvascular comp1îcations is not supportcd by 
the resllits of this cross-sectional study, using malondialdehydc-lcvcls and the 
susceptibility of LDL to in vitro oxidation as parameters of oxidativc stress. We 
could not disclose a direct relationship between lllctabolic control and oxidatÎve 
stress, assessed by malondialdehyde conccntration and susccptibility of LDL to 
in vitro oxidation. In addition, thcse two parameters appeal' not to differ 
betwecn paticnts with and without nucrovascnlar complîcations. 
Lipid peroxidation and microvascular complications 
REFERENCES 
The Diabetes Control and Complications Trial Research Group. The eflèct of inten-
sive treatment of diabetes on thc dcve10pmcnt and progression ofIong-tenn compli-
eations in insulin-dcpendent diabetes lllellitus. N Engl] lvled 1993;.129:977-986. 
2 Klein R, Klein BEK, Moss SE. Relation of glycemic control to diabetic lllicrovas-
cular eompIications in diabetes mellitus. Ann Intern Nled 1996;124:90-96. 
3 Giugliano D, Cericllo A, Paolisso G. Oxidativc stress and diabetic vascular compli-
catÎons. Diabetes C.1re 1996;9:257-267. 
4 Jcnkins AJ, Klein RL, Chassereau CN, Herlllayer KL, Lopes-Virella !vlE LDL 
fiom patients with well-controlled rDDM is not more sllSceptible to in vitro oxi-
dation. Diabetes 1996:45:762-767. 
5 Tsai EC, Hirsch IB, BflinzellJD, Chait A. Redueed plasma pcroxyl radieal trap-
ping capacity and increased sllSceptibility ofLDL to oxidation in poorly controlled 
IDDM. ])i,1betes I994;43:IOIO-IOI4. 
6 Rabini RA, FlIlllelli P, Galassi R, Dousset N, Taus M, Fcrrctti G, Mazzanti L, 
Curatola G, Solera .ML, Valdiquie P. Increased slisceptibility to lipid oxidation of 
low-density lipoproteins and erythrocyte membranes fiom diabetic patiellts. 
Nletabolism 1994;43:I470-I474. 
7 Babiy AV, GebiekiJM, Sullivan DR, \Villey K. Inereased oxidizability ofplasma 
lipoproteins in diabetic patients ean be decreased by probucol therapy and is not 
duc to glycation. Bioehem PharmJeo! I992;43:995-1000. 
8 Gugliucci A, Menini T, Stahl AJC. Suseeptibility to coppcr-enhanced autoxidation 
of VLDL+ LDL fractions fiom diabetic patients. Biochem Mol Biol Inter 
1994;]2:T39-T47· 
9 American Diabetes Association. Treatlllent ofhypcrtension in diabetes. Diabetes 
Care I993;16:I349-I401. 
10 Esterbaucr H, Striegl G, PuhI H, Rotheneder M. Continuous monitoring of in 
vitro oxidation of hUlllan low density lipoprotcin. Free Radie Rcs C01ll1IlS 
1989;6:67-75· 
11 Prineen HMG, Van Duyvenvoordc \V, Buytenhck lt, Van der Laarse A, Van 
Poppel G, Gevers Leuven JA, Van Hinsbergh VWM. Supplementation with low 
doses vitamin E protects LDL fiom lipid peroxidation in men alld women. 
Aterioscler Tmmb \fase Bio] 1995;I5:.125-333. 
12 Princen HNlG, Van Poppel G, Vogelczang C, Buytenhck R, Kok FJ. 
Supplementation \vith vitalllin E but not beta-carotene in vivo protects low densi-
t)' lipoprotein from lipid peroxidation in vitro. Eflèct of cig,lrette smoking. 
Artlleriosc1cr Thromb I992;12:554-562. 
13 Scheek LM, WisemJn SA, Tijburg LBM, Van Tol A. Dialysis of isolated low den-
sity lipoprotein induces a loss of lipophilic antioxidants alld increases susceptibility 
to oxidation in vitro. AtheroscJerosis I995;[[7:I39-144. 
88 
Chapter 5 
I4- Hau M-P, Smelt AHM, Bindels AJGH, Sijbr,1I1ds EJG, Van der Laarse A, 
Onkcnhout W, Van Duyvenvoordc Vi, Princcn HMG. Effects of fish oil on oxi-
dation resistallce of very 10\v dcnsity lipoprotein in hypcrtriglyceridcmÎc patients. 
Artcrioscl Tromb Vasc Biol 1996;16:II97-1202. 
IS Brussaard HE, Gevers LcuvenJA. Kluft C, Krans HM], Van Duyvenvoordc \V, 
Buytenhek R, Van der Laarse A, Princen H1v1G. Effèct of 17 beta-estradiol on 
plasma lipids and LDL-oxidation in postmenopausal ,vomen with type 2 diabetes 
mellitus. Arteriosclcr Thromb V~!Sc Biol 1997;17:324-33°. 
16 McNam,1filJR, Campos H, OrdovasJM. PetersonJ, Willon P\VF, Schaefer EJ. 
Effect of gemIer, age and lipid status on low densit), lipoprotein subfraction distri-
bution: Results from the Framillgham offipring study. Arteriosderosis 1987;7:483-
490. 
17 Austin lvlA, King M-C, Vranizan KNl, Kr,Hlss RM. Atherogenic lipoprotein phe-
notype. A proposed genetic marker for coronary heart disease risk. Circuhtioll 
199°;82:495-5°6. 
IS Austin MA, Brcslow JL, Hennckens CH, Buring JE, Willett WC, Kraus RM. 
Low dell5ity lipoprotein subclasses patterns and risk of myocardial infarction. 
JA/vlA 1988;260:1917-1921. 
19 Hoving EB, Laing C, Rutgers HM, Teggeler Nl, Van Doonnaal]J, Muskiet FA]. 
Optimized determination of malondialdehyde in pbsma lipid extracts ming 1,3-
dicthyl-2-thioharbitmic acid: Înfluence of detection method and relations with 
lipids and fint)' acids in plasma from hc'1lthy adults. C1ll1 Chim Acta 1992i208:63-
76. 
20 Friedcwald \VT, Levy RI, Frcdrickson DS. Estimation of the conccntration oflow 
dcnsit}7 lipoprotein cholestcrol in plasma without the use ofthe preparativc ult-
racentrifügc. Clin ChC111 1972;18:499-502. 
21 Low[y OH, Roscnbrollgh NJ, Fan AL, Randall RJ. Protein measurelllent with 
tbc Folin phcnol reagent.j BiD1 Chem 1951;193:265-275. 
22 Klenk DC, Hermanson CT, Krohn RJ. Detennination of glycosylated hCllloglohin 
by affinity chromatography: companson with colorimcric and ion-exchange 
mcthods and cffccts of common interfercnces. Clin Che111 19S2;28:2088-2094. 
23 Panteghini M, Bonora R, Pagani F. Deterl11ination of gl)'cated apoIipoprotein U in 
serum b)' a combinatioll of afHnit)' cluomatography and illllllullonephelometry. 
Ann Cml Biochclll 1994:3 1.)44-549. 
24 Zaman Z, Fielden P, Frost PG. Simultaneous dctcrmination ofvitamins A and E 
and carotcnoids in plasma by revcrscd-phase HPLC in ddcrly and younger sub-
jects. C1ll1 Cht'11l 1993:39:2229-2234. 
25 Jafic M. Uchcr den Niedcrschlag ,velchcn Pikrinsaure in normalen Ham crzellgt 
und nbcr cine neue rcaction des Krcatilli1l5. Z Physiol ChC111 1886;IO:391-400. 
(Germ<ln) 
Lipid peroxidation alld microv,lscubr complications 
26 Cockcroft DW, Gault .MH. Predictiall of creatinine clearance from serum creati-
nine. Nephwn 1976;I6:31-41. 
27 De Jong PTVM. Screening op diabetische retinopathie. Ned Tijdschr Geneeskd 
1993,·137:170I-[705. (Duteh) 
28 HolewskiJJ, Stress RM, GrafPM, Grunfeld C. Aesthesiollletry: quantification of 
cutalleous pressure sell5ation in diabetic peripheral neuropathy. J Rehab Rcs De\' 
1988;1J: 1057-1061. 
29 Altomare E, Vendemiale G, Chicco D, Procacci V, Circlli F. Increascd lipid 
peroxidation in type 2 poody controlled diabetic patiellts. Diabete Mctab 
I992; I 8:264-271. 
30 Ozben T, Nacitarhan S, Tuneer N. Plasma and urine malondialdehyde levels in 
non-ill5ulin-dependcnt diabetic paticnts with and \vithout microalbuminuria. Int J 
CHn L1b Rcs 1995;25:162-[64. 
3 I Yaqoob M, Mc Clelland P, Patrick A\V, Stevell50n A, Masoll H, \Vhite MC, BeB 
GM. Evidence of oxidant illjury and tubular damage in early diabetic nephropa-
thy. QjM 1994;87:601-607. 
32 Beaudeux JL, Guillausseau PJ, Peyllet J. Enhanced susceptibility oflow-density 
Iipoprotein to in vitro oxidation in type I and type 2 diabetic paticnts. CHn Chil11 
Act,1 I995;239:131-14T. 
33 Sauchez-Quesada]L, Perez A, Cai.xas A, Ordon1l1ez-Llallos J, Carreras G, Payes 
A, Gonzalea-S~lstre F, de Leiva A. Electronegative Iow demity Iipoproteill subform 
is increased in patients with short-duration IDDIvl and is closely rclated to glycae-
lllia control. lJÏ.1betoJogi,1 1996:39:1469-1474. 
34 Dimitriadis E, Grifl-în M, Owcns D, Johnson A, Collins P, Tomkin GH. 
Oxidation oflow density lipoprotein in NIDDM; its rclatioll5hip to f.ltty acid 
composition. DiabetoJogia 1995;]8:1300-1306. 
35 Collier A, RlIlllley A, RlIlllley AG, Paterson]R, Lcach]p, Lowe GO, Small M. 
Free radical aetivity and hemostatie [1.ctors in NIDDM patients with and without 
microalbuminuria. Diabetes 1992;41:9°9-913. 
36 Noberasco G, Odetti P, Boen D, Mailclio M, Adezati L. Malondialdehyde 
(MDA) levels in diabetic subjects. Relation with blood glucose and glycosylated 
hemoglobin. Hiollled Pharmacother 1991;45: [93-[96. 
37 CerieIIo A, FalIe ti E, Bortolotti N, Motz E, Cavarape A, Russo A, GOllallo F, 
I3aroli E. Increased circulatillg intercellular adhesion lllolecule-I levels in type II 
diabetic patients; the possibie mIe of metabolic control and oxidative stress. 
MctaboHsm 1996;45:498-501. 
38 Sakuzay T, Tsuchiya S. Superoxide production fiom nonenz)'lll'Jtically glyeated 
proteins. FEBS (letter) [988;236:406-410 .. 
39 WolfT SP, Deall RT. Glucose autoxidatioll and protein modification. Thc potential 
mIe of'autooxidative glycosylation' in diabetes. Biochem] 1987;2245:243-25°. 
Chapter ,5 
40 HuntJV, Smith eeT, \VolfSP. Autooxidative glycation alld possible involvement 
of peroxides alld free radicals in LDL modification by glucose. Diabetes 
1990;]9: 1420-I424· 
41 Davies ]V, Grimths W, Philips GO. Pulse radiolysis of aqueous carbohydrate solu-
tions. In: Puls radiolysis, Proceedings of the International Symposium held in 
Manchester, UK April I96,5.(E's Ebert M, Keene JP, Swaliow AJ, Baxendale JH) 
pp 181-191. Academic press, London I965. 
42 Lorenzi M, Nordberg JA, Toledo S. High glucose prolongs celi cycle travcrsal of 
cultured human endothelial celis. Diabetes 1987:J6:126w-1267. 
43 LO\v PA, Nickander KK. Oxygen free radical efiècts in sciatic l1ervc in experi-
mental diabctes. Diabetes 1991;40:87]-877. 
44 Ha H, Kim KH. Role of oxidative strcss in the developmcnt of diabetic nephro-
pathy. Kidney Int 1995;48:518-521. 
45 Jennings PE, ]ones AF, Florkowksi CM, Luncc], Barnett AH. lncreased diene 
coqjugates in diabetic subjccts "\vith microangiopathy. ])i,1bctic Med 1987;4:452-
457· 
46 Morrow JD, Frei B, Longmire A\V, Gaziano M, Lynch SM, Shyr Y, Strauss \V, 
Oates JA, Roberts LJ. Incrcase in circnlating products oflipid peroxidation (F2-
isoprostalles) in smokers. Smoking as cause of oxidative damage. N Eng] Med 
1995;Jj2:II98-[203. 
9 1 

Health status in patients with 
insulin-dependent diabetes mellitus; 
relationship with metabolic control 
Health status and metabolic contral 
SUMMARY 
Given tbe importance of good glycaemic control in thc prevention of diabetic 
complications, and the enormons interest in health status (HS), as one of thc 
outcomcs in stlldying efIectiveness of medical care, the goal of this study ·was to 
examine the relationship between metabolic control and HS in patients "\vith 
insulin-dependent diabetes mellitus (IDDM). The associatioll between 
metabolic control (glycosylated haemoglobin, glycosylated apolipoprotein B 
alld mean glucose valucs), diabetic (hypoglycaemic and hyperglycaemic) 
complaillts and HS (Short Form 3ó alld Euroqol) were therefore studied in a 
grOllp of 275 IDDM patients. 
In general, metabolic control, was not or anI)' weakly related with HS. In 
contrast, diabetic complaints (bath hypo- and hyperglycaemie), showed astrong 
assoeiation with most of the dimensions of tbc SF-3ó and Euroqol, with a 
highly negative impact on health status. 
The results of th is study indicate th at attention should be paid to the different 
types of outcome of care in evaluation of the efiects of care, in any case to 
clinical paraIlleters and healtb status. Given the strong negative impact of 
diabetic complaints on health status, achieving strict metabolic control for tbc 
prevention of diabetic complications should not be the only goal in diabetes 
therapy. A daily life without hyperglycaemie complaints or hypoglycaemic 
events should be an equally important objective. 
Suhmitted as: J.H. Assink, E.G.T. Nijs, A.E Casparie, D.B. Grobbee, R.P. Stolk, H.J.G. Bilo. 
Hcalth status in patients v,!ith insl1lill~dependellt diabetes Jlldlitus; relarionship with Jllctabolic contral 
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INTRODUCTION 
Health status (HS) has become an important concept in studying the eftèct of 
carc l , Because health status represents what a patient perceives as one of the 
nlOst important outcomes of medical carc, HS is increasingly regardcd as a 
relevant adjuvant to traditional biological and clinical parameters of outcOl1le 
sneh as metabolic control. 
The importance of strict metabolic control for the prevention as wcll as the 
progression of long-term diabetie cOluplications has been shown for patients 
with illsulin-depclldcnt (typc I) diabetes mellitus'. 13ccause of this inereased 
emphasis on bettcr mctabolic control, the burden on pcrsonal welfare is 
growing. Illsulill thcrapy is cOllUllOilly intensified by an illcrcascd frequency of 
injections or by admillistrating insulin by pump thcrapy with the obligation to 
increase the ficqllency of self-monitoring of blood glucose levels and an 
increascd risk for hypoglycaemie events. The possiblc efiècts on health status to 
achieve this objective are mostly neglected or considered as less important. 
Previous studies desCl'ibing the relationship bctween l1letabolic control and 
hcalth status have reported conflicting rcsultsl-~, In nlOst of these studies this 
rclatiollship was investigated in populations restricted to NIDDM paticntsJ-S or 
consisting ofboth NIDDM and IDDM patients7'S, Although it scelllS reasonable 
to believe th at the direct eflèct of lllctabolic control 011 health status willnot be 
different for NIDDM and IDDM patients, difièrenccs in trcatment regime as 
weil as other paramcters related to metabolic control, could be modifiers of 
these associatiollS, Also in most of these studies not all aspects of metabolic 
c011trol were assessed, In partiClllar the presellce of diabetic complaillts, as 
paralllcter of l1letabolic control was left out of consideration. 
Wc cOllducted a study to investigate the relationship between mctabolic 
control, diabetic complaints and hcalth status-variables in well defilled group of 
patients with insulin-dcpcndcllt diabctes l1lellitus . 
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PATIENTS AND METHODS 
Patients 
Thc present study was conducted at the outpatient c1inie of the 'De 
Wcczcnlanden' hospital in Zwolle, a middle-sizcd town in the eastern part of 
thc Nctherlands. FrOlllJanuary 1995 to January 1996, 293 consecutive patients 
with IDDM were invitcd to participate in the study. IDDM was defined as the 
start of insulin replacemcnt therapy before the agc of 30 years, or the absence 
of C-pcptide secretion. Twclvc patients refhsed to participate in the study. All 
patients applied self-contro,l by blood glucose 11l0llltoring and administered 
their insulin by insulin-pen or pump (continuous subcutancous insl1lin infüsioll 
(CSII)). The study protocol was approved by the hospital scicntific and ethical 
coml11ittees and all patients gave thcir infonned consent. 
Stud)' protocol 
Patients were exallllned according to a standardized protocol by one trained 
physician. The schclncs ofinsulin administration (2-3 or 4 times daily injectiol1s, 
and CSII) as wèll as co-nlOrbidity were recorded. Co-morbidity consisted of 
the following diseases: dllOlllC bronchitis, other lung diseases, serious back 
problems1 rheumatism or articular complaints 1 callcer, discases of the nervous 
system, and diseases of the thyroid gland. Metabolic control was asscssed by 
haemoglobin Ale (HbArc) and glycosylated apolipoprotein B. HbArc was 
lllcasured by affilllty chromatography (picrcc columns, Glyco test II) (npper 
muit of normal 6.0%)9, Glycosylated apolipoprotcin B, as percentage of total 
apolipoprotein B ,vas detcnnined according to Pantcghini lO • In all patiellts 
metabolic control was mcasurcd at the same day the hcalth status questionnail:es 
were filled out by the paticuts thclllselves. 
Mean blood glucose values froll1 day-curves, as measured by the paticnts at homc 
were llsed as all additiOl1a1 parameter of lllctabolic control. For each of the tluee 
lllonths precedillg thc outpatient visit the fiTSt rcported day-curve of six or more 
UICaSUrel11ents was rccorded. This was done to prevent confounding by 
illdication, because paticnts arc normally instrncted to pcrform a complete day-
curvc (more than sL....: 11lcasurcnlents per day) at least evcry two weeks or more 
aften when necessaly. FrOlll these day-curves l11ean glucose v"lhres \Vcre 
calclllatcd ror a period of anc and duce 1110nth precedillg thc outpaticnt visit. 
In addition patients recordcd all hypoglycaemie events and hypcrglycacnllc 
complaints (thirst, polyuria, polyphagia, C1tigue, pruritus), dllring thc prcccdillg 
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three l11011ths. Hypoglycaemia was defined as an insulill reaction, which 
required illlluediate food intake by the patient hinlSelf or the assistance fiom a 
relative or physician, who injectcd glucose intravenously or glucagon 
illtramuscularly, or for whieh hospital admissi0l1 was neccssary. In the latter 
three instances the hypoglycaemie event was graded as severe. 
The presence of lllicrovascular cOluplications was defined as having 
nephropathy (albuminuria of more than 30 mg/ 24 hours or the use of an ACE-
inhibitor), retinopathy (background or pre-/ proliferarive assessed by 
fundoscopy in lllydriasis classificd according to national standards) or 
neuropathy (sensibility and vibration threshold testing: one or more abnol1nal 
test result) as described previously in more detailChlrt,r 2. 
Health status 
Health status was measured by the SF-3ó and the Euroqol, two generic 
instnunents for quality oflife assessment. The SF-3ó, the short-fonn version of 
the health survey used in thc Medical Outcome Study",!2 has been valielatcd for 
the Dutch sitllation,),q as has the Euroqol, an instrument developed by the 
international Euroqol group'$. The SF-36 encompasses eight dimensions of 
health: physical fimctioning, social functiollillg, functional role illlpairment 
(role functional) , emorional role impairment (role emorional), mental health 
and general health perception, and one itenl measuring health change: health 
transition. For each of these diInensions, itenl scores were coded, sllmmecl and 
transformed to a scale from 0 (worst health) to 100 (best healthr,,'6. In addition 
to the scores for the eight dimensions of the SF-36 a physical ancl a lllental 
component summary scale were calculated as described by Ware anel Jenkinson 
using US-based population nOtlllS'7,ls. The Euroqol contains two dilllensions: 
the thennometer and the weighted Euroqol score. 
A supplement of the questionnaire contained questions regarding socio-
econOlnic characteristics (education and type of health insllrallce) of the 
patients. Education was graded by the highest fillishcd schooling according to 
the Dutch edllcational systclll. High education was defined as 'Hoger Algemeen 
Voortgezet Onderwijs' or better. Patiellts werc also classified by the kind of 
medical insurance (compulsory or private) as another parameter for socio-
economie status. The income level when compulsoly insnrance has to be 
changcd to private insurance is dctcrmined in the Netherlands at approximatcly 
48.000 guilders (about 25.000 US dollars) before taxe'. 
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Data analysis 
The ehi-square test was llsed to compare frequencies. Statistieal difièrenees 
betwecn groups were calculated by ANOVA using Dunean's multiple range test 
(whieh eorreets for multiple testillg) as post hoc test. Multiple linear regression 
analyses were used to analyse the associatiolls between eOlltinuous variabics and 
to adjust for possible eonfounders. 
The dimellsions 'role physical' and 'role emotional' of thc SF-36 were trcated 
as a continuolIs variables, although they consist of only five respectively four 
outeome levels. This is usually done in studies with a large llumber of 
participants, for reasons of easilless of presentation and interpretation of 
cliftèrences. Becallse na change in health status was studied, health transition, 
the only single item scale of the SF-36 was not included in the analysis. Two 
sided P-values $; 0.05 were considered to be statistically significant. Analyses 
were performed using SPSS 6. 1.3 for Windows. 
RESULTS 
Two hunclrccl ancl sevcnty-five of the 281 patients eompletecl the hcalth status 
questionnaires (a response rate of more thall 97 %). Tablc I sunuuarÏzes the 
demographic alld clinical characteristics of these patients. Mctabolie control, as 
assessed by HbAIC and glycosylated apolipoproteill B did not significantly difIcr 
betweenlllen ancl women (8.07 % (SD 1.99) vs 8.49 % (1.77); 3.09 % (0.88) vs. 
2.99% (0.92), respectively), although there appeared to be a tendency for worse 
llletabolic control in fcmales. Only glycosylated apolipoprotein B was associated 
with age (regression cocflicient 0.01 per cent per year (SEM 0.01) p::; 0.05 af ter 
adjustment for gender). No difference could be found rcgarding the various 
schellles of inslilin adlllinistratioll (2-3, 4 times daily, or CSII). Duratioll of 
diabetes was also not related with any of the parameters of metabolic control. 
During the threc lllonths preceding the out-patient visit, 224 patients (81.5%) 
had hypoglycaemic events, of them 62 (27.7%) more than rune times. One or 
more severe hypoglycaemie evcnts were reported by 48 patients (17.5%). One 
hundred and fifty paticnts (54.5%) suffered from ane or more hyperglycaemie 
complaints. More wamen compared to men experienced hyperglycaemie 
complaints ancl hypoglycaemie cvents (83 (65.9%) vs 67 (45.0%) anel 109 
(86.5%) vs. "5 (77.2%), respectivcly, bath pS; 0.05). Thc occurrenec ofscvere 
hypoglycaemic events did not diflèr between the sexes. Metabolic control, age 
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and duration of disease wcre not significalltly associatcd with thc presellCe of 
hypoglycacmie events or hyperglycaemic complaints. 
Health status and metabolic control 
The mean physical and mcntal component score of thc SF-Jó \Vere 52 (SD 8) 
Table I. Dcmographic and clinical charactcristics 
Nlll11ber of paticnts 275 
Gender (male) 149 (54.2%) 
Age (years) 38.3 (12.5) 
Duration of discase (years) 17.2 (10.8) 
Smokers 89 (32.4%) 
Alcohol users 167 (60.7%) 
Level of mctaholic control 
- HbAlc (%) 8.27 (1.90) 
- glyeosylated apolipoprotein B (%) 3.05 (0.90) 
- lllcan glucose values 1 month (n111101/1) 7.27 (1.67) 
- mean glucose values 3 month (n111101/1) 7.36 (2.20) 
Socio-economie position 
- level of educ.tion (high) 90 (32.0%) 
- health insurallce (compulsory) 186 (66.2%) 
Co-morbidity 177 (63.0%) 
(one or more chronical medical conditions) 
Microvascular complications (one or lllore) 182 (66.2%) 
- nephropathy 57 (20.3%) 
- neuropathy 141 (51.3%) 
- retinopathy 89 (32.4%) 
Values are numbcr of patients or l11eans with percentage or standard 
deviations between parentheses. 
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aud S' (ro), respectively. The scores for thc Euroqol were 8I (IS) for the 
thermometer aud 90 (14) points for the weighted Euroqol score (TabIe 2). 
Mctabolie eontrol, as assessed by HbA I C was ollly weakly associated with the 
SF-36 dimcnsions; physical functioning, general health and the thennmnctcr of 
thc Euroqol (TabIe 2 eu 3). Af ter further adjustment for co-morbidity, type of 
illsulin thcrapy, socio-economie position and duration of disease these 
associatians lost their statistical sigllificance. Exeept far thc mean (3 nlOllth) 
Table 2. Health status in IDDM paticuts specified by quartilcs ofHbAIc 
Total group 
SF-36 
Physical summary score 52 (8) 
Mental summary score SI (10) 
Physical Functioning 90 (IS) 
Rolc Physical 83 (32) 
Bodily Pain 87 (20) 
General Health 70 (20) 
Vitality 67 (20) 
Social Functioning 87 (20) 
Role Emotional 84 (32) 
Mental Health 77 (17) 
Euroqol 
Thermometer 
\Veighted Score 
81 (IS) 
90 (14) 
lowcst 
«6.9%) 
53 (6) 
94 (9)*# 
83 (JI) 
88 (17) 
70 (I9) 
69 (19) 
90 (16) 
81 (IJ) 
92(12) 
Quartiles of HbArc 
second third 
(6.9-8.2%) (8.2-9.3%) 
sz (8) 
88 (20)* 
88 (28) 
53 (8) 
50 (Il) 
92 (Il) 
82 (J2) 
88 (20) 
70 (20) 
66 (20) 
86 (22) 
8J (33) 
76 (16) 
81 (IS) 
90 (14) 
Values are mean scores with standard deviatiollS between parentheses. 
[*] difTerence betweenlowest quartile and second quartile of HbArc: p:S; 0.05 
[#J difference between lowcst quartile and highest quartile ofHbAIC: p :s:.o.OS 
IOO 
highest 
(>9·3%) 
49 (12) 
88 (I6)# 
77 (39) 
78 (36) 
74 (20) 
79 (17) 
87 (16) 
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glucose values, which was related to weighted Euroqol score, the other 
parameters of rnetabolic control were not associated with health status. On thc 
other hand, all dimensions ofboth SF-36 and Euroqol were inversely related to 
the nllmbcr of hyperglycaemie complaints (TabIc 4). A1so the presencc of 
hypoglycacmie cvents in the past three months, in particular the OCClU'renee of 
more than nine events, was strongly associated with rIlast of the dimensions of 
the Euroqol and SF-36. Further adjustment for dnration of diabetes, co-
Table 3. Health status and parameters of mctabolic control 
SF-36 
Physical summary score 
Mental summa!)' score 
Physical Functianing 
Rale Physical 
Badil}' P .. lÎn 
Gcncral Health 
Vitality 
Social Functioning 
Role Emotional 
Mental Hcalth 
Euroqol 
Thermometer 
\Veighted Score 
Gl)'cos)'latcd 
HbAICI apolipoprotcin B2 
-0.3 (0.2) -0.2 (0.5) 
-0.4 (0.3) -0.5 (0.7) 
-0.9 (0.4)* -0.6 (1.0) 
-0.9 (1.0) -0.2 (2.2) 
-0.6 (0.6) -0.8 (1.3) 
-1.3 (0.6)* -0.5 (1.4) 
-0.8 (0.6) -1.4 (1.4) 
-0.9 (0.6) -1.1 (1.3) 
-1.3 (1.0) -1.2 (2.2) 
-0.8 (0.5) -0.6 (1.1) 
-1.1 (0.5)* 0.6 (1.0) 
-0.7 (0.4) -0.9 (0.9) 
Mean glucose values 
I month3 3 month4-
-0.6 (0.5) -0.4 (0.3) 
0 (0.7) -0.5 (0.5) 
-1.2 (1.0) -1.3 (0.7) 
-0.1 (2.3) -1.0 (1.6) 
-0.4 (1.4) -1.4 (0.9) 
-1.8 (1.3) -1.2 (1.0) 
-1.4 ([.4) -1.1 (1.0) 
-0.8 (1.5) -1.6 (1.0) 
0.9 (2.4) -1.1 (1.6) 
0 (1.3) -0.9 (0.9) 
-0.4 (1.0) -0.8 (0.7) 
-1.4 (1.0) -1.7 (0.7)* 
Valucs arc mcan changes (estimated by linear regression caefficicnts) with standard errors 
bctwccn parcntheses aCter adjustmellt for age and gendcr. 
I change per percent ofHbAlc. 
2 change per percent of gl)'cosylatcd apolipoprotein B. 
3 change per mmolIl glucosc pcr 1 Illonth period. 
4 change per mmolIl glucose per 3 rnollth period. 
*:::; p :$; 0.05 
lOl 
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Table 4. Hcalth status and diabetes syrnptoms 
Hyperglycaemie Hypoglyc.aemie Sevcrc hypoglycaemie Hyperglycaemie Hypoglycaemie 
complaints I A eventsi B eventsIC complaintsZ A cvents2 B 
SF-36 
Physical summary score -1.8 (0.3)*** -2.4 (1.0)* -1.7 (1.2) -1.7 (0.3)~ -1.2 (1.0) 
~entUs~score -3.3 (0.4)~ -4.2 (1.4)** 0.6 (1.6) -3.4 (0.4)~ -3.1 (1.3)* 
Physical Functioning -3.1 (0.6)~ -2.6 (2.0) 1.4 (2.2) -3.4 (0.6)*** -0.7 (2.0) 
Role Phys;cal -8.9 (1.4)~ -15.2 (4.6)** -9.0 (5.3) -8.9 (1.4)*** -10.3 (4.3)* 
Bodily Pam -4.5 (0.8)*** -3.7 (2.8) -8.2 (3.2)* -4.3 (0.8)*** -2.0 (2.7) 
Genera} Health -5.8 (0.8)*** -9.2 (2.8)** 1.5 (3.2) -5.7 (0.8)*** -5.7 (2.7)* 
Vü:ility -7.7 (0.8)*** -9.7 (2.8)~ 0.4 (3.3) -7.8 (0.8)~ -7.1 (2.4)** 
Socia! Functioning -6.5 (0.8)~ -7.9 (2.8)** -1.6 (3.2) -6.7 (0.8)~ -5.1 (2.5)* 
Role Emotional -9.5 (1.3)*** -9.4 (4.6)* -1.9 (5.2) -9.8 (1.3)~ -5.0 (4.2) 
Mental Health -4.6 (0.7)~ -7.2 (2.3)** 1.7 (2.7) -4.9 (0.7)~ -6.1 (2.2)** 
Euroqol 
Thcnnometer -5.4 (0.6)~ -9.6 (2.1)~ 0 (2.5) -5.2 (0.6)*** -6.9 (1.9)*** 
Weightcd Score -4.5 (0.6)~ -7.0 (2.0)~ -1.6 (2.3) -4.5 (0.6)*** -4.9 (1.9)** 
I Values arc mean changes (estimated by lincar regression coefficients) with stanclard errors between parentheses afeer adjustmcnt for age and gender. 
z Valucs arc mem changes (estimated by linear regression coefficicnts) with standard errors betwccn parentheses after adjustment for respectivcly 
hypoglycaemie events :md hyperglycaemie comphints. 
A mean change per diabetic complaint. 
B mean change for more tban nine hypoglycaemie events during tbe last 3 montb: present vs absent. 
e mean change for sevcre hypoglycaemie evcnts during tbe last 3 month in patients witb hypoglycaemie events (n=224): present vs absent. 
*= P ~0.05, **= p';O.Ol. ~= p';O.OOl 
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morbidity, socio-economic positioll (both education or type of insurance), type 
of insulin therapy, mctabolic control or the presencc of microvascular 
complications did not csscntially change these relationships. Both hyper-
glycaemic complaints and hypoglycaemie events were indcpcndcntly fiom each 
othcr associated with most ofthc diIuensions ofthe Euroqol and SF-36 (TabIe 4). 
DISCUSSION 
In dus study, the rclationslup between metabolic control and health status in 
paticnts with insulin-dcpendent diabetes mcllitus was cxanuned. As indicators 
of mctabolic control we used the biological paramctcrs (HbArc, glycosylatcd 
apolipoprotein Band self-recorded blood glucosc levels) as well as clÎIucally 
important paralueters as hypoglycacmic cvcnts and hyperglycaemic complaints. 
Health status was measured by SF-3ó as well as hy the Euroqol. 
The relationship between the biological parameters of metabolic control and 
health status was rather weak or abscnt. Both hypoglycaemie cvcnts and 
hyperglycaemie complaints werc accompanied by a decreasc of SOlue health 
status dimensions. 
Hcalth status scorcs of the patients 111 our study werc sllbstantially higher 
compared to diabctes specific nOrms of the Mcdical OutcOlue Study" as well as 
to the patients of other thc studics using the SF-36+·J,7,'9, One possible 
explanation for the higher health status scores fonnd in our study may be that 
the patients in these studies wcrc older and therefore more likcly to have severe 
complications and co-morbidity, two L1ctors suggested to be strongly associated 
with a diminution of hcalth status+-'-O,..", An other explanation could be found in 
thc socio-ccononuc and cllltural diflèrellces of the study populations, which arc 
alm sllggcstcd to be strong determinants of hcalth status". 
The results concerning the abscnt or vcry wcak relation between mctabolic 
control alld health status in diabetic paticnts are in agreement with other studies 
that also used the Short Fonu 36H >2 as weIl with as other gCllcric hcalth status 
measuring Înstrumentsl','J-'5. Studies that fOlmd stronger associations 1l10Stly used 
arbitrary cutofr points, illstcad of a continuOlIs relationships7>~"9,2f>-2~, 
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In our study health status was measurcd by two generic instruments, the Short 
Farm 36 and the Euroqol, because at the time of the study no diabetes speeific 
instrument was validated for the Netherlands. Same health status questionnaires, 
conditional upon way the dimensions are assessed and the type of dimellsions, 
are suggested to be more sensitive to detect a relationship behvecn nlctabolic 
control and health statuss. This might cxplain why Bardsley and collcagucs 
found a significant but rather weak relationship (correlation coefficiellts lower 
0.26 ) behveen dUllensions of the Nottingham Health Profile, the Functional 
Limitations Profile and metaboIic control, while no associations were found 
with a scale of the Positive Well-being questionnaire6 • The same phenomenon 
was described recently hy Anderson, who alm suggcsted that a disease-specific 
questionnaire (in his study the Diabetes Care profile) would be a better 
instrument to study the relation hetween health status and metabolic controlJ• 
Given the absence of an association between tnetabolic control and health status 
in studies using the (disease-specific) Diabetes Health Profile (DHP) and the 
Diabetes Quality ofLife (DQol)"'''. it wil! at least not be valid for evely diabetes 
specific questionnaire. In the other studies assessing this relationship which alm 
used diabetes specific questionnaires, thc association was also found to he 
wcakJo-J2 , indicating that metaboIic control, assessed by biological parameters, is 
at least from a heath status point of view not vcry important. 
The rather strong relationship between health status scores and the number of 
hypoglycaemic events confinns the clinical experience that hypoglycaemia 
influences daily life of the diabetic paticnt in a substantial way. The sanle is true 
for hyperglycaemic complaints. The fact that bath hypoglycaemie evellts alld 
hyperglycaemie cOIllplaints are associated with some health dimensions 
illdcpendently of HbAIC, indicates that fi'Olll a health status point of view it 
renlains important in poor as weIl as in good regulated patients to optimise 
metabolic control without inducing hypoglycaemie events or hyperglycaemic 
complaillts. 
These findings arc of importance for health services researchers as \yell as for 
clinicians. In the evaluation of the efièct of mcdical care, attention should be 
paid to the different types of outcome of medical care, in any case to clinical 
parallleters as weIl as health status. 
Clillicians have to realise that for the patient, his hcalth status is far more 
important than most clinical parameters are. Nevertheless, their treatment is 
based nlOstly on assessment alld illflucncing clinical parallleters such as HbAIC 
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or self reported glucose values. Hmvever, in a nlore paticnt-centred care, 
clinicians should also pay attention to the hcalth status of thcir patients by 
assessing anel tryillg to improve it by therapeutic nlOdalities tailorcd towards the 
individual patient. Although it is considereel that health status is partly bCyOlld 
the control of mcdical provide~·s, clillicians should 1113ke attempts to direct their 
treatment on this determinauts as much as possible. Thc presencc of 
hyperglycaemie or hypoglycacmic complaint cau be considcred as a useful 
indicator of decrcased health status in clinical practice in diabetes mellitus. 
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SUMMARY 
The importance of strict metabolic control for the prevention as wen as the 
progression of long-term diabetic complications has been proven for patients 
,vith inslllin-dependent diabetes mellitus. Because of this inercased desire for 
bettcr metabolic control, thc bUl'den on personal wclE'lrc eOllld aIso inerease. 
Given the importance of good gIycaemic control in thc prevention of diabetic 
complications, and the growing interest in health status (HS) as one of the 
outCOlllCS in studying effcctiveness of medica I care, the goal of this study was to 
exallline the relationships bctween type of Însulin replacelllcnt therapy, self-
control and HS in patients with illsulin-dependent diabetes lllcllitus (lDDM). 
The association between typc of insulin replacemellt therapy (fi'Cqueney of 
iqjections), sclf-control (number of day-eurves/ measurements) and scores on 
Short Fonn 36 and Euroqol ,vere thcrefore stlldied in a group of 275 IDDM 
patients. Metabolic control (HbAle) anel eliabetic (hypoglycaemie ancl 
hyperglycaemie) complaints, were asscsscd as possible eonfounders. 
The efièct of trcatmcnt, as assessed by frequcney of self-control was found to be 
strongly associated with the physical oriented duncnsions ofthe SF-36 and both 
dimcnsions of thc Euroqol. These associations were independent frol11 
metabolic control, cliabetic complaints, or type of illSulin replacement therapy. 
Thc lower dimension scores found for patients trcatcd with continuous 
subcutaneous insulin infusion compared to patients with eonventional 
treatment (daily 2-3 times üticctions) or four or more insulill illjcctions per day, 
could be traccd back to the f.'lct that these patients perfonned self-colltrolmore 
fi'equently than their counterparts. 
From the results of th.is stud)' it seems ünportallt to realise that the frequency of 
sclf-control ean havc a negative impact on percievcd health. 
Submitted as: J.H. Assink, H.G.T. Nijs, A.F. Casparie, D.E. Grobbee, R.P. Stolk, HJ.G. Bilo. 
Health status in p<lrients with insulin-dependent diabetes mellitus; the consequences of ther<lpy. 
IrQ 
Chapter 7 
INTRODUCTION 
Health status (HS) bas becOlne an important concept in studying thc effect of 
carc l • Because health status represents what a patient perceives as one of thc 
most important outCOlncs of medical care, HS is increasingly regarded as a 
relevant adjuvant to traditional biological and clinical parameters of outcome. 
Thc importance of strict nlctabolic control for the prevention as weIl as thc 
progression of long-tenll diabetic complicatiolls has been provcn for patients 
with insulin-dependcnt diabetes mellitus l • Bccause of th is incrcased wish for 
better metabolic control, the burden on pcrsOllal welt:1re is gro\ving. Insulin 
ther"lpy is conullOllly intensified by an increased fi'equency of iqjections or by 
administrating inslllin by pump therapy with the obligation to increase the 
frequency of sclf-nlOnitoring of blood glucose levels. Thc possible effects on 
health status to achieve this objectivc are mostly neglcctcd or considered as less 
important. 
We cOllducted a study to investigate the relationships between type of illsulin 
rcplaccillent therapy and thc frcquency of self-control to health status-variables. 
PATIENTS AND METHODS 
Paticnts 
The prcsent study was conducted at the outpatient clinic of the 'Dc 
Weezeillanden l hospital in Zwolle, a middlc-sized town in thc castern part of 
the Netherlancls. FrOlllJalluary 1995 to January 1996, 293 conseclltive paticnts 
with IDDM were invited to participatc in the study. IDD!vl was defined as the 
start of Înslllin replacement therapy before the age of 30 years, or the absence 
of C-peptide secretion. Twelve patients refused to participate in the study. All 
patiellts applied self-control by blood glucose monitoring and administerecl 
their insulill by insulin-pen or pump (subcutalleous insulin inftlsion (CSII). The 
study protocol was approved by the hospital scieutific and ethical committecs 
aud all patients gave their informed consent. 
Stud)' protocol 
Patients werc cxamined accordillg to a standardized protocol by one trained 
physiciall. The type of insulin replacemcnt thcrapy (frcquency of iqjections) as 
weU as co-morbidity were rccorded. Co-morbidity consisted of the following 
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discases: chronic bronchitis, other lung discases, serious back problems, 
rhcumatism or articttlar cOlnpiaints, cancer, discases of the nervous systenl, and 
discases of thc thyroid gland. All blood glucose values from day-curves, as 
measured by the patient, were collected for the three lllonths preceding the 
out-patient visit. Sincc patients of our outpatient department, trcated ,vith 
insulin-pen therap)', are nonnally instructed to perfonu a complete day-curve 
(more than si.x llleasureIuents per da)') at least every two weeks or more of ten 
when necessaly, and patiellts, administerillg tbeir insulill by pump therapy 
(CSIl) are advised to perforIll additional llieasuremellts ever)' day before 
breakfast and before going to bed, a da)'-curve was therefore defined as two or 
more blood glucose measurelllents on the samc da)'. Frequellcy of seIf-control 
was expressed as tbc number of day-curves or the number of glucose values 
measurcd per week. 
Metabolic control was assessed by haclllogiobill Arc (HbAIC), Illcasurcd by 
affinity chromatography (pierce columns, GIyco test II) (tIpper limit of nonnal 
6.0%)3. Paticnts also recorded all hypoglyeaemic evcnts and hyperglycaemie 
eOlllplaints (thirst, polYllria, polyphagia, L1tigue, pruritus), dming the last tluce 
mOllths. Hypoglycaemia was defined as an insulin reaction, whîch required 
inUllcdiate food intake by the patient himself or the assistancc ft'om a relative or 
physician, who illjected glucose intravenously or glucagoll Î..ntramuscularly, or 
for which hospital admission was necessary. In all patients metabolic control was 
measured at the samc day the questionnaires wcrc filled out by thc patients 
themselves. 
The presellce of microvascular complications was defined as havillg 
nepluopathy (albuminuria oflllOre than 30 mg/ 24 hOUl"S or the use ofan ACE-
inhibitor), retillopathy (background or prc-/ proliferative assessed by 
fundoscopy in lllydriasis classificd according to national standards) or 
neuropathy (sensibility and vibration threshold testillg: one or IllOre abnormal 
test result) as descdbed prcviously in IllOrc detaif"'-r(èrl. 
Hcalth status was measurcd by the SF-J6 and the Euroqol, two gelleric 
instrulllents for quality oflife asscssment. Thc SF-36, the short-form version of 
the health survey used in the Medical OutCOlllC Study+" has been validated for 
the Dutch situatiOl{',7 as has thc Euroqol, all instrument dcvcloped by the 
international Euroqol groups. The SF-36 ellcOlnpasses cight dimensions of 
health: physical fUllctioning, social functioning, functional role impairment 
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(role functional), elllOtional role uupairment (role cruotional), rucntal health 
and general health perception, alld ane item mcasuring health change: health 
transition. For each of these dimensions, item scores .. vere coded, summed and 
transformed to a scale from 0 (\vorst health) to 100 (best healthy~. In addition 
to the scores for the eight dimensions of the SF-3ó a physical and a melltal 
component sUllllllary scale were calculated as described by Ware and Jenkinsan 
using US-based population nOrIllS10,,,. The ElIroqol contains two dimensions: 
the thermometer and the weighted Euroqol score. 
A supplement of the questionnaire contained questions regarding socio-
economic characteristics (education anel type of health ulsurance) of the 
patients. Education was graded hy the highest finished schooling according to 
the Dutch cducational systcrll. High educatioll \vas defined as 'Hoger Algemeen 
Voortgezet Onderwijs' or better. 
Patients ,vere also classif1ed by the kind of medical insurance (eompulsm)' or 
private) as another parameter for socio-economie status. The incOlue level 
when eompulsory insnranee has to be changed to private illsurance is 
determlned in the Netherlancls at approximately 48.000 guilders (about 25.000 
US dollal~) beforc taxes. 
Data analysis 
The chi-square test was used to compare frcquencies. Statistical diftèrences 
between groups were ealculated by ANOVA using Duncan's multiple range test 
(with eorrection for multiple testing) as post hoc test. Multiple Iinear regression 
analyses was used to analyse the associations between continUotlS variables "md 
to adjusted for possible confounders. The dimensiolls role physical alld role 
emotional of the SF-3ó were treated as a continotlS :variables, although they 
eonsist of onIy f1ve respectively four outcome levels. This is usually done in 
studies with a large number of participants, for reasons of easiness of 
presentation and interpretation of difièrences. Because na change in health 
status was stlldied, health transition, the anI)' single item scale of the SF-36 was 
not ulcluded in the analysis. Two sided P-values ::; 0.05 were considered to be 
statistically significant. Analyses were perfonned using SPSS 6. 1.3 for Windows. 
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RESULTS 
Health status questionnaircs \Vere completed by 275 out of 281 patients (a 
response rate of lllore thcn 97%). Thc denlOgraphic and clinical charactcI;stics 
of thcsc patieuts specificd by type of insl1lin replacement therapy are 
sUl1ullarized in Tablc I. Regarding thc varîolls schcmes ofinsl1lin administration 
no significant difference could be found far metabolic contral, socio-economic 
status, or co-morbidity. As expected paticllts administering their il1sulin by CSII 
had a significantly higher frequency of self-contra!. A!though there appeared to 
bc a tendcncy in patient trcated by conventional therapy to have marc 
nlÎcrovascular complicatiolls compared to thei[ counterparts, this differencc was 
not statistieally significant. 
During the three months preceding thc outpatiellt visit ISO (53.4%) patients 
sllffcred fi'om anc or lllOre hypcrglycaemic complaillts and 224 paticnts (79· 7%) 
had hypoglycacmic evcnts, of thcm 63 (28.1%) morc than rlÎnc times. More 
patieuts admülÎstcring thcir illsulin by CSII had hypcrglycaeulÎc camplaints 
compared to those using an insulin-pen (55 (76.3%) vs 95 (46.8%); p" 0.05). 
The ducc treatmcnt modalitics did not differ for thc presence afhypaglycaemic 
cvcnts. Paticnts experiencÎng hyperglycaclllÎc camplaints pcrfall11cd 
significantly more sclf-control measurcmCllts pcr wcek (3.4 day-curves per 
,veek (SEM 0.2) vs 2.1 day-curves per week (0.2) and 14.1 mcasllremellts pcr 
wcck (1.0) vs. 9.1 lllcasllrements per week (1.0» comparcd to those not 
expcáencillg hyperglycacmic complaints. The same goes for paticnts havillg 
hypoglycacmie events «3.a day-curves per weck (0.2) VS 2.1 day-curves per 
week (0.4) and 12.6 measurements per week (0.8) vs. 8.6 l11easurcmcnts per 
wcck (1.5». Metabolic control, as asscssed by HbAIC, was associated with both 
thc numbcr of day curves and cOl1trol measuremcnts (regrcssian coefficicnts -
0.1 I % per day curve per week (0.5); -0.03 % per I11CaSUrcment per wcek (0.1), 
respcctively P:S;o.05 aftcr a<ljustmcnt for gcnder age and therapy). 
Health status 
Averagc scores for the SF-36 eight lll~or düncnsiolls rangcd froll1 a low of 67 
(SD 20) for vitality to a high of 90 (SD IS) for physica! functioning. The mean 
physica! (PCS) and menta! component score (MCS) of the SF-3ó were 52 (SD 
8) and SI (ro), respectively. Th" scores for the Euroqo! were 81 (IS) for the 
thermometcr and 90 (14) points far the weighted Euroqol scorc. 
Mctabalic control, as assessed by HbAIC was on1y weakly associated with thc 
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SF-36 dimensiol1s; physical flltlctioning, general health and the dimensioll of 
the Eurogol. In contrast, most of thc dimensiolls of SF-3ó alld Eurogol were 
inverscly related with the presence hypoglycaemie events as ,veIl as with the 
11l1111bcr ofhyperglycacmic eomplaints (see Chapter 6). 
Table I. Demographic and clinical charaeteristics specified by type of treatmellt 
Conventional Intensive treatmcnt 
2-3 times/day <1- timcs /day ContillllouS 
Nllll1ber of patients 33 (12.0%) 170 (61.8%) 72 (26.2%) 
Gender (male) 24 (72.7%)*# 99 (58.2%)*+ 26 (36.1%)#+ 
Age {)'ears} 46.6 (3.0)*# 36.4 (0.9)* 38.9 (1.1)# 
DUl'ation of diseasc (ycars) 26.3 (2.4)*# 14.6 (0.7)*+ 19.3 (1.1)#+ 
Doses inslllin per kg body weight 0.71 (0.04) 0.75 (0.02), 0.61 (0.02)+ 
(units pCl' day) 
Metabolic control (HbA Ic (%)) 8.6 (0.3) 8.2 (0.1) 8.4 (0.2) 
Self-control: number of 
- day-curve (per weck) 1.8 (0.4)# 2.1 (0.2)+ 5.2 (0.3)#+ 
- control measurcmcnts (per week) 7.9 (1.7)# 8.6 (0.8)+ 21.6 (1.4)#+ 
Socio-economie position 
- level of education (high) 7 (21.2%) 56 (32.9%) 27 (37.5%) 
- health insurance (complllsory) 22 (66.7%) 113 (66.5%) 51 (70.8%) 
Co-morbidity (anc or more 20 (60.6%) 106 (62.4%) 51 (70.8%) 
chronicalmcdical condition) 
Microvascular compIicatiollS 27 (81.8%) 105 (61.8%) 50 (69.4%) 
(one or marc) 
VaIues are 11llll1ber of patients or means \vith pcrcentage or stalldard errors bctween 
parentheses. 
f*J diftèrence bctwecn conventional and 4 injections per da)' : p ::'::0.05 
[#] diflèrence between convcntional and continuom ÎllSulin in fusion: p $0.05 
ftl diftèrellce betwecll <1- injections pcr da)' and continllous illSulin in fusion: p ::'::0.05 
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Health status aud thcrapy 
The dillèrence in hcalth status scores between patients with conventiollal (2 or 
3 times injections pcr day) and intensive insulin replacement thcrapy (4 or more 
ittiection per day or CSII) is sUlllmarized in Table 2. No difièrence in health 
status was fotllld bctween paticnts with convcntional and intensive therapy. 
Howevcr patients administering insulin by CSII had significantly lower health 
status scores comparecl those using an însulin-pen. These differences were 
csscntially the salllC after adjustlllent for agc, gender, HbAlc-lcvels, the 
prcsence of microvascular complications, co-morbidity, hypoglycaemic events 
Tablc 2. Hcalth status anel insulin replaccment tllerapy 
COllvelltional I Intensive treatlllent I Insulin treatlllent2 
2-3 timesl da)' 4 times Ida)' eSIl CSII versus lP 
SF-36 
Ph)'sical sUl11mar)' score 50 (1)* 53 (0)*+ 50 (1)+ - 1.3 (1.2) 
Mental sUlllmar)' score 55 (1)# S' (I). 48 (1)11. -2·3 (1.7) 
Physical FunctiollÎng 87 (J)* 93 (1)*+ 87 (2)+ -2.4 (2.4) 
Role Physical 82 (5) 88 (2). 72 (5)+ -7.0 (5.6) 
Eodily Pain 87 (j)* 89 (I). 8 I (2). -2.6 (j.3) 
Genera! Health 70 (4)* 72 (I). 63 (3). -5·9 (J.4) 
Vitality 70 (3)# 70 (1)+ 61 (j)#. -3·9 (H) 
Sodal Functiollillg 89 (j)# 89 (I). 81 (3)#+ -2·4 (3·3) 
Kole Emotional 96 (2)# 86 (2)+ 74 (4)11+ -10.1 (5.5) 
Mental Health 8 I (3)# 78 (I). 72 (2)1It -3.4 (2.8) 
Euroqol 
Thermometer 8 I (2) 82 (I). 77 (2). -0.5 (2.6) 
\Veightcd Score 90 (j) 92 (I). 84 (2)+ -3·9 (2·4) 
Valucs are mean scores "\vith standard errors between parentheses. 
[*1 difIcrcnce between convelltional and 4 iqjet:tiol15 per da)': p '::;;0.05 
2 
[iI] diffcrcnce between conventional and continuom insulin infilsion: p '::;;0.05 
[:j:] diflèrence betweell 4 injectiollS per da)' and continuous inslllin infusion: p '::;;0.05 
Values arc l11ean changes (cstimated by linear regression coefiîcient) with standard 
errors between parentheses af ter adjustment for age, gender <lnd self-contral. Mean 
change for therapy: continuom insulin therapy (CSII) versus insulin-pcn (lP) 
thcrapy. 
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or hyperglycaemic complaillts. Further adjllstment for the numbcr of blood 
glucose measurements showed that this difference between regimes of therapy 
could be attributed completcly to the fi-equency of self-control. Duration of 
diabetes and total insulin doses ,vere not associated with any of the dimensions 
of the Euroqol or SF-36. 
The associations between the frcquency of self-control, as asscssed by the 
numher of day-curves or llleasurements per week are shown in Table 3. Except 
for tbe mental cOlnponcnt score alld the dimensions role cmotion and mental 
health of the SF-36, hcalth status was strongly related with frequency of self-
control. These associations were essentially the same after further adjustment for 
duratioll of diabetes, co-morbidity, microvascular complications, socio-
Table 3. Hcalth status ancl self-control 
Numbcr of Number of 
day-curves! measurements2 
SF-36 
Physical SUlllluary score -0.7 (0.2)*** -0.2 (0)*** 
Mental sunllnary score -0.2 (0.2) -0.1 (0.1) 
Physical Functioning -0.9 (0.3)** -0.3 (0.8)** 
Role Physical -2.3 (0.8)** -0.7 (0.2)*** 
Bodily Pain -1.8 (004)** -0.5 (0.1)*** 
General Health -1.2 (0.5)** -aA (0.1 )*** 
Vitality -1.2 (0.5)* -0.3 (0.1)** 
Social Fllnctioning -1.2 (0.5)** -004 (0.1)*** 
Role Elllotional -1.2 (0.8) -0.3 (0.2) 
Mental Health -0.2 (aA) -0.1 (0.1) 
Euroqol 
Thermometer -0.7 (004)* -0.3 (0.9)** 
\Veighted Score -0.7 (0.3)* -0.3 (0.1)** 
Valucs are mean changes (estilllated bl' linear regression cocfficients) with standard 
errors between parentheses af ter adjustment for age and gellder. 
I change per day-curve per weck 
2 change per blood glucose !1lCasurelllellt per week 
* p ::;0.05, **= P :::;;0.01, ***= P :::;;0.001 
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econollllc positioll and/ or metabolic control (HbAIC, hyperglycaemie 
complaints and hypoglycaemic events). In addition, the same results were found 
when thc analysis was limited to patients, treated with insulin-pen therapy. 
DISCUSSION 
In this invcstigation, the relationship between type of insulin replacement 
therapy and se1f-control to health status in patÏents with insulin-dependellt 
diabetes l11ellitus was studied. Metabolie control as assessed by HbAIC, as weIl 
as hypoglycaemic events and hyperglycaemie complaints were asscssed as 
possible eonfounders. Health status was llleasured by SF-36 as weU as b)' 
Euroqol. 
The eftèct of treatment as assessed by frequeney of sclf-eontrol was found to be 
strongly associated witb the physieal oriented dil11ensions of the SF-36 and both 
dÎ111ensions of the Euroqol. These associations were independent 1Î"0111 
l11etabolic control or diabetic cOl11plaints. The lower dÎ111ension scores fotllld for 
patients trcated with continuous sllbclltaneous insulin infusion compared to 
patients '\vith conventional treatment (daily 2-3 times injections) or four or 
more insulin injections per day, could be traced back to the L1ct that these 
patients performed more frequently se1f-colltrol than their counterparts. 
Health status scores of the patients in our study were substantiaUy higher 
compared to diabetes spccific nornl5 of tbe Medical Outeome Study5 as weli as 
to the patients of other the studies USillg tbc SF-36'~-'5_ One possible explanation 
for the higher health status scores found in our study may be that the patients 
in these studies were older and therefore more like1y to have severe 
complications and co-morbidity, bath L1ctors suggested to be strongly associated 
with a dimÎnution ofhealth status lt"(','7. An other explanation conld be found in 
thc socio-economic allel cultural diffcrences of the study populations, which arc 
a1so suggested to be strong determinants of health status'7. 
Our findings that health status is strongly rclated with tbc fi-equency of self-
control differ fi.'om othcr studies's.,~, whieh reported no significant assocÎatioll. 
It has to be luentioned tbat the absence of astrong correlation between self-
control alld HS as described in the article by Wredling'\ was only stated and no 
rcsults were prcsellted. In a reeently perforl11ed study, assessing tbe determinants 
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of hcalth status in 1800 diabetic patients, self-control was positively rclated with 
the dUllcnsion mental health of the SF-20, indicating better health status with a 
highcr frcquency of self-control'7. In this study self-control was rccorded 
indircctly using items drawn ft'om thc Smllmary of Diabetes Self-carc activities 
qucstiollnaire'7. In the study perforIllcd by Gilden and his collcagucs health 
status was found to be Împrovcd by ultroducing blood and urinc glucose 
mcasurClllent in all group of older diabetes patientsl8 • Givcn thc [1ct that 
edueation was also part of the intervcntÎon this could be an explanation for thc 
ulCrease in health status. 
In this study health status was lllcasured by two general instrlllllents, the Short 
Form 36 and the Euroqol, because at the time of the study no diabetes-specific 
instrument was validated for the Netherlands. Howcver, when assessed by 
diabetes-specific qucstionnaires, being more scnsitivc tuwards clinical relevant 
issues l6 we would aspect to find even strongcr association between self-control 
and health status. 
Although thc resnlts of this investigation shmdd be interpreted with caution, 
SUlCC it a cross-sectionaI study, thc [1ct that self-control was associated with 
hcalth status independently ti'om type of insulin replacement thcrapy, met.bolie 
control alld co-morbidity lcavcs the sllggestion th at, au highcr frequency of sclf-
control per se could bring abollt a decrease in health status. In contrast to what 
we expected, self-control was associated only with tbc physical componcnt of 
tbe SF-36, indicatulg that there was or is na lllcntal burden ft'om self-controL 
Even though it is obvious that tbe mcasurement of blood glucosc values is 
painflll and interfering with apaticnts daily living, we could not fOlll1d an 
cxplanation wh)' this is not afiècting the mental componcnt of thc SF-3ó. 
These findings are of Îlllportance for health serviccs rcsearchers as weIl as for 
clillicians. In thc cvaluation of the eftèct of mcdical care, attelltion should be 
paid to the differcnt types of otltcome of mcdical care, in any case to health 
status. Clinicians have to realise that for the patient, his health status is [1r more 
important than clinical parameters are. However medical treatlllcnt is based 
1110stl)' on the assessment and control of clinical paramcters snch as HbArc, 
amo11g other ways by se1f-control. Clinicians have to bc alcrt that apatients 
health status can be adverscl)' influenced by the frequcncy of sclf-control. 
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Management of patients with 
insulin-dependent diabetes mellitus 
Managcment of lDDM paticnts 
METABOLIC CONTROL 
Insulin-dcpendent diabetes Illcllitus is a chronic discasc reqUlnng life-Iong 
treatment, including life-Iong drug use. The lnost important aim of the 
manageIllcnt of these patients is to prevent symptOIllatic hyperglycaemia and 
hypoglyeacmia, whieh are related with morbidity and IllOrtality. However, aftel' 
the introdl1etion ofinsulin treatmellt in 1923, it beeame apparcnt that diabetes 
lllelliws is assoeiated with a number of scrious disorders, so callcd microvascular 
complieations, which includes retillopathy, nephropathy, and ncuropathy. Also 
thc risk of cardiovascular disease is inercascd. Therefore, the prcvclltÎon of 
diabctie complieations has become an important aim of the manageIllcllt of 
IDDM patiellts. 
Sinee diabetic eOInplications also develop in patients with other types of 
diabetes, hyperglyeaemia has long been suspeeted as thc eause of these disorders. 
Indeed, a number of studies has shown an association between glycaemic 
contral and the prevalenee and incidence of complications'-J. Moreover, several 
studies havc been published sllggesting that strict metabolie control has a 
preventive effect on the developmellt of nlÎcrovascular COlllplicationsH • The 
eOllfinnatioll that strict metabolie control, achieved by an intcnsivc inslllill 
treatlllent regimen, efièctively delays the onset anel slows the progression of 
microvascular eOIllplications was given by the results of the Diabetes Contral 
alld Complications Trial (DCCT)'·w. 
The apparent association between glycaemia and eomplieations, as well as 
be'tween improved metabolic control and diminished oeeurrencc of 
eomplications, has shifted the focus ofthe lnanagement oflDDM patients frOln 
the prevention of SyIllptOlllS to reaching nOrIllo-glycaemÎa. 
Still, even under near-nonllo-glycaemic cirCUIllstances, microvascular 
complications do developS,TT. The rcsults in Chapter 2 show that in a population 
of adequately llletabolic controlled patients there is no dear association betwcen 
the level of HbA1C and the presence of complications. One explallation of tllÎs 
apparent discrepallcy lllight be that HbAle is not the optimal indicator of thc 
effects of hyperglycacmia in these patients. Other glycosylated proteins sneh as 
apolipoprotein B or Advanced Glycosylation End prodncts may be l110re 
appropriate measures. In our studies no association was found between 
glycosylated apolipoprotein B alld eomplications (Chapter 2). However, more 
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studies on the (clinical) use of these new glycaemic l11easures are needed before 
a decision can be made on the clinical usefulness. 
Other valiables rclated to I11etabolic control, especially lipid concentrations or 
modified lipid partides l11ay better reflect the risk of complications. Although 
there is a dear rclation between dyslipidemia and the development of 
macrovascular (cardiovascular) complications'l • the association with 
microvascular complications is less dear (Chapters 2 and 5). Because of the 
aging of the IDDM population, assessment and treatment of cardiovascular risk 
:f:1ctors becomcs nlOre Ü11portant. Therefore, in clinical practice lipid profile 
sholild be assessed on an annual basis. This is in agreement with the 
recomlllcndations by the National Cholestcrol Consensus to screen high risk 
groups ycarly'3. 
OXIDATlVE STRESS 
As discussed above, metabolic control alone does not [uily explain the 
development of diabetic cOluplications. A recently proposcd lnechallism, which 
mal' pIa)' a role in the devcl0pl11cnt of microvascular complications, is based on 
tissue damage resulting frOl11 the formation and "action" of free radicals. Under 
physiological circumstances, these radicals arc neutralized by various anti-
oxidant SystClllS. Whell the balallCe betwecn these defence systems and the 
fOfmation of free radicals is disturbed, oxidative stress emerges'4. 
In diabetic patients, the fOfmation of frce radicals can be enhanccd by increased 
glucose concentration through nOll-enzymatic glycation of proteill substrates, 
auto-oxidative glycation, and activation of protein kinase c q . Under 
hyperglycaemic circumstances, increased activity of thc polyol pathway lllay 
mcrease oxidative stress by depletion of the NADPH cell stores 
(pseudohypoxia)'5. In addition, diabetes is known to induce changes in the 
content and activity of ceilular anti-oxidant cnzYInes'ó-,s. Therefore, it seems 
that oxidative stress is increased both by thc presence of diabetes, as well as by 
thc dcgree of metabolîc control. 
In vivo measurements of free radicals are virtually Împossible given their 
rcactivity, short half-life, and vcry lo\v concentrations. VarÎous methods bave 
been developed to ll1easurc oxidative processes indircctly. One of these 
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proposed indirect indicators of oxidativc stress is the level of (serum) anti-
oxidants"}. 
It is important to realisc that the damage of frce radicals could be loeal and that 
absolute levels of individual circulating <lnti-oxidants might not be the onIy 
f:1ctor dctcrmining thc dcgree of anti-oxidant defence activity. Anti-oxidants 
are members of a rather large and activcll' cooperating famill' of chemical 
substances. Sl'nergistic interactions between anti-oxidants arc ,vcll known and 
mal' include anti-oxidant rcgeneration. As aresuIt, when thc levels of some 
anti-oxidallts fall the protcctive efièct of anothcr anti-oxidant mal' become 
inadequate dcspite its apparcntll' normal concentration'4. As aresuit, it is oflittle 
use to measurc single specific anti-oxidants in thc management of IDDM 
patients. This is also suggested bl' the results in Chapter 3. 
It would probabll' better to measure anti-oxidants as a whoje. The use of thc 
so-called total radical-trapping anti-oxidant parameter (TRAP) has recently 
been proposed to cxplore the anti-oxidant properties of a plasma samplC>°,.-". 
This TRAP ean be lllcasured directll' bl' an fluorescence-bascd method, but is 
oecasionally calculated bl' a mathematical fOl'lllula, including the scrum levels of 
four natural anti-oxidants (protein bound SH groups, udc acid and vitamin E 
alld vitalllin Ct. Since dircct TRAP measurClllcnt is a e1aborativc analysis it 
might not be med in routinc clinical care. Recent studies, using thc dircct 
measurement indicated that TRAP activity is decrcased in diabetic patients!O.~l. 
Further research, prcferable prospective studies, has to be performed before the 
TRAP activitl' might be induded in individual patient work-up in clinical 
practice. 
Other possible indirect indicators of oxidative strcss are malondialdchl'dc lcvels 
and the susceptibility ofLDL to in vitro oxidation14 • As for the meaSl1rClllcnt of 
anti-oxidants, thc use of these two lllcasures of lipid pcroxidation is limited bl' 
the 10cal activities of the fi-ee radicals and the interaction with other fktors 
(notabil' lipid profile and anti-oxidantsy'-~5. In our studies, no relationship could 
be found bctween thesc two meaSllres and the preset1Ce of diabctes (Chapter 4), 
the degree of metabolic control, or the presence of rnicrovascular complications 
(Chapter 5). Given these rcsults, it is deal' that these 11leaSUrcs of lipid 
pcroxidation arc not llseful in clinical practice. 
Although there sccms cllrrentll' 110 role for measures of oxidative stress in thc 
managcment of IDDM patients, it could still be possible that fi-ee radicals 
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contributc to thc dcvelopment of diabetie eomplieations. LDL-oxidation takes 
place in thc vascular wall!l\ and tnight therefore be related to endothclial 
activity. Fonnation of oxidized LDL is not always through lllctal-ion-
dependcnt oxidation of lipids. FOf example, myeloperoxidase aetivity can lead 
to lllctal-ion-indcpcndcnt mcidation of lipids and proteins in LDL particlcs'7-!? 
Moreovcr, phospholipase A2 aetivity has been suggested to be an altcrllative 
pathway to thc fonnation of oxidized LDLJo. As a eonsequence, an in vitro test 
of LDL-oxidation may not properly refleet oxidative stress in thc vesscls. It 
might be better to measure oxidized LDL directly in plasma salnplcs. These 
assays are cUlTently developed. 
HEALTH STATUS 
Apart from diahetic complications, pcrccivcd health is another important result 
of thc care of IDDM paticnts. It is irnportant to realise that in general, health 
status is L11" morc important for patients than are clinical parameters, despitc thcir" 
kllowlcdgc about the risk of diabetie eomplications. Adding this dimension to 
the doctor-patiellt interaction should help to achieve more treatmcnt goals and 
more satisf..1ction for both the physician and -most important- Cor thc patient 
with insulin-dependent diabetes mellitus. 
Given tbe importance of good glycacmic control in thc prevention of diabetic 
cOluplications, trcatmcnt of IDDM patients is nlOstly based on biochemical 
parameters such as HbAlc and (self-reported) glucose levels. Side eftècts of 
therapelltic llleasures to reaeh strict metabolic control are sometinles rcgarded 
as unavoidable by treating physicians. The results presented in Chapters 6 and 
7 indicate that the most important determinants of hcalth status are 
hypoglycaemie events and hyperglycaemie complaints, as well as the number of 
se1f blood glucose measurcmcnts. 
Given thc importance ofhealth status for the patiellts, metabolic control should 
be optimised without inducillg hypoglycaemÎC events or hyperglycacmie 
eomplaints. Moreover, physicians should be aware of the impact of thc therapy 
descdbed as well as of the frequency of self-control llleasuremcnts Oll the 
perceived health of the patient, and incorporate this infonnation in the 
treatment plan. The presence of hyperglycaemie or hypoglycacmie eomplaints 
may be considered as useful indicators of clecreascd hcalth status in clinical 
practice in diabetes mellitus. Ccrtainly, asscssmcnt of sllbjeetive complaints 
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shollid wcigh as lllllCh as objective biochemical meaSllrements in the approach 
to optîm.isc care and health status in diabetic patients. 
In conclusion, thc prescnce of mÎcrovascular complications was not associated 
with incrcascd HbAIC concentrations or parameters of oxidative stress. 
Ho\vcvcr, givcn thc literature it remains important to imprave glycacmic 
control. Howcvcr, clinicians have to be alert that a patients' health status can bc 
negativly illflucnccd by intensive therapy and increased fi-equcncy of self-
control. 
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Summary 
Sununary 
INTRODUCTION 
The pathophysiologicaI mechallisllls by which hyperglycaelllia leads to 
microvascular cOlllplications in diabetes mellitlls are as yet poody understood. 
Fllrthermore, even with intensive treatmellt and strict metabolic control, a 
numbcr of patiellts still develops microvascular COlllplications. Many hypotheses 
have bcen fOrIlllllatcd and învestigations perforIllcd, with a variabie degree of 
success. Some of these hypotheses, in partîcular the hypothesis about oxidative 
stress, have been formulated and studied within the scope of this thesis. In 
additioll, the impact of metabolic control ;md illsulin replacemcllt thcrapy on 
health status was illvcstigated. 
METABOLIC CONTROL, LIPID PROFILE DISTURBANCES 
Ta assess Olle possible mechanisl11, we invcstigated in a cross-sectional stud)' the 
associatioll between metabolic control, as assessed by HbArc, serum lipids, and 
the presencc of microvasclliar complications (Chapter 2). This assocÎation ,vas 
stlldied in a group of 28r consecutive patients with IDDM (r53 men and 128 
women) of the outpatient department of the 'De Weezenlalldcn Hospita!' in 
Zwolle the Netherlancls. IDDM was defined as starting inslllin replacement 
therapy within 6 lllonth af ter the first sign of diabetes mellitlls and beforc the 
age of 30 years, or thc absence of C-peptide secretion. Patients were gcncrally 
weil cOlltrolled (meall HbAle 8.3% (SD 2.0)). 
In these paticnts with IDDJ'vl there was no rc1ationship bct\vcen HbArc and the 
prcsence of diabetic nephropathy and retÎllopathy. In contrast to this, HbArc 
conccntrations were fOllnd to be significantly Încreased in patients with an 
abnanllal vibratian threshold. Thc results also shawed that thc presellCe of 
diabetic neuropath)' or retinopathy was not related ta scrum lipid 
cancentratÎons. Onl)' far diabetic llephropathy an association was found with 
trigl yc eri de-co neentra tio 11S. 
Although the fesults of this a cross-sectÎonal study shol1ld be interpreted with 
caution, the L.1ct that tlus association was found to be independent fiom 
metabolic control leaves the sl1ggestion that increased triglyceride levels I11ight 
be an additional risk L.1ctor in the devclopment of dbbctic nephropathy. 
Howcver, whcther the rise in triglycedde levels has onl)' a lllcrc relationship 
with the actual prcsence of diabetic nephropathy or with the devclopment of 
diabetic nephropathy has to be invcstigated b)' IOllgitudinal studies. 
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OXIDATIVE STRESS 
In diabetic patients, the formation of free radicals, highly reactive particles, 
which are also fonncd in tulder norl11o-gll'caemic conditions, is suggested to be 
enhanccd. Under normal physiological cOllditions the cell is protected bl' several 
anti-oxidants systems against tissue dal11age as the resuits of an overprodllction of 
ft'ee radicals, 
Incrcascd oxidativc stress, dcfilled as a distm'bed balance betwecn the formation 
of fi'ce radicals and the anti-oxidant systel11s, conld be a basic l11echanislll 
involved in the dcvelopl11cnt of microvascular complicatiollS in patients with 
insl1lill-dependent diabetes mellitus. Since oxidative stress is not exclusivcly 
relatcd to hypcrglycaemia, but is also influenced hy othcr [1ctors lik:c dietary 
C'lctors (the intake of anti-oxidants) or hereditarl' [ïctOrs (rcgulation of enzymatic 
anti-oxidants), it mayalso account for the developlllellt of lllicrovascular 
complications in subjects \vith diabetes l11ellitus, despitc strict l11etabolic control. 
In vivo llleasnrements of ft'ee radicals is virtually impossiblc given their 
reactivity, short half-life, and very low concentrations. Thcrcfore, various 
l11ethods have been developed to investigate indirectly whethcr sllch oxidative 
processes occur. anc of these proposed indirect indicators of oxidative stress is 
the content of anti-oxidants, illdicating the total anti-oxidant status. 
ANTI-OXIDANTS IN INSULIN-DEPENDENT DIABETES 
MELLITUS 
In Chapter 3 we studied serum anti-oxidant concentrations, as parameter of 
oxidative stress, in the same 28r patients with IDDM as described in chapter 2 
and in 98 non-diabctic control snbjects, as weil as thc association between anti-
oxidants alld microvascular complications. These healthy cOlltrols (4-9 men and 
49 women), \Vere enrollcd from a group of patients who were admitted for 
minor surgcry at the department of anaesthesiology, in thc same period as the 
IDDIVI patiellts were recruited. 'Healthy' was defincd as 'no current diseases' 
except the indication for surgery (ASA classification category I) and not using 
medicatioll, except oral contraceptives. 
In this studl' somc of the anti-oxidants (retinol, trallsferrin, and uric acid) were 
indeed found to be decreased in patiellts with insulin-dependent diabetes 
mellitus comparcd to controls. In patients with diabetes, some of these anti-
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oxidants (uric acid, alL1- and ganuua-tocopherol alld transfcn;n) ,vcre also 
associatcd with the dcgree of metabolic control. However, the prescnce of 
especially nephropathy, was found te be associated with increascd levels of anti-
oxidants (retinol, ferritin and uóc acid), whilc no significant associations were 
found for the presencc and sevcrity of retinopathy and neuropathy alone. 
These contrasting findil1gs of dccreased anti-oxidants levels in diabetes patients 
compared to control subjects aud increased levels in diabetes patients espccially 
with nephropathy may suggest the presence of a counteracting mechanisl11 
leading to increased levels of anti-oxidants when diabetic nephropathy devclops 
or is present. To our knowledge there arc na other reports on tbc existellcc of 
snch a mcchanislll. Still, in recent studies there is evidencc that enzymatic anti-
oxidant systems arc in deed modlllated to meet thc biological need imposed by 
oxidative stress. 
MALONDIALDEHYDE AND LDL-OXIDATION 
In Chapter 4 \ve studicd the presence of oxidative stress by hvo other indirect 
parameters, malondialdchyde levels and the slIsceptibility of LDL to in vitro 
oxidatioll. The latter has rccently been proposed as an appropriate measure of the 
response to in vivo oxidative stress, which is thought to occur within the matrÏ..x 
of thc vessel wall close to the endotheliulll. Malondialdehyde is a degradation 
product of lipid peroxides, and the most cOlllmonly used marker of oxidative 
stress. When using thcse parameters, we could not confinu the existence of 
oxidativc stress in patients with insulin-depcndent diabetes mellitus when 
compared to con trol subjects. Tbe results even indicated that patients with 
insulin-dependellt diabetes mellitus were expericllcing lcss oxidative stress than 
healthy controls. 
As desC1;bed in Chapter 5, oxidative stress, as measured by the susceptibility of 
LDL to in vitro oxidation and lllalondialdehyde concentrations, was not 
associated with the prescnce of microvascular compIications. Aho, no association 
was found bet\vcen oxidative stress and the dcgree of metabolic control. In 
contrast, tbe extcnt of glycosylation of apolipaproteill TI was found ta be 
inversely correlatcd with in vitro oxidation ofLDL. This finding could indicate 
that hyperglycael1lia not only might cause oxidativc stress, but plays a rale in thc 
defencc against oxidative strcss. 
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The (bio)chemical studies in th is thesis were an atteillpt to identit), a possible 
common pathophysiologicalmechanislll, by ",hich microvascular complicatians 
develop or progress in insulin-dependent diabetes mellitus. Despite the available 
evidence and suggestions in literaturc, the data in this thesis do not support 
either a difièrent degree of oxidative stress in diabetic versus non-diabetic 
subjects, nor a definitc influenee of the degree of lllctabolic control (at least 
when assessed by HbArc) on oxidativc-anti-oxîdative state. This can mean, that 
we did not study thc 'appropl;atc' population with diabctes mellitus: studies in 
people with non-insulin dependcnt diabetes mellitus might yield different 
results. It is also possible, that thc parameters employcd are incorrect, and other 
lllethods to assess the true extcnt of oxidative strcss shauld be uscd. As for the 
presented rcsults, however, it only can be concluded, that the initial hypo thesis 
rcgarding the influence of oxidative stress on thc development and progression 
of diabetic complications is not supported by the results obtaincd. 
HEALTH STATUS 
Insulin-dependent diabetes mellitus is a chranic disease whieh can aflèct many 
aspects of cvcryday life. To maintain satisfactory blood glucose level in order to 
avoid hyperglycaemie eomplaints and hypoglycaentic events, food intake, 
excrcisc and insulin doses BlUst be balanccd. In addition, many patients arc 
continuously aware of thc risks of devcloping ane or morc nticrovascular 
complications. This cvcr-present responsibility far daily balance and wordes 
about future hcalth and well-being nwy represent an extra burden in thc daily 
life of paticnts with insulin-depcndent diabetes mcllitns. Despite thc cxcellent 
results in thc DCCT, the main side effeets of strict nletabolic control from thc 
paticnts side of view are considcrable weight gain :md a threefold increased risk 
of scrious hypoglycaentia. Ta many paticnts, these side effects may seem an 
unacceptable priee for strict metabolic control, because of both physical alld 
emotional consequcllCCS. Furthermorc, stricter metabolic control may rcquire 
more intensive thcrapy, sneh as nmltiple daily doses of insulin (by nlanual 
Înjection or by insulin pump) and fi-equent mcaSl1rcments of blood glucose 
valucs. The latter regimen nwy as such already have negativc effects 011 a 
paticnts hcalth statns. 
In the secOlld part of this thesis we presented the results of a stl1dy, which had 
as objective to investigatc the possible association between nlctabolic control, 
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insulill replacement therapy and thcir consequences on health status. In general, 
Illetabolic control, as assessed by HbAIC, glycosylated apolipoproteill E, and 
Illean sclf-reported glucose values, was not or only weakly related with health 
status. In contrast, diabetic complaints (both hypo- and hyperglycaemic) 
showed astrong association with most of the dimensions of the SF-36 and 
Euroqol, with a highly negative impact on health status (Chapter 6). 
Assessing the effect of treatlllent on health status (Chapter 7), fiequellcy of 
self-control was found to be strongly assocîated with thc physical oriellted 
dimellsions of the SF-3ó and bath dimensions of the Euroqol. These 
associatiolls were independcnt fi'om metabolic control or diabetic complaints. 
The 10we1" dimensioll scores found for paticnts trcatcd with continuous 
subcutaneous ins ui in illfilsion (CSII) cOlllpared to patients with conventional 
trcatment (daily 2-3 times injcctions) or four or nlOre insnlin illjections per da)', 
could be eXplained by the filct that these patients performed self-control more 
ficquently. This finding confinlls that treatnlcnt may indeed have its own 
negative effects on apatients health status. 
Tn chapter 8 "\ve discussed the consequences of oxidative stress and health status 
on the management of patients with IDDM. At this time there is na relSOll for 
measnring individual serum anti-oxidants or parJIlletcrs oflipid peroxidatioll in 
clinical practice. 
However, with regards to health status, physicians shollid be aware of tbe 
impact of intensive insulin therapy, as well as of the fi'equency in sclf-control 
l1leaSurelllents on the perceived hcalth of the patient, and incorporate this 
infonnation in the treatment plan. The presencc of hyperglycaemic or 
hypoglycaemie complaints might be considered as an useful indicator of 
decreased health status in clinical practicc in diabetes nlcllitus. 
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INLEIDING 
De pathofysiologische mechanismen waardoor hoge bloedglucosewaarden 
leiden tot het ontstaan en het voortschrijden van microvasculaire complicaties 
(diabetische nierschade, oogschade en schade aan het zenuwstelsel) zijn tot op 
dit moment nau\velijks bekend. Duidelijk is, dat centraal hierbij de verhoogde 
bloedglucosewaarden staan. Daarnaast ontstaan er echter bij een aantal patiënten 
microvasculaire complicaties ondanks intensieve behandeling en nauwgezette 
llletaboie regulatie (zeer lage HbArc waarden). Om dit te kunnen verklaren zijn 
vele veronderstellingen onderzocht, echter gecn enkele gaf een eenduidig 
antwoord. Een aantal van deze hypotheses, in het bijzonder met betrekking tot 
het vetspectrum en oxidatieve stress, zijn bestudeerd in het kader van dit 
proefSchrift. Tevens wcrd er onderzoek vcrricht naar de gevolgen van het zo 
goed mogelijk regelen van de bloedglllcosewaarden voor de 
gezondheidsbeleving van patiënten met insuline-afhankelijke diabetes mellitus 
(IADM). 
METABOLE CONTROLE EN AFWIJKINGEN VAN HET 
LIPIDEN PROFIEL 
Ecn van de veronderstellingen, zoals boven aangeduid, zou kunnen zijn dat 
afivijkingen van het vetspectrum verklaren waarom cr toch complicaties 
ontstaan bij deze goed gereguleerde mensen met diabetes mellitus. Deze 
veronderstelling is onderzocht door te kijken of er een verband bestond tussen 
metabole controle, gelllcten via het HbArc, serum lipiden en het al dan nict 
bestaan van microvasculairc complicaties. Dit verband werd onderzocht in een 
groep van 281 patiënten met IADM (r53 manncn en I28 vrouwen) die werden 
behandeld op de diabetes polikliniek van het Zickenhuis 'De Weezcnlanden' in 
Z\volle. Mensen werden beschouwd insuline-afllanke1ijke diabetes lllellitus te 
hebben wanllcer vóór het dertigste levens jaar en binnen zes maanden na de 
eerste diabetes klachten de noodzaak bestond om met insuline therapie te 
starten, of waneer er geen C-peptide secretie meer in het bloed kon worden 
aangetoond (een bewijs dat de eigen alvleesklier geen insuline meer maakt). 
Over het algemeen waren de IADM patiënten redelijk gereguleerd (gemiddeld 
HbArc 8.3%). 
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Er kon gccn verband \vorden aangctoond tussen het HbAIC en de 
aanwezigheid van diabctische nefropathie (nierschade) en rctinopathic 
(oogschadc). Wel waren dc HbAIC waarden verhoogd bij patiënten mct 
tekenen van neuropathie, lnet name bij het afwijkend zijn van gevoelssensatics 
voor trillingen. De resultaten van dit onderzoek toonden ook aan dat dc 
aanwczigheid van diabctische neuropathie (schadc aan het zellll\vstelsel) of 
retinopathie niet in verband kon worden gebracht lllet de hoogtc van serum 
lipidcn concentraties. Allcen voor ncfropathie kon cr een significant verband 
wordcn aangetoond mct de triglyceride concentratics. 
Hocwel de resultatcn uit een transversaal onderzoek (d.w.z. cClllnalige meting 
in de tijd) altijd met de nodige voorzichtigheid dicnen te worden 
geïnterpreteerd, blijft de suggcstie bestaan, dat verhoogde triglyceriden 
concentraties ccn extra risico [,1ctor zouden kunnen zijn voor het ontstaan van 
diabetischc ncfropathie. Of cchter een tocname van triglyceriden concentraties 
inderdaad hct ontstaan van llierschade kan bevordcrcn, kan allccn wordcn 
uitgezocht door mensen langere tijd tc vcrvolgen. 
OXIDATIEVE STRESS 
Vrije radicalen zijn chcmisch zeer rcactieve deeltjcs, die ook onder nonllale 
omstandigheden (b.v bij lage bloedglucosewaarden) wordcn gevormd. Bij 
patiënten met diabctes zou de vorming van vrije radicalen, zijn toegenomen. 
Onder normale omstandigheden wordt het lichaam beschcnnd tegen deze vrije 
radicalen door verscheidene anti-oxidant systemen. Dit systeem van chemÎschc 
stoffen bicdt bescherming tegen het optreden van \vcefSelschadc, welke zou 
kunnen ontstaan door ccn overmatige vorming van deze vrije radicalen, door 
ze te inactiveren of het ontstaan ervan te voorkónlen. 
Tocgenomen oxidative stress, gedcfinieerd als een verstoring van de balans 
tussen de vorming van vrije radicalen en de bescherming door deze anti-oxidant 
systemen, zou een verklaring kunnen zijn waardoor microvasclliaire 
complicaties ontstaan bij patiënten met insuline-afhankelijke diabetes nlellitus. 
Aangezien oxidatieve stress niet uitsluitend behoeft te worden veroorzaakt door 
hyperglycaemie (hoge bloedglucose waarden), maar ook dool' andere factoren 
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zoals dicetfactorcn (innamc van anti-oxidantcn in dc voeding) of crfelijke 
factorcn (b.v dc rcgulatie van enzymatische anti-oxidantcn) wordt bepaald, zou 
deze stress ook hct ontstaan van complicatics kunnen vcrklaren bij dic diabetes 
patiëntcn, bij \vic de bloedglucosewaarden zcer goed gereguleerd zijn. 
Aangezien het llleten van vrije radicalen in een levend organismc onmogelijk 
is, zijn er verschcidene methoden ontwikkeld om op een indirecte manier aan 
tc toncn dat dczc oxidaticve processen plaatsvinden. Eén van deze indirecte 
indicatoren voor de mate van oxidatieve stress is het mcten van serum anti-
oxidantcn. 
Anti-oxidanten bij patiënten met IADM 
In Hoofdstuk 3 ondcrzochten we de serum anti-oxidant concentraties als maat 
voor oxidatieve stress, bij 281 mensen met IADM (dezelfde groep diabetes 
patiënten als beschrcven in hoofdstuk 2) en in 98 niet-diabetes (controle) 
patiënten. Tevens onderzochtcn we het verband tussen anti-oxidantcll 
bloedspiegels en het hebben van microvasculaire complicaties. De controle 
groep van mensen zonder diabetes (49 mannen en 49 vrouwen) werd 
willekeurig gckozen uit de groep patiënten, die de afdeling anesthesiologie 
bezochten voor een pre-operatief consult in verband met een kleine 
chirurgische ingreep. Als gezond werden beschouwd die personen, die geen 
andere zickte of aandoening hadden dan die waarvoor zij de ingreep moesten 
ondergaan (ASA classificatie categorie r) en die (behalve orale anti-conceptiva) 
geen andere medicatie gebruikten. 
Uit dit onderzoek bleek dat de concentraties van somnllgc anti-oxidanten 
(retinol, transferrine en urinezuur) zijn verlaagd bij mensen met IADM, 
wanneer zij werden vergeleken met de gezonde controle personen. Binnen de 
groep diabetes patiënten bleken de concentraties van sOllllllige anti-oxidanten 
(urinezuur, al[1- cn gamma-tocopherol en transferrine) gerelateerd te zijn aan 
de mate van metabole regulatie. Verder bleek alleen de aanwezigheid van 
diabctische neft'opathie geassocieerd te zijn met verhoogde concentraties van 
sommige anti-oxidanten (retinol, ferritine en urinezuur), terwijl er gecn 
aantoonbaar verband bestond tussen concentraties van anti-oxidanten en de 
ernst en/ofhct hebben van retinopathie en neuropathie. 
Deze tegenstrijdige bevindingen met encrzijds afgenomen anti-oxidant 
concentraties bij mensen met diabetes en anderzijds verhoogde concentraties bij 
diabetische nefropathie, kunnen wijzen op een lllechanismc, waarbij 
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concentraties van anti-oxidanten toenemen, wanneer zich nierschade 
ontwikkelt of reeds bestaat. Voor zover wij weten is het bcsta:tn v:tn zo'n 
rcgulatie mechanisme voor anti-oxidant systemen in hct bloed nooit 
aangetoond. In recente onderzoeken bestaan er echter wel aanwijzingen, dat 
cnzymatischc anti-oxidant systemen in de cellen zelf wel kunnen worden 
aangepast om weerstand tegen oxidatieve stress te bieden. 
Malondialdehyde en LDL oxideerbaarheid 
In Hoofdstuk 4- wordt het bestaan van oxidatieve stress verder onderzocht met 
behulp van twee andere indirecte parameters: malondialdehyde concentraties en 
de gevoeligheid van LOL-cholesterol declûes voor oxidatie buiten het lichaam. 
Van deze laatste parameter \verd recent gesuggereerd dat het een gesdtikte maat 
zou zijn voor de reactie van het lichaam op oxidatieve stress, welke optrcedt 
dicht bij de endotheelcellen (cellen die de wand van de bloedvaten bekleden). 
Malondialdehyde, de meest fi:equcnt gebruikte mate voor oxidatieve stress, is 
een afuraakprodukt van lipidenoxidatie (de chemische reactie van vetten met 
zuurstof). 
Gebruik makend van deze parameters konden wij het bestaan van verhoogde 
oxidatieve stress bij mensen met diabetes ten opzichte van de controle groep 
niet bevestigen. De resultaten van deze onderzoeken gaven aan dat mensen met 
diabetcs zelfs minder oxidatieve stress zouden hebben dan mensen zonder 
diabctes. 
Zoals beschreven in Hoofdstuk 5 bestaat er ook geen verband tussen oxid:ttieve 
stress, gemcten middels LOL-oxidatie en malondialdehyde concentratics en het 
bestaan van microvasculaire complicaties. Verder bestaat er geen verband tussen 
oxidatieve stress en de mate van metabole controle. 
Het biochemisch onderzoek in dit proefSchrift vonnde ecn pogmg een 
mogelijk mechanismc te ontdekken, waardoor microvasculaire complicaties 
ontstaan en voortschrijden bij mensen met insuline-afhankelijke diabetes 
lnellitus. De bevindingen van dit proeC'ichrift ondersteunen noch het bestaan 
van een verschil in oxidatieve stress tussen diabeten en niet diabeten, noch het 
bestaan van een duidelijke invloed van de mate van 111etabole controle (althans 
gemeten middels HbA J c ) op de mate van oxidatieve stress. Dit kan komen 
omdat we deze verbanden ltiet bij de juiste patiënten groep hebben bestudcerd; 
mensen met niet-insulinc-afhankelijke diabetes lllcllitus zouden andere 
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onderzoeksllitkomsten kunnen laten zien. Het is ook mogelijk, dat de gebruikte 
parameters hiervoor niet geschikt zijn en dat andere chemische methoden om 
oxidatieve stress vast te stellen hiervoor wel kunnen worden gcbruikt. Voor de 
gepresenteerde resultatcn kan n1en slechts concluderen dat de aanvankclijke 
hypothcse met betrekking tot de invloed vJn oxidatieve stress op het ontstaan 
en het voortschrijden van diabetische complicaties niet wordt ondersteund door 
de verkregen resultaten. 
GEZONDHEIDSBELEVING 
Insuline-afhankelijke diabetes mellihls is een chronische aandoening, die 
gevolgen kan hebben voor een groot aantal LlCetten van het alledaagse leven. De 
inname van voedsel, lichaamsbeweging, en het aantal te spuiten eenheden 
insuline dienen telkens weer op elkaar te worden afgestemd om de 
bloedglucosewaarden op cen acceptabel peil te houden en hyperglycaemischc en 
hypoglycacmische klachten te vermijden. Daarnaast zijn sommige patiënten zich 
er terdege van bewust dat cr altijd een kans blijft bestaan 0111 cen of 11leCr 
complicaties te krijgen, hoc goed men de bloedglucoscwaardell ook heeft 
gereguleerd. 
Deze veranhvoordelijkheid voor het ondcr alle omstandighcden goed regelen 
van dc bloedglucosewaarclen en de mogelijke zorgen ovcr de toekomstige 
gczondheid en hct welzijn, vormen een extra belasting voor het dagelijks leven 
van mensen met IADM. Hoewel uit de resultaten van de DCCT is geblekcn 
dat middels het zeer goed rcguleren van bloedglucosewaarden de kans op het 
onhvikkelen van complicatics kan worden verkleind, bleken belangrijke 
neveneffecten van deze regulatie onder andere cen aanzienlijke 
gewichtstoename en een driemaal zo grote kans op het krijgen van een crnstige 
hypoglycaemie te zijn. Gezien de nlOgelijke lichamelijke maar ook emotionele 
gevolgen hiervan zoudcn deze neveneffecten voor vele patiënten een 
onacceptabele 'prijs' kunllen inhouden, die zij moeten betalen voor het 
verminderen van de kans op het krijgen van complicaties. Tevens is het 
noodzakelijk om hiervoor de insuline therapie verder te intcnsieveren, 
frequenter insuline injecties toe te dîenen, over te gaan op insuline toediening 
middels een insulinepomp en vaker glucose-dagcurves te prikken (zelfcontrole). 
Dit laatste zou op zichzclf al een negatief effect kUI1llen hebbcn op hoe de mens 
met diabetes zijn gezondheid ervaart. 
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In het tweede gedcelte van dit proefSchrift hebben we dan ook de resultatcn 
beschreven van een onderzoek, met als doel de relatie te ondcrzoeken tussen 
metabole controle cn de fi-equentie van insuline toediening enerzijds en zelf-
controle, en de gezondheidsbeleving van mensen met diabetcs anderzijds. 
Hoewel het moeilijk lijkt om de ervaringen met betrekking tot het gevoel te 
meten, bestaan er sinds enkele jaren vragenlijsten, die de gczondheid en het 
gevoel van gezondheid en ziekte kunnen meten. T\vee van deze 
meetinstrumentcn (de SF-36 en Euroqol) zijn in dit proefSchrift gebruikt als 
maat voor iCInands gezondheidsbelcving. 
Over het aigelllcen genomen was er geen of slechts een zeer zwak verband 
tussen Illetabole controle (o.a. HbAIC) en hoe een patiënt zijn gezondheid 
ervaart, gemeten met behulp van de SF-36 of Euroqol (vragenlijsten). Echter, 
het hebben van diabetische klachten (zo\vcl hyperglycaemische als 
hypoglycaemische) bepaalde in sterke mate hoe diabetes patiënten hun 
gezondheid ervaarden, waarbij het hebben van mcer klachten samen bleek te 
gaan met een verminderd 'gevoel van gezond zijn' (Hoofdstuk 6). 
Wanneer men het eflcct van de behandeling op de gezondheidsbeleving 
onderzoekt, blijkt er een sterk negatief verband te bestaan tussen hoe vaak mcn 
zelfcontrole verricht en de op lichamelijke aspecten georiënteerde 
gezondheidsbelcving. Dit verband bleek niet te berustcn op de mate van 
metabole controle of hoe vaak Incn diabetes klachten heeft. De bevinding dat 
patiënten, die worden behandeld middels een insulinepomp hun gezondheid als 
minder goed ervaren ten opzichte van patiënten die behandeld worden met 
insuline pennen, bleek te kunnen worden verklaard door het feit dat deze 
patiënten vaker zelfcontrole verrichtten. Tezamen genomen bevestigen deze 
bevindingen dat de behandeling van nlensen met diabetes inderdaad negatieve 
gevolgen kan hebben op hoe ielnand zijn/haar gezondheid ervaart. 
In hoofdstuk S wordt beschrevcn \vat de consequcnties van dit onderzoek naar 
oxidatieve stress en gezondheidsbeleving voor dc behandeling van nlensen met 
IADM zouden kunnen zijn. Het belangrijkste is, dat het al dan nict aanwezig 
zijn van hypo-en hyperglycaemische klachtcn kan worden beschouwd als een 
bruikbare aanwijzing voor het verlaagd zijn van de gezondheidsbeleving van de 
diabetes patiënt. Op dit moment bestaan er voor de klinische pratijk gccn 
redenen voor het meten van serum anti-oxidanten of parameters van 
vetzuuroxidatic. Echter, met betrekking tot de gezondheidsbeleving dienen 
behandelaars zich bewust te zijn van de gevolgen van intensieve 
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insulincbehandelillg (met namc van de frequentie van zelfcontrole) voor het 
'gevoel van gezond zijn' bij individuelc patiënt, en dcze informatic mee te 
nemen in de adviczen naar de patiënt. 
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